Site Map
User Menu
Menu list
- SPJ Journal
- News
- Business News
- Galapagos and AbbVie Expand Collaboration to Include Crohn's Disease Program
- Unraveling Accreditation, Certification, and Certificate Programs
- National Association of Specialty Pharmacy™ (NASP™) appoints Mark Montgomery, CEO, Axium Healthcare Pharmacy, to Board of Directors
- National Association of Specialty Pharmacy™ (NASP™) Launches the Specialty Pharmacy Education Center™ (SPEC™)
- Study Shows Variance in Initiatives with Specialty Drugs by Health Plan Type
- AbbVie Secures Rights to Alvine's Experimental Treatment for Patients with Celiac Disease
- Walgreens Extends CVS Caremark's Network Provider Agreement
- Specialty Pharmacy Certification Board™ (SPCB™) Announces Board Education Director
- NASP and ASCP Discuss Future of Specialty Pharmacy in Aging Market at Upcoming ASCP Conference
- Specialty Pharmacy Certification Board™ (SPCB™) Setting the Standard for Specialty Pharmacy Practice
- Florida Compounding Pharmacy Recalls Drugs Due to Sterility Issues
- Takeda Acquires Inviragen for Vaccines for Infectious Diseases
- Specialty Pharmacy Certification Board™ (SPCB™) Establishes Code of Conduct, Eligibility Requirements and Fees for Certified Specialty Pharmacist™ (CSP™) Program
- Specialty Pharmacy Certification Board™ (SPCB™) Approves Content for Certified Specialty Pharmacist™ (CSP™) Certification Exam
- Florida Approves a Bill Blocking Provisions in Biosimilars Bill
- Celgene Corp Enters $300 Million Deal for Concert Pharmaceuticals' Deuterium-Modifying Platform
- Association for Value-Based Cancer Care's (AVBCC) Annual Conference Highlights
- Armada's Specialty Pharmacy Summit Brings Together Industry Leaders
- Drug Trend Insights Report Shows Prescription Drug Costs Increase Driven by Specialty Drugs
- Arseus Acquires US Compounder Freedom Pharmaceuticals
- Valence Life Sciences Provides Funding to Support Celator's Acute Myeloid Leukemia Late-Stage Trial
- Proposal Seeks to Boost FDA's Oversight on Compounding Pharmacies
- OPKO to Acquire Prolor for $480 Million
- National Association of Specialty Pharmacy Appoints Thomas Blissenbach, RPh, MS as a Member of The Board of Directors
- Teva Announces Creation of Global Specialty Medicines Group
- NACDS Awards Bob Loeffler and David Pinto with the Sheldon W. Fantle Lifetime Achievement Award
- Alchemia Collaborates with AstraZeneca for VAST Discovery Platform
- GSK and Avalon Ventures Collaborate to Fund up to 10 Drug Discovery Startup Companies
- NACDS Announces New Roles of the Association and Foundation at its Annual Meeting
- NACDS Kicks off its Annual Meeting Marking its 80th Year
- Avella Specialty Pharmacy Assists Patients to Lower Cost of Specialty Drugs
- Illinois House Approves Marijuana for Certain Medical Conditions
- Ropers to Acquire MHA for $1 Billion
- Pfenex and Agila Biotech Enter Joint Venture to Develop Biosimilar Products
- HealthGuard Emergency Card Available for Patient Protection
- ASCP's Upcoming Spring Conference and Exhibition Covers Several Hot Topics in the Healthcare Industry
- Pharmacy Advantage Specialty Pharmacy Receives URAC Accreditation
- Walgreens Research Shows How Health Systems could Prevent Triple Fail Events
- Coldkeepers, LLC Announces International Expansion through Partnership with European Packaging Leader Sofrigam S.A.
- NASP Announces Jim Smeeding, RPh, MBA, as Executive Director
- MHA Completes Sixth Annual Independent Long Term Care Study
- Avella Announces Launch of Dispensing Excellence
- Covis Announces Agreement with Sanofi for Commercial Rights of Several Drugs in the US
- NASP Closes Inaugural Specialty Conference to a Sell-Out Crowd
- Elan Announces Closing of Tysabri Deal with Biogen
- Bind Therapeutics and Pfizer Collaborate to Develop and Commercialize Multiple Accurins
- NASP Specialty Pharmacy Conference Highlights
- NASP Inaugural Specialty Pharmacy Conference Sells Out – More than 500 Individuals Attend
- BioPlus Guarantees Patient Acceptance in Two Hours
- Health Departments Launch Investigation on Oklahoma Dentist who May have Exposed 7,000 to HIV and Hepatitis C
- Oncodesign and Sanofi Sign Second Research Collaboration Agreement
- Managed Health Care Associates, Inc. (MHA) Announced Erik Halstrom, Vice President of MHA Specialty Pharmacy Solutions, Will Serve on The National Association of Specialty Pharmacy (NASP) Board of Directors
- James Lang Joins NASP Board of Directors
- AstraZeneca and Moderna Enter Exclusive Agreement for Development of New Treatment Options
- FDA Warns of Additional Compounding Pharmacy Recalls
- Pharmacy Quality Alliance and CECity Launch Quality Measurement, Benchmarking, and Reporting Platform for Pharmacies and Health Plans
- AmerisourceBergen Announces Long-Term Relationship with Walgreens and Alliance Boots
- Amdipharm and Mercury Pharma Announce Merger
- New Leaf Rx Announces Partnership with NASP
- The Scripps Research Institute and Takeda Expand Research Collaboration for New Drug Targets
- Receptos and AbbVie Enter into a Development License and Option Agreement for a Rare Disease Drug
- The NASP-AMCP Specialty Pharmacy Conference Expands Meeting Space
- Shire Acquires Premacure Expanding Its Rare Diseases Pipeline
- PhRMA Reports 907 New Biotech Drugs in Development
- Coldkeepers, LLC Announces New Pre-qualified 72 Hour Thermal Shipping Solution for Specialty Pharmacies
- PTC Therapeutics Closes $60 Million in Financing
- Phil Hagerman, CEO, Diplomat Specialty Pharmacy, Joins NASP Board of Directors
- Specialty Pharmacy Certification Board™ Defining Specialty Pharmacy Practice
- Sorrento Signs an Exclusive Option to Acquire IGDRASOL
- Study Shows Tightly Managed Specialty Pharmacy Benefits Can Cut Specialty Drug Spend in Half
- Ajinomoto Agrees to Acquire Althea Technologies
- CVS' Acordant Health Services Receives URAC's Case Management Accreditation
- Innovatix, LLC Joins the National Association of Specialty Pharmacy (NASP) as a Founding Member Sponsor
- Presage Biosciences and Celgene Collaborate to Identify Novel Drug Combinations for Cancer
- Express Scripts' 2012 Drug Trend Report Ranks Specialty Therapy Classes by PMPY Spend
- The FDA Conducts Surprise Inspections on Numerous Compounding Pharmacies
- Mylan Agrees to Acquire Agila for $1.6 Billion
- Royalty Pharma Announces Proposal to Acquire Elan in Response to Elan’s Recent Release on the Company’s Restructuring Plan
- Destroying the Status Quo: The Independent Pharmacy Benefits Growth Conference
- Sobi and Savient Agree to Co-Promote Kineret
- California Community Pharmacies Applaud Anthem Decision to Suspend HIV Program that Would Have Harmed Patient Choice
- Roche and Chiasma Collaborate for Development and Commercialization of Chiasma’s Octreolin
- Managed Health Care Associates, Inc. (MHA) Announced as Founding Member Sponsor of The National Association of Specialty Pharmacy (NASP)
- Cardinal Announces Plans to Acquire AssuraMed
- Lycera and Merck Announce A Collaborative Agreement for Developement of Novel Autoimmune Disorder Treatments
- New Regulations for Compounding Pharmacies on the Horizon
- Perrigo Acquires Rosemont Pharmaceuticals for $283 Million
- Walgreens Infusion Services Prevented an Estimated 429 Hospital Days in 3 Months
- NASP Announces Partnership with Gerry Crocker to Advance Specialty Pharmacy Industry
- Banner MD Anderson Cancer Center Acquires Elekta Cancer Management Solutions
- Biogen Agrees to Purchase Elan's Interest in Tysabri, Obtaining full Strategic, Commercial and Decision-Making Rights to the Drug
- Opexa and Merck Serono Execute an Agreement for Development of Tcelna for Treatment of Multiple Sclerosis
- National Association of Specialty Pharmacy Board of Directors Call for Volunteers
- Aduro Acquires GVAX Assets from BioSante Expanding its Cancer Portfolio
- CVS Expands ExtraCare Loyalty Program Rewarding Customers for Filling Prescriptions
- Walgreens Enables Third-Party Mobile App Developers to Leverage Its Prescription Refill Technology
- Judge Freezes Assets of Meningitis-Linked Pharmacy Owners
- The 2nd Annual Foundation for Managed Care Pharmacy (FMCP) Research Symposium Releases Research Proceedings
- Olean General Hospital Notifies Patients of Possible Sharing of Insulin Pens
- Progenics Acquires Molecular Insight Expanding Its Oncology Pipeline
- H.D. Smith Announces Establishment of H.D. Smith Specialty Solutions
- Thermal Shipping Technologies – Packing Heat?
- Why the NASP - AMCP Inaugural Specialty Pharmacy Conference is Different
- Costco Launches Pharmacy Benefit Management Business
- Fitango Launches e-Health Platform to Improve Patient Adherence
- H.D. Smith Announces Its Plans on Securing Majority Ownership in Pharmacy Support Services Company Triplefin
- Possible Exposure of HIV and Hepatitis from Reused Insulin Pens at the Buffalo VA Medical Center
- Centene Corporation to Acquire Specialty Therapeutic Care Holdings
- Vertex Outlines Its Business Priorities of 2013, Revealing its First Two Breakthrough Therapy Designations
- Study Shows a Strong Demand for Online Services for Chronic Disease Patients and Caregivers
- URAC Releases Revised Claims Processing Accreditation Standards
- Ernst & Young Report Shows Future Difficulty for Big Pharma to Close Growth Gap
- Governor Proposes New Rules for Tighter Regulations on Compounding Pharmacies
- CVS Caremark’s Study Associates Practical Social Support with Improved Medication Adherence
- The FDA Approves 39 New Drugs in 2012, a 16-Year High
- BelHealth Acquires Town Total and Hires Michael A. Nameth as CEO
- Phil Hagerman of Diplomat Specialty Pharmacy Named A Michigander to Watch by MLive Media
- Victory Pharma Pays $11.4 Million to Settle Kickback Claims
- Walgreens Infusion Services Chosen as Contracted Provider for Gattex
- WellPoint Completes Acquisition of Amerigroup
- The New England Compounding Center Files for Bankruptcy
- Halozyme Partners with Pfizer for $8 Million
- The Implications of the Meningitis Outbreak on Specialty Pharmacy
- Humana RightSource Specialty Pharmacy Launches Split-Fill Program For Improved Outcomes and Quality of Life
- Sanofi Settles False Claims Case for $109 Million
- LeClairRyan Reacts to Additional Oversight on Compounding Pharmacies Although CDC Says Meningitis Outbreak Could Have Been Worse
- Public Citizen Expresses Strong Opposition of FDA Proposals for Compounding Pharmacies
- Meningitis-Related Deaths Continue to Rise
- Biogen & Eisai Align to Strengthen Manufacturing Capabilities
- Gilead to Acquire YM BioSciences Expanding Its Oncology and Inflammation Pipeline
- Walgreens Gains Ownership Stake in Cystic Fibrosis Specialty Pharmacy
- Aetna and Cardinal Health Specialty Solutions Design Program to Improve Cancer Care in Michigan
- Meningitis Outbreak: Lawmakers Investigate Compounding Pharmacy Group; Drug Shortages Increase
- Amgen to Acquire deCODE Genetics for $415 Million
- New Meningitis Legislation Introduced by US House Democrats
- Geron Announces Discontinuation of GRN1005 to Focus on Development of Imetelstat
- QS/1 Partners with CoverMyMeds to Automate the PA Process
- Grand Jury Searching Pharmacy Linked to Meningitis Outbreak
- Your Opportunity to Participate in Defining Specialty Pharmacy Practice
- BioCryst and Presidio Mutually Terminate Merger Transaction
- Public Citizen Group Asks FDA to Re-Inspect 16 Compounding Pharmacies
- Judge Allows Civil Suits in Meningitis Outbreak to Progress
- NCPA Releases Report Examining Their Success in Advancing Medication Adherence
- Express Scripts' Drug Trend Reports Specialty Drug Spend Increased 22.6 Percent
- Continuing Efforts by Health Departments As Meningitis Infection Sickens Over 500 Nationwide
- New Rule Approved Prompted by National Meningitis Outbreak
- Study Identifies Communication Gap Between Physicians and Pharmacists
- Lawyers Argue Over Motion to Freeze Assets of NECC Companies & Executives
- HHS Releases Implemented Provisions to Healthcare Law
- FDA, State Pharmacy Boards, and CMS Receive Letters Questioning Regulatory Actions Related to the Meningitis Outbreak
- IntelliDex Developing Capability for Pharmaceutical Knowledge/Decision Support System to Read EHR
- Financial Affordability Considered Main Cause for Lack of Compliance to Current Guidelines
- FTC Gives Clearance For Valeant Medicis Deal
- New Regulatory Rules Needed for Compounding Pharmacies
- Kroger Announces Merger with Axium Pharmacy, Gaining Entry to the Specialty Pharmacy Market
- Pernix Acquires Cypress and Hawthorn for $101 Million
- MannKind Sells Cancer Drug Rights to Colby
- Panel Rigorously Questions FDA Over Lack of Regulation on Compounding Pharmacies Acting As Manufacturers
- State pharmacy officials knew convict led oversight firm
- FDA Reports Contamination Issues at Ameridose
- Novogen to Acquire Triaxial for $1.8 Million
- Specialty Pharmaceuticals: Facts, Figures and Trends Executive Summary
- Ameridose Will Lay off Hundreds of Employees As Meningitis Investigation Continues
- Immune & EpiCept Enter into Definitive Merger Agreement
- Director of Massachusetts Pharmacy Board Fired
- Obama's Re-Election Eliminates Repeal of Healthcare Reform Law, but Challenges Still Exist
- FDA Will Delay Decisions For Certain Drugs Whose Target Dates Were During Hurricane Sandy
- Massachusetts Board of Pharmacy Approves Emergency Regulations on Compounding Pharmacies
- NECC Sister Company Recalls Products Due to Potential Sterility Concerns
- Watson Announces Their New Name: Actavis
- Express Scripts Study Shows Medication Use for Normal Aging Conditions Overtakes Costs of Treating Most Chronic Diseases
- Beaumont Health System & Henry Ford Health System Plan to Merge
- Walgreens & Alliance Boots Form Joint Venture Company
- Amgen & KPCB Form Atara Biotherapeutics Focused on Therapies for Chronic Diseases
- ViiV & Shionogi Announce New Agreement for HIV Integrase Portfolio
- Value Creation in the Specialty Space- The Investor’s Perspective Panel Discussion
- The Evolution of the Specialty Pharmacy Industry Panel Discussion
- Catamaran Launches BriovaRx Specialty Pharmacy Program
- Meningitis Cases Rise to 317, Deaths total 24, Victims File Suit Against Physicians and Clinics for Administering Tainted Shots
- Therigy Kicks-off 1st Annual Leadership Congress Tonight
- Therigy’s Specialty Pharmacy Leadership Congress Convenes This Week
- Pfizer to Acquire NextWave for up to $700 Million
- BioCryst & Presidio Sign Merger Agreement, Expanding Hep C and HAE Portfolio
- Specialty Pharmacy Certification Board Announces Certified Pharmacy Officer Feasibility Study
- CSI Group to host 1st Annual TEXAS HOLD ‘EM TOURNAMENT and Silent Auction to Benefit National Hemophilia Foundation Travel Scholarship Fund.
- Kerr Drug Launches Mobile Pharmacy App
- Walgreens WellTransitionsSM Provides Discharge Services to Help Hospitals and Health Systems Reduce Readmissions
- Health Care Reform Impact: More Insured Americans Compared to 18 Months Ago, BusinessOne Technologies, Inc, Reports
- Study Shows Priority Review Drugs Are More Likely to Have Safety Issues
- Sanofi and Massachusetts General Hospital Launch Oncology Research Collaboration
- MedImmune Joins Forces With Leading Cancer Organizations to Advance Novel Immunotherapy Research
- National Association of Specialty Pharmacy Inaugural Event Held
- Therigy to Host First Annual Specialty Pharmacy Leadership Congress
- Update from AMCP's 2012 Educational Conferece, Cincinnati, Ohio
- SPCB contracts with Comira to develop Certified Specialty Pharmacist Exam
- Catamaran Corporation Unveils New Specialty Pharmacy Offering
- FDA Campaign Aims to Protect Consumers from the Risks of Fake Online Pharmacies
- West Penn Allegheny Health System Moves On From Affiliation Agreement with Highmark
- CSPN Announces A Preferred Vendor Partnership with Rx Timer Cap
- Valeant Acquires Visudyne Drug from QLT
- Novo Nordisk Invests An Additional $100 Million to Expand Facilities in China
- Specialty Pharmacy Certification Board Announces Inaugural Board of Directors
- National Association of Specialty Pharmacy (NASP) Plans Launch
- Bionomics Limited Acquires Eclipse Therapeutics
- Understanding Professional Certification
- AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
- Valeant Agrees to Acquire Medicis for $2.6 Billion
- Specialty Pharmacy Certification Board (SPCB) Considers Adding Hep C as Additional Qualification to their CSP Credential
- Janssen Wins Worldwide Agreement with Genmab for Daratumumab
- Hospira Receives A Warning Letter Over Costa Rica Infusion Pump Plant
- Merz Acquires The Orphan Drug Cuvposa Oral Solution
- Navarro Health Care Services' Prescription Fulfillment Center Facility is Leading the Way In Best In Class Pharmacy Care
- FDA Issues A Warning for Reumofan Plus and Reumofan Plus Premium
- Allergan Enters into An Exclusive Alliance with Molecular Partners
- MOMS Pharmacy Acquired by AIDS Healthcare Foundation
- Application of Automatic Co-Pay Reductions Programs On the Rise in Select Therapeutic Categories
- Express Scripts Launches New Tool to Help Patients Understand their Therapy
- Specialty Pharmacy Certification Board Partners with SeaCrest Company to Develop Certification Program
- Codman’s MEDSTREAM Receives FDA PMA Approval
- Making it Official: Certification of Health Professionals for Specialty Pharmacy
- CSL Behring Awards Advocacy Grants to Patient Groups in Six States: NC, CA, WA, PA, IL, NY
- CoramRx Specialty Pharmacy Services Receives URAC Specialty Pharmacy Accreditation
- Prime Therapeutics Announces Prime Therapeutics Specialty Pharmacy
- Cystic Fibrosis Foundation Unveils a New Logo
- Advanced Specialty Rx Opens Long Term Care Pharmacy
- URAC Awards MedPro Rx with Specialty Pharmacy Accreditation
- CVS/pharmacy's "Project Health" Bringing Free Health Screenings to 10 Cities During August
- New Specialty Pharmacy Certification Board to Certify Specialty Pharmacists
- New Specialty Pharmacy Certification Board™ to Certify Specialty Pharmacists
- CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
- Diplomat Specialty Pharmacy’s 2012 Physician Satisfaction Survey Results Affirm Success of Company’s Education & Training Program
- Express Scripts and Walgreens Announce New Pharmacy Network Agreement
- New Study Shows Interferon Beta to be Ineffective in Preventing MS Patients' Progression to Irreversible Disability
- European Commission Grants Orphan Medicinal Product Designation for Emmaus Medical's Sickle Cell Treatment
- TPG to Acquire Par Pharmaceuticals for $1.84 Billion
- GSK to Acquire Human Genome Sciences for $3.6 Billion
- CVS Caremark Research Identifies Positive Link Between Medication Adherence and Employee Productivity
- BioRx Acquires Coagulife Pharmacy
- Omnicare Buys Five Star Pharmacy Business for $30.7 Million
- FDA Mandating Opioid Makers Fund Training Programs
- SXC Health Solutions Unveils a New Name Following Merger: Catamaran
- WellPoint to Acquire Amerigroup Corporation for $4.9 Billion
- Apothecary Shops buys Colorado Pharmacy
- CSL Behring Launches New Hizentra® Dosing Calculator App for Healthcare Professionals on the Move
- Amgen Completes Acquisition of KAI Pharmaceuticals
- Unapproved Oxycodone Drugs Ordered Off the Market by FDA
- Walgreens to Acquire USA Drug Pharmacy Chain in Mid-South
- The Zitter Group announces new management team to continue its rapid growth
- GSK Will Pay $3 Billion for Fraud Settlement
- Vertex’s Shares Fall Despite Positive Final Results for Cystic Fibrosis Drug
- Janssen Completes Acquisition of CorImmun GmbH
- How Today's Approval of Obamacare Affected Different Branches of the Health Care Industry
- House Sends FDA Bill to Senate
- ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product for Patients with Sickle Cell Disease
- Community Specialty Pharmacy Network Announces Partnership with CoverMyMeds
- SXC Health Solutions Awarded URAC Specialty Pharmacy Accreditation
- Walgreens and Alliance Boots Form Strategic Partnership to Create the First Global Pharmacy-Led, Health and Wellbeing Enterprise
- Producers of Biosimilars Concerned About Possible Over-Turning of Affordable Care Act
- Valeant Pharmaceuticals Agreed to Acquire Orapharma for $312 Million
- Apothecary Shops to Become Avella in August 2012
- Florida Hospital Medical Group and MinuteClinic Enter Into Clinical Collaboration in Central Florida
- Upsher-Smith Announces Transaction to Acquire UK-Based Proximagen
- NIH & Children’s National Medical Center Collaborate to Find New Treatments for Rare Disorders
- Amber Pharmacy and Argus Health Systems Collaborate to Expand Specialty Pharmacy Options
- Express Scripts Sees Benefits from Merger
- CVS Caremark Research Finds Most Consumers who Qualify for Health Care Reform Subsidies Haven't Heard of State Insurance Exchanges
- McKesson and ValueOptions Announce their Strategic Partnership to Increase Coordinated Care
- House of Representatives Vote in Favor of FDA Funding Bill
- Many Health Plans Fail to Meet New Standards In the Evolving Health Plan Landscape
- Walgreen’s Specialty Pharmacy moving forward with novel patient services
- CVS Research Finds FDA Drug Warnings Can Have Immediate Negative Impact on Medication Adherence
- Messaging in Anticoagulants Category Ahead of Plavix Patent Loss
- Cornerstone Therapeutics will Acquire EKR Therapeutics
- Walgreens Launches New & Improved Prescriptions Savings Club
- GSK Acquires Cellzome for $99 Million
- Cardinal Health Settles with DEA for Their Lakeland Distribution Center
- Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
- Medicaid Service Fees to Increase with New Health Law
- H.D. Smith Announces Their Three Year Prime Vendor Agreement with PharmacyGPO
- Walgreens Completes Acquisition of BioScrip's Community Specialty Pharmacies & Centralized Specialty Mail Service Pharmacy Businesses
- CVS Caremark's First Quarter Results Reflects Strong Performance
- Expansion of Prior Authorization Policies for Oncology Agents
- Amerigroup Closes Previously Announced Acquisition of Health Plus
- Specialty Rx Source Announces Launch of Specialty RN Source at the INS Annual Convention
- Cigna’s Reliance on Managed Medicare
- Baxter Completes Purchase of SIGMA
- Amgen Acquires Mustafa Nevzat Pharmaceuticals
- Specialty Pharma First Quarter Earnings Reports
- Therigy Launches eNewsletter: Specialty PharmaSource
- NABP Raises Awareness of Internet Drug Sites
- Enbrel Sales Reps Affected by Transition from Pfizer
- AstraZeneca to Acquire Ardea for $1.26 Billion
- SXC Health Solutions Buys Catalyst
- BioPlus Launches TAP App for Physicians to Monitor Patient Specialty Pharmacy Treatments
- Alaska State Bill Approves "Child-Only" Insurance to Reduce Costs for Specialty Drugs
- Express Scripts Launches ScreenRx
- Valeant Pharmaceuticals to Acquire Pedinol Pharmacal
- Abbott's HUMIRA® (adalimumab) Approved in Europe for Treatment of Ulcerative Colitis (UC)
- AnaptysBio Announces Strategic Antibody Discovery Partnership With Celgene Corporation
- WellCare Health Plans, Inc. Agrees to Pay $137.5 Million to Resolve False Claims Act Allegations
- Express Scripts Deal: Injunction Request Date Set
- Express Scripts Completed the Acquisition of Medco Health Solutions
- Health Care Law Outcome to be Decided Today
- Abbott's New Future Research-Based Pharma Company Named AbbVie
- Express Scripts’ Purchase of Medco May be Delayed by Potential Legal Action
- AmerisourceBergen Agrees to Purchase World Courier Group for $520 Million
- CBO Says Health Law will Cost Less, yet Cover Less
- BCBST Case Settled for $1.5 Million
- Advisory Panel Recommends to Continue Trials of Painkillers
- CareFusion to Acquire Pharmacy Automation Technology Leader
- TherapeuticsMD, Inc. Launches VitaMedMD Plus Rx, the First Prescription Prenatal Vitamin with Quatrefolic and Plant-Based DHA
- EURORDIS Recognizes CSL Behring as a “Pioneer” for Rare Diseases
- DEA Blocks Cardinal Health From Shipping Painkillers in Florida
- Draft Rules for Biosimilar Drugs Issued by the FDA
- Cost Concerns Continue to Dominate Benefit Design
- Walgreens to Acquire BioScrip Businesses for $225 Million
- Congressman Carney Addresses Drug Shortage Prevention Act
- FDA Approves Ivacaftor, a Cystic Fibrosis Drug
- Amgen Agrees to Buyout Micromet for $1.16 Billion
- FDA Warns Novartis and Celgene on Drug Promotions
- BioLineRx Becomes a Buyout Target due to Hep C Pill
- Health Technology's New Think Tank
- Prescription Price Case Settled for CVS
- Biopharma and Payers Are Optimistic About the Future of Drug Development
- Inhibitex Acquired by Bristol-Myers Squibb
- Shared System REMS for TIRF Products are FDA Approved
- Walgreens Will Move on Without Express Scripts
- Takeda to Acquire Intellikine
- Cigna Acquires HealthSpring
- Data When You Need It, Where You Need It — The Latest Facts, Figures and Trends
- Data When You Need It, Where You Need It- The Latest Facts, Figures & Trends Now Available
- NORD Study- FDA flexible- Therapies for Rare Diseases
- Payers Not Leveraging Specialty Pharmacy Programs: EMD Serono Report
- APhA releases second REMS white paper
- Medco Report: Specialty Trend Growth Will Challenge Payers
- Eight Megatrends Shaping the Future of Specialty Pharma
- FDA requests input on development of user fee program for biosimilar and interchangeable biological products
- Specialty Pharmacy Education Center (SPEC) Issues Call for Education Gap Analyses and Needs Assessments
- Report: Novartis to boost biosimilars portfolio
- Biosimilars Coming to US Market but will Face Major Hurdles
- Center For Healthcare Supply Chain Research Publishes Impact Study Of REMS
- HDMA 2010 Specialty Pharmaceuticals: Facts, Figures and Trends
- FDA approves Rituxan to Treat Two Rare Disorders
- Merck to Buy Eye-Care Firm
- Valeant CEO showcases savvy dealmaking style
- Cystic Fibrosis
- Pharmaxis' Cystic Fibrosis Drug is not Recommended for Approval by the FDA Advisory Committee
- Orlando to Host World's Largest Cystic Fibrosis Medical Meeting
- OrPro Therapeutics Receives NIH Grant Award to Advance Development of Recombinant Thioredoxin for Treatment of Cystic Fibrosis
- Grifols Initiates Safety Study Following Orphan Drug Designation for their CF Drug
- Diabetes
- Plaintiffs Awarded $6.5 Million for Damages Associated with Takeda's Actos
- Pfizer and Merck Collaborate for Type 2 Diabetes Treatment
- Eli Lilly Releases Positive Results from Additional Trials for its Diabetes Drug
- FDA Committees will Reassess Safety of GSK's Diabetes Pill, Avandia
- Janssen's Invokana Receives FDA Approval for Type 2 Diabetes
- FDA Investigates Reports of Increased Risk of Pancreatic Cancer with Certain Diabetes Drugs
- Mylan Enters A Settlement Agreement for its Generic Diabetes Drug
- Gilead's Ranexa Reduces Angina Frequency for Patients with Type 2 Diabetes
- Study Identifies Genetic Mutation that May Lead to New Treatment Options for Type 1 Diabetes
- Kaiser Permanente Study Shows Diabetes Patients are not at an Increased Risk During Knee Replacement Surgery
- Study Shows New Diabetes Drug May Double Pancreatitis Risk
- FDA Accepts Sanofi's Diabetes Drug Application
- Mylan and Biocon Enter an Agreement for Three Insulin Products
- The FDA Rejects Novo’s Diabetes Drug
- Crown Marketing Pharmaceuticals Announces Positive In-Vitro Testing Results for Diabetes Drug
- Takeda’s Three New Diabetes Therapies Receive FDA Approval
- GlaxoSmithKline Submits a Regulatory Application for its Diabetes Drug
- Expert Panel Recommends Approval of Johnson & Johnson's Diabetes Pill
- Zogenix Announces U.S. FDA Acceptance for Review of Zohydro ER(TM) New Drug Application for Treatment of Chronic Pain
- FDA Approves Weekly Injected Type 2 Diabetes Drug
- Sanofi's Lyxumia Shows Promise In Phase III Trials for Diabetes
- Meta Analysis: Diabetes Add-On Drug Classes Have Similar Benefits
- Actos patients at higher risk for bladder cancer
- More Data on Diabetes Risk With Statins
- Actos Cut Risk of Prediabetes Becoming Diabetes in Study
- New Diabetes Statistics Further Highlight The Urgent Need For Prevention And Early Detection
- Precise New Sensor Employs Hydrogels
- Medication Education Key To Adherence
- Quality Varies In Social Networking Websites For Diabetics
- Study Reveals How Omega 3's Work In Preventing Several Forms Of Blindness
- Endocrinology
- First Cushing’s Syndrome Treatment Approved
- High Costs Associated with Precocious Puberty, Researchers Say
- Hormone Improves Long-Term Recovery From Stroke
- Osteoporosis Recs Urge Screening for More Women
- Antidepressant a Chill Pill for Hot Flashes
- Antioxidants May Boost Male Fertility
- CVD Risk Linked With Bone Loss
- FDA Rejects Inhaled Insulin
- Rare Diseases
- Cornerstone Therapeutics Acquires Exclusive Rights for Pertzye in the US
- Novartis' Ilaris Receives FDA Approval for Treatment of Systemic Juvenile Idiopathic Arthritis
- Lumena Receives $23 Million Funding for its Lead Program for Rare Liver Disease
- Nimbus and Shire Partner for Therapies for Rare Diseases
- Genentech's Actemra Receives FDA Approval for Rare Form of Arthritis in Children
- Scioderm Receives Breakthrough Therapy Designation for its Investigational Rare Disease Product for Epidermolysis Bullosa
- Raptor Pharmaceuticals' Procysbi Receives FDA Approval for Cystinosis
- FDA Approves CSL Behring's Kcentra
- FDA Grants Orphan Drug Designation to Teva and Xenon's Pain Drug for Rare Autosomal Condition
- Vertex Announces Positive Results from Mid-Stage Study of Combination Drug for Lung Function in Cystic Fibrosis Patients
- Orphan Drug Accelerator, Cydan, Announces Launch with $16 Million in Financing from NEA & Pfizer
- European Commission Grants Marketing Authorization for CSL's Privigen for Treatment of Rare Neurological Disorder
- FDA Grants Orphan Drug Designation to Acceleron's Rare Blood Disorders Drug
- Novartis' TOBI Podhaler Receives FDA Approval for Certain Patients with Cystic Fibrosis
- Pharmaxis Receives a Complete Response Letter from the FDA Regarding Bronchitol for Cystic Fibrosis Patients
- Novartis' Ilaris Receives EU Approval for Patients with Gout
- FDA Expands Approval of CSL Behring’s Corifact
- Takeda and Resolve Partner to Develop Compounds for Treatment of Lupus and Other Autoimmune Diseases
- Isis Pharmaceuticals Earns $7.5 Million from GSK for Initiating Phase 2/3 Study for Rare Disease Drug
- Genzyme Announces Positive Results from Its Phase III Studies for Treatment of Gaucher Disease
- FDA Approves Hyperion’s New Orphan Drug
- CSL Behring Awards Grants for Patient Advocacy Organizations Promoting Early Diagnosis and Access to Care
- FDA Expands Approval of Novartis' Exjade to Treat Rare Genetic Blood Disorder
- Biogen Discontinues Its Asmyotrophic Lateral Sclerosis Drug After It Fails in a Phase III Study
- Proteins Found That May Enable Diagnosis of Rare Disease in Children
- Novartis’ Signifor Receives FDA Approval for Cushing’s Disease
- Biodel's Glucagon Receives Orphan Drug Designation
- Protalix & Pfizer Expand Agreement for Gaucher Drug
- FDA Grants Orphan Drug Status for Seattle Genetics' Adcetris
- Aspireo Receives Positive Opinion from EMA for Orphan Disease Designation for Somatoprim
- Atox Bio Announces Positive Results in Phase II Trial of Experimental Drug AB103 for Treatment of NSTI
- Shire & Boston Children’s Hospital Collaborate for Novel Therapies in Rare Diseases
- FDA Advisory Panel Votes 10-0 in Favor of Novartis' Signifor for Cushing's Disease
- Novartis' Treatment for Cushing's Disease Appears to Be Effective
- BioMarin Announces Positive Results from Phase 3 Study for Treatment of Rare Disease, MPS IVA
- Link Between Gluten and Immune Reaction Revealed for HLA-DQ8 Celiac Disease
- Alexion Announces Data from Phase II Study for Experimental Therapy for Rare Neurological Disorder
- Cystran Receives FDA Approval for Treatment of Corneal Cystine Crystals in Cystinosis Patients
- Gastroenterologists Advise on Prescribing Challenges for Emerging Crohn's Therapies
- FDA Notifies of The Risk of Cataracts for Pediatric Patients Taking Vertex’s CF Drug
- Humira Shows Promising Signs for Children Suffering from Crohn’s Disease
- Pluristem Prepares to File Application for Orphan Drug Designation for Its Experimental Bone Marrow Therapy
- Amicus & GSK Collaborate for Potential Fabry Disease Medications
- Protalix and Pfizer's New Gaucher Drug Fails to Gain Recommendation by EU Regulators
- FDA Issues Complete Response Letter For Pfizer's Tafamidis Meglumine New Drug Application
- Vertex Corrects Previously Reported Data for their Combo Therapy for Cystic Fibrosis
- FDA Reviewers Recommend Rejection of Pfizer’s tafamidis
- Advisory Panel Votes Against Recommendation of Regeneron’s Gout Drug
- FDA Expresses Concern of Arcalyst's Risks for Prevention of Gout
- FDA Approved Elelyso for Gaucher Disease
- Amylin Completes Biologics License Application for Metreleptin to Treat Diabetes and/or Hypertriglyceridemia in Patients With Rare Forms of Lipodystrophy
- Lexicon's Telotristat Etiprate is Granted Orphan Drug Designation
- Growth Hormone
- Aeterna Zentaris Requests Fast Track Designation for Their GHD Diagnostic Test
- Children on growth hormone more likely to have diabetes
- Hormone Combo Boosts Height in Turners Syndrome
- Drug Maker From China Pleads Guilty
- Waterloo U. in Canada Bars Team for Steroids Use
- Assistant to Galea Pleads Guilty
- Baseball Using Minor Leagues for a Drug Test
- Cyclists Said to Back Claims That Lance Armstrong Doped
- Am I Young Yet?
- Hematopoietics
- FDA Grants Orphan Drug Designation to Apgenix's Apocept for Myelodysplastic Syndromes
- Study Shows Preventive Defibrotide May Help Kids after Hematopoietic Stem Cell Transplant
- New induced stem cells may unmask cancer at earliest stage
- Sangamo BioSciences Announces Four Data Presentations at CROI 2011 of Novel ZFN Therapeutic Approaches to the Treatment of HIV/AIDS
- Chronic graft-versus-host disease may remain stable after hematopoietic cell transplantation
- Allo-HCT in first complete remission extended life expectancy for some intermediate- and unfavorable-risk AML
- Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerix's Lead Antiviral CMX001
- Vical Receives Positive Scientific Advice From EMA for TransVax(TM) Phase 3 Trial
- Hemophilia
- FDA Accepts Biogen's BLA for its Hemophilia A Candidate
- American Management Association and Biogen Partner to Develop Workshops for Hemophilia Patients
- World Federation of Hemophilia Announces 50 Years of Improving Care on World Hemophilia Day
- Biogen Submits a Biologics License Application to the FDA for its Hemophilia A Drug
- FDA Accepts Biogen's Biologic License Application for its Hemophilia B Drug
- Baxter Submits a Biologics License Application for Its Hemophilia Drug
- Baxter Agrees to Acquire Inspiration BioPharmaceuticals’ Investigational Hemophilia Compound
- First Patient Enrolled in CSL Behring’s Pediatric Phase III Study for Hemophilia Treatment
- Octapharma's Octaplas Receives FDA Approval for Patients with Blood Clotting Disorders
- Baxter Announces Positive Results from Hemophilia Study
- Baxter Submits Investigational New Drug Application to the FDA for Its Hemophilia A Treatment
- Biogen Submits Biologics License Application to the FDA
- Novo Nordisk Launches HemaGo Application for Hemophilia Patients and Caregivers to Track Treatment Details
- Specialty RN Source Announces Agreement to Provide Nursing Services for The Hemophilia Alliance Members
- National Hemophilia Foundation’s Annual Meeting: “Mapping Our Future”
- Novo Nordisk Submits Regulatory Applications for Hemophilia A Drug
- Biogen and Sobi Announce Positive Results for Long-Lasting Recombinant Factor IX FC Fusion Protein in Hemophilia B
- Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
- American Society of Hematology Launches Multi-Million-Dollar Grant Program to Support Critical Blood Disease Research
- FDA Puts Hold on Ipsen’s Hemophilia Drug
- China Biologic Receives SFDA Manufacturing Approval Certificate for Human Coagulation Factor VIII
- CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
- CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
- CSL Behring Renews Pledge to Provide Significant Funding and Donated Coagulation Factor to World Federation of Hemophilia Over 3-Year Period
- First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
- CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and for Hemophilia B Patients Who Have Inhibitors
- First Clinical Trial Site Initiated in CSL Behring Phase II/III Pivotal Study of Recombinant Fusion Protein Linking Coagulation Factor IX with Recombinant Albumin
- TikoMed AB TM-400 receives orphan drug status
- Michigan Researchers Develop Disease-Specific Stem Cell Lines
- Biogen to build blood disorder drug franchise
- ViroPharma to Participate in Two March Healthcare Conferences
- Journalism award launched to promote hemophilia awareness
- CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
- FDA Approves Revised Alphanate® Labeling to Include Reduced Infectivity of an Experimental Model Agent for vCJD
- Hepatitis C
- Janssen's Investigational Hepatitis C Treatment is Granted Priority Review by the FDA
- AbbVie's Investigational Hepatitis C Combination Drug Receives Breakthrough Therapy Designation from the FDA
- Janssen Submits Marketing Application for Approval of Its Hepatitis C Drug in Europe
- Boehringer Ingelheim Announces Positive Results from Its Phase 3 Study of its Combination Regimen for Hepatitis C Patients
- Merck and BMS Enter a Non-Exclusive Agreement for a Phase II Trial for a Combination Regimen for Hepatitis C
- Roche and Ascletis Collaborate to Advance Hepatitis C Treatment Options in China
- FDA Clears Echosens' FibroScan for Non-Invasive Liver Diagnosis
- Gilead Submits NDA to the FDA for Sofosbuvir for Treatment of Hepatitis C
- Vertex and Bristol-Myers Squibb Enter Agreement for Phase 2 Studies of Hepatitis C Combo Treatment
- Experimental Hepatitis C Drug Shows Promising Results
- EMA Backs Roche's Pegasys for Chronic Hepatitis C in Children Five Years and Older
- Hepatitis C Continues to Lead the Specialty Area for Highest Increase in Drug Spend
- Gilead Announces Positive Results for Hepatitis C Treatment
- Idenix Will Discontinue Development Programs for Two Experimental Hepatitis C Treatments
- Gilead’s Sofosbuvir Meets Primary Endpoints in Two Phase III Studies for Treatment of Hepatitis C
- Interferon for Retreatment of Hepatitis C May be More Harmful than No Treatment
- Boehringer Ingelheim Enrolls First Patients in its Phase III Trial for Interferon-Free Hepatitis C Program
- FDA Requires Additional Time for Review of Idenix’s Hepatitis C Treatment
- Gilead Shares Positive Update on Hepatitis C Developments
- Hepatitis C Pills Show Promising Future
- Incivek Label Revised to Include Warning of Fatal and Non-Fatal Serious Skin Reactions
- St. Joseph's Hospital Launches State-Wide Program to Help Diagnose and Treat Hep C Patients
- Gilead Announces Positive Results from Phase III Study for All-Oral Hep C Drug Program
- FDA Approves Promacta for Hep C Patients with Low Blood Platelet Counts
- Abbott Plans Phase III Studies for Hep C Drugs Due to High Cure Rates in Aviator Trial
- Vertex & GSK Collaborate for Hep C Treatment
- BioCryst Withdraws Investigational New Drug Application for HCV Drug
- Antiviral Drugs May Reduce Liver Cancer Risk in Patients with Hepatitis C
- Abbott's Investigational Hep C Drug Cures 99 Percent of Hard-To-Treat Patients
- Aethlon Medical Releases Hepatitis C Virus (HCV) Treatment Protocol and Inclusion/Exclusion Criteria Underlying Compassionate-Use Commercialization Program
- New Hepatitis C Data from Boehringer Ingelheim to be Presented at AASLD Annual Meeting
- Achillion Announces Positive Proof-of-Concept Data with ACH-3102
- Vertex Ends Work on One Hepatitis C Drug, Continues Another
- Hepatitis C Biopump Trials Receives Green Light
- What the Future Holds for HCV Sufferers
- FDA Puts Hold on Another Idenix Hep C Study
- Bristol-Myers Squibb Forced to Halt Studies of its Experimental Hep C Treatment
- FDA Puts Idenix’s Hep C Drug on Hold due to Heart-Related Side Effects
- Hepatitis C Treatment May Stunt Growth in Children
- Achillion's Experimental Hep C Drug Shows Promise in Mid-Stage Trials
- BMS’ Hep C Drug Clinical Trial Suspended due to Safety Issues
- Vertex's Hep C Drug Shows Positive Results
- Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) Seven Days After Initiation of Hemopurifier® Therapy in Genotype-1 Patients
- Ligand and GSK Granted Priority Review for Treatment of Thrombocytopenia in Patients with Hep C
- Idenix's Experimental HCV Drug Granted Fast Track Designation by FDA
- Idenix's Experimental Hep C Drug Shows Promise
- Study Shows Hep C Causing More Liver Damages
- CDC Proposing Test for Hepatitis C for All Baby Boomers
- Achillion's Hep C Drug Gets Fast Track Designation by FDA
- Aethlon Medical Reports Undetectable HCV in Genotypes 1, 3, & 5 Patients Treated with Hemopurifier Therapy
- Patients Taking Interferon for Treatment of Hep C May Develop Depression
- FDA Issues Drug Safety Communications for Victrelis
- HCV Drug Trial Stopped Due to Cases of Pancreatitis
- Data For Gilead’s HCV Drug To Be Presented Next Week
- Abbott’s Hep C Therapy Shows Positive Results for Previously Untreated Patients
- Model Shows Broadening HCV Testing to be Cost Effective
- Serious Risks Associated with Statins and HIV/HCV Protease Inhibitors
- Nail Salon Nightmare
- Idenix's Potential New Hepatitis C Drug
- New Potential Therapy Approach for Hepatitis C Found
- Inhibitex Acquired by Bristol-Myers Squibb
- Pharmasset, Inc. Announces Further Expansion of Electron Trial in Hepatitis C
- Hep C patients may see boost with 4-drug combo therapy
- New Advances in Hep C Therapy
- Hepatitis C: Creating Better Outcomes Through Customized Adherence Programs
- SPJ Exclusive: New Hepatitis C Drugs Create Unique Opportunities, Challenges
- FDA approves Incivek for Hepatitis C
- FDA approves Victrelis for Hepatitis C
- Boceprevir Receives FDA Priority Review and EMA Accelerated Assessment
- Hepatitis C Infection Rates Are Stable
- Study: Osteoporosis is more common among patients with HIV and hepatitis C
- Blood victims' payouts increased
- Hepatitis C Can Lead to Liver Cirrhosis
- Phase 2 Trial Shows Telaprevir Lowers Hepatitis C Viral Levels In People With HIV And Hepatitis C (CROI 2011)
- Hereditary Angioedema
- CSL's Berinert Receives Expanded Approval from European Health Authorities
- CSL Behring Launches Co-Pay Assistance Program for Berinert Patients
- ViroPharma Launches ‘Moments Missed’ Campaign for Hereditary Angioedema
- Analysis Finds Improvements in Health-Related Quality of Life for Hereditary Angioedema Patients Treated with C1-Inhibitor
- FDA Allows Halozyme & ViroPharma to Resume Clinical Trials for HAE Drug
- ViroPharma Receives FDA Approval of Cinryze® (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
- CSL Behring Initiates SubQ Administration of C1-esterase Inhibitor in Patients with HAE
- Study Confirms Early Berinert Treatment Provides Faster Relief for HAE Patients
- CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
- Therapy Update: C1 Esterase Inhibitors highlighted in treatment of acute edema attacks caused by HAE
- Shire's Firazyr Wins FDA Panel Backing for Angioedema
- Halozyme, ViroPharma sign $83M licensing deal
- Hereditary Angioedema: The Unsuspected Diagnosis
- European Commission Approves Self-Administration Label for FIRAZYR(R) (icatibant) for the Symptomatic Treatment of Acute Hereditary Angioedema Attacks
- Pharming's U.S. Rhucin setback sends shares down
- HIV
- FDA Approves Bristol-Myers Squibb's Sustiva for Pediatric Patients with HIV
- FDA Says it Cannot Approve Gilead's Current Applications for HIV Treatment Regimens
- Government Halts Largest HIV Vaccine Trial After Interim Review
- Federal Guidelines Recommend New HIV Testing Method
- First HIV Baby Cured of the Disease
- Mylan Introduces HIV AIDS Drug Portfolio in South Africa
- FDA Grants Priority Review for ViiV's Dolutegravir for Treatment of HIV
- Researchers Identify a Potential HIV-Fighting Protein
- AIDS Healthcare Foundation Announces Rebranding of MOMS Pharmacy
- Researchers Develop a New Mobile Device that Performs Laboratory-Quality HIV Testing
- Early Treatment for HIV Optimal for Better Recovery
- Generic HIV Drugs Could Save Patients Financially but not Clinically
- Generic Version of HIV Therapy Receives FDA Approval
- Report Shows Cancer Drug May Eliminate Latent HIV Infection
- AIDS Foundation of Chicago Partners with Abbott to Launch Need2Know HIV
- CDC Report: Over Half of Young HIV Infected Americans Are Unaware They Have It
- UNAIDS World AIDS Day Report Shows Promising Results
- ViiV Announces Dolutegravir Reduces Virus Count in Treatment-Resistant HIV Patients
- FDA Approves Higher Strength of HIV Drug
- New Methods to Fight HIV Discovered in New Research Study, Significant Connections Made
- Study Reaffirms Effectiveness of HIV Prevention Pill
- New Common Application for HIV/AIDS Medicines Available Through Johnson & Johnson Patient Assistance Foundation, Inc.
- New Discoveries about HIV Vaccine Revealed
- Cellectis: Progress Towards a New AIDS Therapy
- Experts Determine The HIV Preventive Pill May Have Small Affect in the US
- FDA Delays Decision on Salix’s Drug for HIV-Related Diarrhea
- Gilead’s Quad Pill Receives FDA Approval for Treatment of HIV
- The US Preventive Services Task Force May Make HIV Testing A Standard Practice
- HHS Awards $68 million in Grants for HIV/AIDS Care
- Connection Between Hormonal Contraception and Tenofovir Levels Still Undetermined
- Walgreens and HHS Collaborate on Development of Medication Therapy Management Model to Help Improve Health Outcomes for HIV Patients
- New Study Finds Greatly Elevated HIV Infection Rates Among Young Black Gay and Bisexual Men in the U.S.
- U.S. Launches Interactive HIV/AIDS Database on Census.gov
- Scientists Set New Road Map for AIDS Cure
- The American Fertility Association Announces 'Family Building Options for Men with HIV'
- FDA Approves First Drug for Reducing the Risk of Sexually Acquired HIV Infection
- Gilead's HIV-Prevention Drug Truvada Experiences High Success Rates in Recent Studies
- GSK’s HIV Drug Displays Superiority to Gilead’s Atripla in a Phase III Study
- FDA Approves Over-the-Counter HIV Test
- Gilead Submits NDA for Cobicistat, HIV Drug Boosting Agent
- Walgreens, Erase Doubt and Greater Than AIDS Team Up to Give Free HIV Screenings in Honor of HIV Testing Week 2012
- The AIDS Institute Highlights Opportunities for HIV Tests to be Covered by Payers
- HIV Superinfection Rate Similar to Initial HIV Infection
- Gilead’s HIV Prevention Drug’s Expected Approval Date Delayed by FDA
- FDA Rejects Janssen’s Marketing Application for Once-a-Day HIV Drug
- HIV-Related Lymphoma Patients Benefit from Combo Treatment
- Antiretrovirals Linked to Decrease In Hospital Mortality Rates in HIV Patients
- Mylan Receives Final Approval to Launch Generic Version of Viramune
- FDA Discovers Autoimmune Reactions with Anti-HIV Drug
- FDA Approves New Labeling of Isentress
- FDA Panel Recommends First At-Home HIV Test
- Study Suggests Patients with HIV are Four Times More Likely to Die of Sudden Cardiac Death
- FDA Will Review First At-Home Test for HIV
- FDA Panel Recommends Gilead’s Quad
- FDA Panel Recommends Gilead’s Truvada for HIV Prevention
- Gilead’s Truvada Favored by FDA for HIV Prevention
- Early Phase of HIV Treatment found Safe & Acceptable
- Study Shows Gilead’s Quad Pill for HIV Effective & Less Side Effects
- Study Shows Some Cells Shielding Themselves from HIV
- Antiretroviral Drugs May Lead to Birth Defects
- Raltegravir Gets the Nod for HIV-Infected Kids & Teens
- HIV Vaccine Testing gets the Green Light!
- Edurant (rilpivirine) Approved as New HIV Treatment
- Initiation Of Antiretroviral Treatment Protects Uninfected Sexual Partners From HIV Infection (HPTN Study 052)
- HIV Causes Rapid Aging In Key Infection-Fighting Cells, Research Suggests
- Teens With HIV At High Risk For Pregnancy, Complications
- Incidence Of Hepatitis C Infection In HIV-Infected Men
- Why Did The HIV Epidemic Decline In Zimbabwe?
- HIV Protection Without Circulating Blood Antibodies
- Hormonal Therapies
- Pfizer expects to pay almost $1 Billion to settle hormone replacement litigation
- New CCI Buy Signals - AEZ, ARE, BMO, FRA, NGD.WB
- Most survivors of gynecologic cancers have menopausal symptoms
- Considering hormone replacement therapy?
- Hormonal Therapy For Older, Pregnant Horses?
- Association Between Hormone Therapy Begun At Menopause And Risk For Breast Cancer
- Immune Deficiencies
- CSL Behring Announces New Vial Size of Privigen
- Biotest Announces First Commercial Sales and Shipments of Bivigam
- Newly Passed Medicare IVIG Access Act Eases Burden of PIDD Patients
- The Immune Deficiency Foundation Announces the Medicare IVIG Access Act Passed by Congress and Goes to President
- Biotest’s Bivigam Receives FDA Approval
- New Model Compares Subcutaneous Immunoglobulin Therapy with Intravenous Immunoglobulin
- Florida to Test Newborns for SCID, a Life-Threatening Immune Disease
- Published Preclinical Data Demonstrate Ability of Gliknik's Recombinant Stradomers™ to Mimic Anti-Autoimmune Effect of IVIG
- Baxter Announces Discontinuation of GAMMAGARD S/D
- FDA Requires More Information on Baxter's Immune Globulin, Shares Plummet
- Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
- PRIMA Study Shows Treatment with Privigen® Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- IDF Requests Exemption of Immunoglobulin from Biosimilars Pathway
- FDA asks Baxter to provide more long term safety data for combination product of Immunoglobulin and Hyaluronidase.
- CSL Behring Technology & Innovation Meeting Unmet Needs of Specialty Pharmacy Market
- Hizentra Could be Effective for Treatment of PIDD
- CSL Behring Receives European Commission Marketing Authorization for Hizentra®, the first 20 Percent Subcutaneous Human Immunoglobulin for Treatment of Primary and Secondary Immunodeficiencies
- Subcutaneous Immunoglobulin Replacement Therapy with Hizentra®
- FDA approves Zostavax vaccine to prevent shingles in individuals 50 to 59 years of age
- Cancer And Blood Cell Research Benefits From $38.4M NHMRC Program Grants Scheme
- Quarter Of Girls Missing Out On Life-Saving Vaccine: New Website Aims To Reverse Trend, Australia
- Flu Vaccination At Highest Ever Level In Scotland
- Sepsis Beware: Discovery Of Protein Secreted By Roundworm Could Lead To New Treatment
- New Vector Designed For Gene Delivery
- Infectious Disease
- Savara Pharmaceuticals Begins Phase 2 Trial of AeroVanc for MRSA in Cystic Fibrosis Patients
- FDA Delays Approval of Dynavax's Hepatitis B Drug
- Synthetic Biologics to Acquire Clinical-Stage C Diff Infectious Disease Program
- NECC Co-Founder Subpoenaed; Front-Line Employees Could Lose License
- Panel Hearings Scheduled on Meningitis Outbreak
- Two New Illnesses Reported In Successfully Treated Meningitis Patients
- Meningitis Outbreak: 28 Deaths & Compounded Pregnancy Drug Under Scrutiny
- Crisis of Contaminated Drugs Spreads to 19 States, and Causes A Second Compounding Pharmacy to Shut Down
- Meningitis Outbreak Investigation Continues
- Officials Find NECC's Sterility Process Was Not Up to Standard, Number of Cases Rise to 308
- The Meningitis Outbreak Continues to Cause Scrutiny for Compounding Pharmacies & Regulatory Agents
- Federal Authorities Confirm the Meningitis Outbreak Source
- The US FDA Under Scrutiny for Improper Regulatory Actions as The Meningitis Outbreak Causes 4 More Deaths
- US FDA Warns of Additional Contaminated Drugs Made by NECC
- Meningitis Cases, Deaths Continue to Rise
- Meningitis Outbreak Due to Tainted Steroid Injections Cause 12 Deaths in the US
- MRSA Survivors Rally for World MRSA Day
- Walmart Pharmacy Offers Vaccines for Infectious Diseases
- FDA Expands Use for FilmArray Respiratory Panel
- Covalon Technologies Introduces IV Clear at the INS Meeting
- FDA Approves Levaquin for Prevention of Plague
- IDSA Proposes New Drug Approval Pathway for Antibiotics
- Increasing Shortages of Infectious Disease Drugs
- Uncomplicated Skin and Soft Tissue Infections (SSTI): A Comparison of the Old SSTI Guidelines to the New MRSA Guidelines
- Once-Weekly TB Treatment Proven Effective
- FDA clears first test to quickly diagnose and distinguish MRSA and MSSA
- Dual Vaccine Strategy Protects Against Avian Flu (CME/CE)
- HPV Vaccine Prevents Genital Warts in Young Men (CME/CE)
- Deaths Drop With ICU Care-Quality Program (CME/CE)
- Pandemic Flu Vaccine Was Safe, Chinese Say (CME/CE)
- Blood Test Spots Variant CJD (CME/CE)
- Infertility
- Village Fertility Pharmacy Recalls Two Fertility Injectables
- Study Suggests Fertility Drugs are Linked to the Risk of Developing Breast Cancer
- Human sperm gene is 600 million years old, scientists discover
- Embattled Drug Maker Halves Price of Makena
- New test to predict success of IVF treatment
- The hormone IGF-1: A trigger of puberty
- Sperm may be harmed by exposure to BPA, study suggests
- Involuntary childlessness more detrimental than originally thought, study suggests
- Lysosomal Storage Disorders
- Rates, risk factors for CV events associated with Fabry’s disease
- FDA Denies Gaucher's Disease Drug; High Jewish Incidence
- Three-Year Data From Phase 2 Trial Of Genzyme Gaucher Disease Oral Compound Suggest Sustained Or Further Improvement Across All Endpoints
- Protalix BioTherapeutics Presents Data On The Company's Fabry Program And Oral Enzyme Gaucher Program With Experts In The Field Of Lysosomal Disorders
- Synageva BioPharma Corp And To-BBB To Collaborate On Brain Drug Delivery For Rare Diseases
- Macular Degeneration
- Allergan's Trial for its Macular Degeneration Drug is Delayed, Causing Shares to Drop
- NICE Recommends Novartis' Lucentis for Patients with Diabetic Macular Edema
- Study Associates Regular Aspirin Use with Macular Degeneration
- Novartis’ Lucentis Wins Backing from NICE
- Long-Term Aspirin Use in Older Adults Linked to Higher Risk of Macular Degeneration
- European Commission Approves Eylea for Wet AMD
- FDA Approves Jetrea for VMA's
- EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Wet Age-Related Macular Degeneration in Europe
- Novartis Trial Data Confirms Benefits of Lucentis
- FDA Approves Lucentis for DME
- Fuse Science Announces Landmark Licensing Agreement with Industry Leader Macular Health
- New Study Links Avastin with Risk of Intraocular Inflammation for Patients with AMD
- Ophthotech’s Fovista Meets Endpoint for AMD
- New Device in Development that could Restore Sight for Patients with AMD
- Positive Results for Novartis' Lucentis
- Avastin & Lucentis Yield Similar Improvements for Patients with AMD
- Major Breakthrough in Understanding Macular Degeneration
- Study Links Macular Degeneration with Increased Risk of Stroke
- OIG Investigators Request CMS to Establish A National Payment Policy for Avastin
- Novartis Challenges the NHS for Use of Avastin for Wet AMD
- Study on Bevacizumab for Neovascular Age-Related Macular Degeneration
- European Study Finds Frequent Aspirin use Associated with Early AMD and Wet Late AMD
- Genentech diabetic macular edema drug meets primary endpoint
- Brain Hemorrhage Risk Higher With Late Macular Degeneration
- Advanced Macular Degeneration Is Associated With An Increased Risk Of Bleeding Stroke In Elderly
- Report: Affordable Care Act Controls Costs For Early Retiree Coverage
- Looking For Ways To Bridge Generational Technology Gap
- Multiple Sclerosis
- Study Shows Thalamic Atrophy Associated with Multiple Sclerosis
- FDA Approves Biogen's Tecfidera for Multiple Sclerosis
- Genzyme's Aubagio is Recommended for Approval by the EMA
- Biogen's Multiple Sclerosis Drug is Recommended for Approval in the EU
- Biogen's Multiple Sclerosis Drug Receives Patent Extension from the US Patent and Trademark Office
- Biogen Releases Positive Results for Tysabri
- Teva Enrolls First Patient in Its Third Phase III Study Evaluating Its Multiple Sclerosis Drug
- Genzyme's Multiple Sclerosis Treatments Receive Positive News
- Biogen Announces Positive Results for its Multiple Sclerosis Drug
- Biogen and Elan Submit Applications Requesting Expanded Indication for Tysabri
- Teva Files Petition Requesting that the FDA not Approve New MS Drugs
- Vaccinex Initiates Phase 1 Trial for Experimental Multiple Sclerosis Treatment
- Rebif Rebidose Receives FDA Approval
- Study Suggests Eye Scan May Show Progression of Multiple Sclerosis
- Trials Show Lemtrada May Be Useful for Treating MS, But Costs May Be Too High
- FDA Extends Review of Biogen's Multiple Sclerosis Drug
- Biogen Announces Positive Data for Oral MS Drug
- EMD Serono Launches $1.3 Million Research Grant for Multiple Sclerosis Innovation
- Some Physicians Still Using MS Procedure Despite FDA Warning
- Sanofi’s MS Drug Aubagio Gets FDA Approval
- Teva Begins Third Round of Research for its Experimental MS Drug
- New Findings Between MS and Vein Trouble
- Low Dose Ampyra Fails to Confirm Efficacy for MS Patients
- Teva & Active Biotech Announce a Phase III Trial for their MS Drug
- New ALS Study Suggests that Lou Gehrig's Disease Progression May Be Tracked With Simple Blood Test
- FDA Warns Ampyra Increases the Risk of Seizures in MS Patients
- Brain Lesions in MS Patients Reduced by Stress Management
- Department of Defense Awards SRI International with a Grant for Oral MS Drug
- Multiple Sclerosis Association of America's MRI Institute Marks 10 Years of Helping Individuals with Multiple Sclerosis Obtain MRIs
- Teva's New Version of MS Drug Meets Goals in Late-Stage Clinical Trial
- Genzyme Submits Applications for Approval of Lemtrada for Patients with Relapsing MS
- Genzyme's MS Drug Reduces Symptoms in their Phase 3 Study
- World MS Day 2012: Raising Global Awareness
- Growth Factors in Stem Cells May Spur Recovery from Multiple Sclerosis
- Researchers Identify Most Likely MS Patients to Develop a Rare Brain Infection
- FDA Issues A Safety Announcement for Gilenya in Patients with Certain Heart Conditions
- FDA Warns of Risks Associated with MS Liberation Therapy
- US & EU Regulators Accept Biogen’s MS Drug Application
- Biogen Idec Announces Positive Results for MS Drug
- Novartis Changes Gilenya’s Warning Label
- Use of Drug Following First Sign of Possible MS Reduces Likelihood of Progression to MS
- Experimental MS Drug Shows Positive Results
- FDA Cites Biogen for Inappropriate Marketing of Avonex
- New MS Pill Delays Disability
- Prime Therapeutics Contracts with EMD Serono for Rebif
- Biogen’s MS Autoinjector Pen Approved
- 11 Deaths Put Novartis’ Pill Gilenya Under Review
- PML Risk Test for Patients on Tysabri is FDA Approved
- New Imaging Data Back Teriflunomide for Multiple Sclerosis
- Multiple sclerosis is more aggressive in children but slower to cause disability than in adults
- Factors from common human bacteria may trigger multiple sclerosis
- Early protein processes crucial to formation and layering of myelin membrane
- Glial cells can cross from the central to the peripheral nervous system
- Modifying Neural Stem Cells Improves Their Therapeutic Efficacy
- Nephrology
- Amgen's Melanoma Drug Meets Primary Endpoint in its Phase III Trial
- Failed Biologic in Kidney Disorder
- FDA Okays Omontys for Treatment of Anemia in Patients on Dialysis
- Gene Variant Protects Against Anemia in HCV Tx (CME/CE)
- Performance Incentives Flop in Hypertension (CME/CE)
- Diabetes Rising in U.S., CDC Reports
- tPA Busts Dialysis Catheter Complications (CME/CE, with audio)
- Disparities Cut Both Ways in Nephrology (CME/CE)
- Lab Notes: Cancer Drug May Shine in Spinal Injury
- GSK Settles More Avandia Suits
- Control of Cardio Risk Factors Lags
- Waistlines Expand Worldwide (CME/CE)
- CV Risk Factors Often Uncontrolled in Uninsured
- Type 1 Diabetes Linked to Viruses (CME/CE)
- Lab Notes: Caps May Sharpen the Intellect
- New Avandia Label Spells Out Restrictions
- Tumor Genes Yield Hypertension Clues (CME/CE)
- ASA: Early BP Lowering No Help in Acute Stroke (CME/CE)
- Oncology
- Sanofi's JAK2 Inhibitor Meets Primary Endpoint in Late-Stage Trial for Treatment of Myelofibrosis
- Gilead Announces Positive Phase II Trial Results for its Leukemia Drug
- Roche's Investigational Leukemia Drug Shows Impressive Results in Its Phase III Trial
- Bristol-Myers Squibb's Combination Treatment Demonstrates Promising Results for Patients with Advanced Melanoma
- Merck's Investigational Lung Cancer Drug Fails to Meet its Primary Endpoint in a Phase III Trial
- AstraZeneca Plans to Move Three Cancer Compounds to Phase III Development
- FDA Approves Bayer's Prostate Cancer Drug
- Roche's Tarceva Tablets and Cobas EGFR Mutation Test Receives FDA Approval
- The University of Colorado Signs Licensing Agreement with Syndax for Novel Cancer Treatment Approach
- Use of Statins Prior to Diagnosis Reduced Prostate Cancer Mortality
- CytRx Discontinues Tamibarotene Trial and Focuses on Aldoxorubicin and Expanded Oncology Pipeline
- Lilly Discontinues Development of Enzastaurin After Phase III Trial Results
- GenomeDx Releases Positive Results for Decipher in Predicting Metastasis for Prostate Cancer Patients
- Eisai Files for Expanded Indication to the EMA for its Breast Cancer Drug
- FDA Warns Risk of Confusing Kadcyla and Herceptin While Using Generic Names
- Janssen's Investigational Multiple Myeloma Drug Receives Breakthrough Therapy Designation from the FDA
- OncoGenex Initiates Phase II Trial Evaluating Bladder Cancer Drug
- Oxford BioTherapeutics and Boehringer Ingelheim Collaborate for Discovery of Novel Cancer Antibody Targets
- PhRMA Reports Over 240 Medicines in Development for Treatment of Blood Cancers
- Delaying Initiation of Treatment Among Young Women with Breast Cancer Significantly Decreases Survival Rate
- Merck's Investigational Cancer Drug Receives Breakthrough Therapy Designation
- Horizon and AstraZeneca Partner for Development of Novel Cancer Therapies
- AstraZeneca and BIND Therapeutics Collaborate on Nanotech Drug for Cancer Treatment
- Epizyme and Abbott Enter Agreement for Companion Diagnostic Test for Cancer
- Study Shows One-Quarter of Cancer Patients & Caregivers are Dissatisfied with Cancer Care
- FDA Clears Elekta's Versa HD for Shipping and Installation in the US
- FDA Grants Breakthrough Therapy Designation for Pfizer's Breast Cancer Drug
- Janssen Announces Release of Doxil to Market
- Cleave Biosciences Receives $10 Million Investment from NEA to Fund its Lead Cancer Program
- Millennium's Velcade Shows Strong Results in Meta-Analysis for Patients with Multiple Myeloma
- Ibrutinib Receives Third Breakthrough Therapy Designation from the FDA
- Astellas and Ambrx Collaborate for Development of Cancer Products
- Navidea Announces Results of Lymphoseek in Patients with Head and Neck Cancer
- Varian Medical Systems Highlights its Calypso for Reduced Risk of Heart Disease following Breast Cancer Treatment
- NICE Issues Final Draft Guidance Not Recommending Pfizers Kidney Cancer Drug
- Ziopharm Terminates Development of Cancer Treatment Palifosfamide
- NICE Rejects Novartis’ Afinitor for Breast Cancer
- Study Shows Genetic Variations have Major Impact on Childhood Leukemia Risk
- Seattle Genetics Submits Supplemental Biologics License Application for Adcetris
- Galena Biopharma Agrees to Acquire Abstral for Oncology Pain
- Study Shows New Role for Abiraterone in Blocking Tumor Growth for Patients with Castration Resistant Prostate Cancer
- FDA Grants Novartis' Compound LDK378 Breakthrough Therapy Designation
- Navidea's Lymphoseek Receives FDA Approval
- Researchers Discover Possible Origin of Ovarian Cancer
- Aeterna Zentaris Discontinues Its Phase III Trial for Multiple Myeloma Treatment
- Ceptaris Resubmitted a New Drug Application for Its Lymphoma Treatment
- FDA Clears Philips' Mammography System
- Janssen and Araxes Collaborate for Development of Cancer Treatment
- Ablynx and Spirogen Collaborate for Development of an Anti-Cancer Drug
- FDA Expands Approval of Stivarga for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
- Merck's Brain Cancer Drug Fails to Meet Primary Endpoint in Its Phase III Trial
- FDA Approves Kadcyla for Treatment of Advanced Breast Cancer
- Valeant Pays $65 Million Upfront to Eisai for Rights of Targretin Capsules and Gel
- Abbott to Collaborate with Janssen and Pharmacyclics on Development of Companion Test for Investigational Leukemia Therapy
- Erlotinib & Celecoxib, in Combination, Shows Response in Children With Head And Neck Cancer
- FDA Grants Special Protocol Assessment for Puma’s Breast Cancer Drug
- Peregrine Revises Results from its Lung Cancer Trial
- Research Team Stops Progress of Colon Cancer
- Peregrine Announces Positive Results for Bavituximab in Patients with Pancreatic Cancer
- Third Rock Forms Jounce Therapeutics for Discovery and Development of Cancer Treatments
- FDA Grants Priority Review for Algeta and Bayer's Oncology Drug
- ZIOPHARM’s Palifosfamide Reaches Target Number of PFS Events in First-Line Metastatic Soft Tissue Sarcoma
- Study Shows Nurses Involvement with TheONC.org Improves Care for Cancer Patients
- FDA Grants Pharmacyclics Ibrutinib Breakthrough Therapy Designation
- The FDA Approves Celgene’s Pomalyst and Accepts Its Filing for Revlimid for Multiple Myeloma Patients
- Study Discovers a New Protein to Target for Treatment of Lymphoid Leukemia
- Oncolytics Announces Positive Results from Its Phase II Lung Cancer Clinical Trial
- FDA Warns of Counterfeit Versions of Injectable Cancer Drug
- FDA Approves Generic Version of Cancer Drug to Assist with Drug Shortages
- Celsion's Experimental Liver Cancer Treatment Fails in Late-Stage Trial
- Genentech's Investigational Cancer Drug Meets Primary Endpoint and Shows Superiority Compared to Rituxan
- Generex Provides a Status Update on its Cancer Immunotherapy Product
- Merck Initiates Phase III Study of Investigational Pancreatic Cancer Drug, Earning Threshold a $30 Million Milestone Payment
- FDA Approves Novartis' Gleevec for Pediatric Patients with Leukemia
- Study Projects High Impact of Prostate Cancer in 2013
- The Leukemia & Lymphoma Society and Avella Specialty Pharmacy Present Free Chemotherapy Program
- FDA Approves New Use of Genentech's Avastin for Patients with Colorectal Cancer
- Researchers Discover Gene Variant that Drives Breast Cancer Spread
- EntreMed Initiates Phase II Trial for Metastatic/Soft Tissue Carcinoma
- Celgene's Abraxane Shows Promise in Phase III Study for Treatment of Pancreatic Cancer
- The National Comprehensive Cancer Network (NCCN) Includes NovoTTF Therapy in its Guidelines as a Standard Treatment Option
- New Childhood Cancer Prevention and Screening Clinic Announced by Texas Children's Cancer Center
- Important Discovery Made that Could Lead to Better Detection and Treatment of Prostate Cancer
- Boehringer Ingelheim's Investigational Oncology Compound is Granted Priority Review
- The FDA Accepts Astellas' New Drug Application for Its Lung Cancer Drug
- Kaiser Study Shows PSA Measurements Over Time Improve Accuracy of Detecting Prostate Cancer
- Horizon Discovery and Boehringer Ingelheim Enter Collaboration Agreement to Advance Oncology Research
- ArQule and Daiichi Announce Phase 2 Results for Colorectal Cancer Drug
- FDA Grants Fast Track Designation for GTx’s Enobosarm
- The European Group for Blood and Marrow Transplantation Selects Remedy Informatics as Registry Solution
- Adventist Medical Center Provides Advanced Cancer Treatment Technology
- Nexavar Meets Primary Endpoint in Phase III Study for Thyroid Cancer
- Sphingotec Announces Launch of Test for Prediction of Breast Cancer
- Dune Medical Devices Receives FDA Approval for Breast Cancer Assessment Tool
- Watson Confirms Patent Challenge for Oncology Drug
- Bladder Cancer Treatment May Be Shaped by Gene Variation
- National Shortage of Cancer Drug Linked to Higher Relapse Rates in Children
- Merck's Investigational Non-Small Cell Lung Cancer Drug Did Not Meet Its Primary Endpoint
- University of Florida Oncologists Tracking Metastatic Cancer with New Device
- Bayer Submits a New Drug Application to the FDA for Prostate Cancer Drug
- FDA Approves Ariad's Leukemia Drug
- Boehringer Ingelheim Will Initiate a Phase III Study for Experimental Acute Myeloid Leukemia Drug
- Celgene’s Experimental Multiple Myeloma Drug Demonstrates Significant Progression-Free and Overall Survival Improvement
- Seattle Genetics Highlight Clinical Data from Genentech's Two Anti-Body Drug Conjugate Programs
- FDA Expands Approval for J&J’s Zytiga
- MD Anderson & GSK Collaborate to Develop New Approach to Cancer Immune Therapy
- Ariad Presents Positive Results for CML Drug
- Trials Suggest Pharmacyclics’ Ibrutinib Showed High and Durable Response in Chronic Lymphocytic Leukemia
- Lilly & Arcolab Collaborate to Expand Delivery of Cancer Medications in Emerging Markets
- Longer Use of Tamoxifen May Reduce Breast Cancer Deaths
- Pfizer’s Experimental Breast-Cancer Drug Shows Promising Results
- Exelixis Selects Diplomat Specialty Pharmacy as the Exclusive Distributor for Cometriq
- Study Shows Aspirin Reduced Risk of Developing Liver Cancer
- Study Shows Diabetes Drug May Treat Ovarian Cancer
- FDA Approves Cometriq for Treatment of Medullary Thyroid Cancer
- FDA Agrees to Review Experimental Kidney Cancer Drug
- Study Shows Tivantinib Effective As Second-Line Therapy for Certain Patients with HCC
- Study Shows Avastin Effective for Newly Diagnosed Glioblastoma Patients
- CSPN Signs Distribution Agreement with Dara BioSciences for Soltamox
- Genzyme Announces Supply of Oncology Drug, Thyrogen, Has Been Fully Restored
- Celgene's Pancreatic Cancer Drug Met Primary Endpoint in Phase III Study
- Study Suggests Statins May Reduce Risk of Cancer-Related Death
- FDA Grants Priority Review for Genentech's Breast Cancer Treatment
- Supermolecule Could Detect Cancer Early to Help Destroy Tumors and Monitor Treatment
- OncoGenex Completes Patient Enrollment for Phase 3 Study For Prostate Cancer Drug
- MorphoSys and Xencor Report Clinical Data for CLL Drug
- NICE Issues Final Draft Guidance Recommending Two New Treatments for Advanced Malignant Melanoma
- J&J Announce New Supplies of Crucial Cancer Drug in Europe
- Celldex Announces Positive Results in Early Study for Experimental Tumor Vaccine
- Oncology Systems Limited Signed a Multi-Year Research & Collaboration Agreement with UHB
- FDA Approves Teva’s Leukemia Drug
- FDA Grants Priority Review of Ariad Leukemia Drug
- Celgene’s Multiple Myeloma Drug Meets Primary & Secondary Endpoints in a Phase III Study
- Study Finds GSK/Abbott Combo Kills Triple-Negative Breast Cancer Cells
- Study Shows Long-Term Use of Multivitamins May Lower Cancer Risk Among Men
- BMS’ Metastatic Melanoma Drug, Yervoy Received the Prix Galien USA 2012 Award for
- Pfizer’s Inlyta Misses Primary Endpoint in Trial for Advanced Renal Cell Carcinoma
- Lilly's Gastric Cancer Drug Meets Its Primary Endpoint in A Phase 3 Study
- Celgene Announces FDA Approval of Abraxane for Non-Small Cell Lung Cancer Drug
- Cancer Vaccine Demonstrates for 1st Time that a DNA-Based Therapeutic Vaccine Can Produce Immune Responses to Kill Target Cells
- Oxford BioMedica Closes US Study for TroVax for Treatment of Prostate Cancer
- Aragon Raises $50 Million to Advance Their Cancer Pipeline
- Celgene Announces FDA's Decision Against Meeting for Cancer Drug
- Merrimack Pharmaceuticals’ Therapies Show Promise in Certain Advanced Breast, Gastric and Gynecological Cancers
- Quest PharmaTech Acquires Immunoglobulin E Technology to Strengthen its Combination Therapy Approach for the Treatment of Cancer
- New Boehringer Ingelheim Data to be Presented on Health-Related Quality of Life with Afatinib in Patients with EGFR Mutation-Positive Advanced NSCLC
- FDA Approves Stivarga for Colorectal Cancer
- High-Dose Vitamin C Reduces Inflammation in Cancer Patients Study Shows
- Peregrine Says Lung Cancer Trial Data Erroneous, Shares Sink
- Astex Pharma Ends Development of Lung Cancer Drug
- U.S. House of Representatives passes Recalcitrant Cancer Act (H.R. 733)
- New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- New Imaging Device for Dense Breasts Approved for Cancer Detection
- Lundbeck Notifies Physicians of Discontinuation of Their Leukemia Drug, Elspar
- Kaiser Permanente Study Finds Least Aggressive Form of Breast Cancer Still Poses Risk for Death Years Later
- Scientists Develop A Nose-Like Sensory For Cancer Diagnoses
- Genomic Health Announces Positive Topline Results of Large Prostate Cancer Clinical Validation Study; Company to Proceed with 2013 Commercial Launch
- NIH Study Documents Genetic Mutation That Increases Production of Red Blood Cells in Tumors
- Possible Misleading Data on Threshold’s Prostate Cancer Drug Results in A Major Drop in Stock
- Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
- Oncolytics Lung Cancer Drug Meets Main Goal in Mid-Stage Trial
- Generex Biotechnology Announces Presentation of Early Results Showing Activity of Cancer Vaccine in Patients with Triple Negative Breast Cancer
- Oncodesign Enters into Agreement with Sanofi for Oncodesign’s Nanocyclix Technology for Advancement of Kinase Programs
- FDA Postpones Approval of Navidea’s Lymphoseek for Cancer Patients
- Geron Halts Breast Cancer Trial, Stock Hits Life Low
- Pfizer & SFJ Collaborate to Develop A New Lung Cancer Drug
- Walgreens and Ferring Collaborate to Provide Free Access to Fertility Products for Women with Ovarian Cancer
- Eli Lilly's Lung Cancer Trial Fails to Meet Primary Endpoint
- Faster Approvals for Oncology Drugs than Non-Oncology in the US, But Not in the EU
- Merck Serono Announce An Exclusive Worldwide License Agreement with Symphogen for Treatment of Colorectal Cancer
- Pfizer’s Leukemia Drug Bosulif Receives FDA Approval
- Gene Sequencing Project Builds the Foundation for Next Generation of Childhood Cancer Care
- Xtandi Receives FDA Approval for Patients with Prostate Cancer
- Ariad Submits Marketing Authorization Application for Ponatinib to the EMA
- FDA Approves Afinitor Disperz for Pediatric Patients With A Rare Brain Tumor
- Treatment for Severe Neutropenia in Select Cancer Patients Gets FDA Nod
- FDA Grants Priority Review for Janssen’s Zytiga
- New Study Suggests NSAIDs Not Linked to Breast Cancer Risk
- Roche’s Breast Cancer Drug Improves Survival in Breast Cancer Patients
- Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Metastatic Soft Tissue Sarcoma
- Biodesix Announces New VeriStrat® Data to be Presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology
- NICE Says Avastin’s Benefits Do Not Justify Its Cost for Treatment of Metastatic Breast Cancer
- Updated Oncology Guidelines Reflect the Needs of Obese Patients
- Patient Advocate Foundation Receives Significant Support to Aid Non-Squamous Non-Small Cell Lung Cancer Patients through the Co-Pay Relief Program
- Cancer Treatment Potential Found in “Nanojackets”
- At-Home Kits Increase CRC Screening
- Pre-Test Genetic Counseling Benefits Breast Cancer Patients
- Study Shows New Drug Extends Survival for Prostate Cancer Patients
- Denosumab Shows Superiority for Bone Complications in Patients with Breast Cancer
- Biovest Conducts Phase III Review for their Consolidation Therapy in Non-Hodgkin’s Lymphoma
- Treatment for AML May be Improved Due to Gene Discovery
- New Research Triggers a Need for Updated Guidelines on Radiation for Older Breast Cancer Patients
- Bladder Cancer Advocacy Network Announces Major Research Program at Annual Scientific Meeting
- Effects of Daily Aspirin Intake and Risk of Cancer Death Reevaluated
- Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC)
- Supplements Taken During Hormone Depletion Therapy Shown to Increase Cancer Risk
- Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
- FDA Approves Talon's Marqibo for Adults with Rare Leukemia
- Hospira Re-launches its Generic Chemotherapy Treatment
- Agennix’s Experimental Lung Cancer Drug Fails to Meet Primary Endpoint, Shares Fall
- New Class of Cancer Drugs Reduces Cellular Damage from Chemo
- PLX Cells Save Another Life of a Cancer Patient Encouraging Pluristem to Apply for FDA Orphan Drug Approval
- OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
- Zaltrap Gets FDA Approval for Patients with Metastatic Colorectal Cancer
- Ariad Announces Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration
- Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
- Researchers at University of Tennessee Develop Laser that Maps and Zaps Cancerous Tumors
- Enzalutamide Granted Priority Review by U.S. FDA for the Potential Treatment of Castration-Resistant Prostate Cancer in Patients Previously Treated With Chemotherapy
- Biokine Therapeutics Awarded FDA Orphan Drug Designation for Mobilization of Stem Cells in Cancer Patients
- Novartis’ Afinitor Receives FDA Approval for Patients with Advanced Breast Cancer
- FDA Grants Accelerated Approval for Onyx’s Kyprolis Injection for Multiple Myeloma Patients
- BMS' Liver Cancer Drug Fails to Meet Primary Endpoint
- Galena Awarded Patent For Vaccine To Prevent Breast Cancer Recurrence
- Colon and Rectal Tumors Represent a Single Type of Cancer Study Shows
- Vitamin E Intake Associated with Reduced Risk of Liver Cancer
- Four Cancer Drugs with Glass Particles Recalled by Hospira
- New Tools Help Match Cancer Drugs with Gene Targets
- Eisai’s Halaven Does Not Meet Primary Co-Endpoints in Study
- New Guideline Recommendations for Sentinel Lymph Node Biopsy in Melanoma Patients
- $2.5 million gift to establish new treatment center
- Qiagen’s Gene Testing Kit Approved to Identify Patients who will Benefit from Erbitux
- Merck’s Stomach Cancer Drug Fails in Late-Stage Trial
- Zytiga Plus Prednisone Show Improvements in Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer
- Leukemia and Lymphoma Society to Provide Additional $5 Million for Celator's Phase 3 Study of Acute Myeloid Leukemia Drug
- Roche Announces FDA Approval of HIV Viral Load Test
- The FDA Granted Priority Review Designation to Bayer’s NDA for Regorafenib for Colorectal Cancer
- Texas Children's Cancer Center Receives $10 Million Gift to Open The Fayez Sarofim Lymphoma Center
- FDA Approves Blood Test for Detection of Prostate Cancer
- Recommended New Lung Cancer Screening Guidelines
- New Legislation To Make USPSTF More Transparent: Prostate Cancer Roundtable Supports Reform
- New Candidate Drug Stops Cancer Cells, Regenerates Nerve Cells
- New Research Reveals Some Natural Supplements Effective Against Prostate Cancer
- CMTP Publishes Patient-Reported Outcomes Guidance for Adult Cancer Trials
- Gene Sequencing Project Identifies Potential Drug Targets in Common Childhood Brain Tumor
- Health Regulators Say Carfilzomib's Benefits Outweigh its Risks for Patients with Multiple Myeloma
- Inostic’s BEAMing Technology Detects Cancer Resistance through Blood Tests
- Research Shows "Common Cold" Virus Helps Fight Cancer
- Immunomedics Develops Potential New Treatment Regimen For Non-Hodgkin Lymphoma
- Quest PharmaTech Initiates Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in United States
- Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
- Tokai Pharmaceuticals’ Galeterone Receives Fast Track Designation from the FDA for the Treatment of Advanced Prostate Cancer
- Diesel Exhaust Fumes Linked to Lung Cancer
- Patients with Advanced Prostate Cancer Find Hope in Radioisotope Therapy
- Mevion S250 Patented Technology Significantly Reduces the Cost of Implementing and Operating Proton Therapy Centers
- FDA Approves Roche's Drug for Patients with HER2 Positive Metastatic Breast Cancer
- CT Scans Increase Risks of Cancer in Children
- Study Results Realeased at 2012 ASCO Meeting Proves Chemotherapy Superior to Targeted Treatment
- FDA Demands More Information for Merck/Ariad's Experimental Sarcoma Treatment
- Shortages of Oncology Drugs on The Decline
- Ariad’s Ponatinib Shows Signs of Promise for Leukemia Patients
- Combination Therapy for Inflammatory Breast Cancer Deemed Clinically Insignificant by Researchers
- Pharmacyclics® Announces Updated Results for BTK Inhibitor Ibrutinib at ASCO
- Roche’s Cancer Drug Delays Tumor Growth for Patients with Breast Cancer
- Personalized Exercise May Increase Cancer Patients’ Survival
- Boehringer Ingelheim and CancerCare Launch My Cancer Circle
- Prime Enhances Its Oncology Management Program
- Clinical Pathways Can Help Manage Cancer Patients
- Anti-Inflammatory Drugs Shown to Reduce Risk of Skin Cancer
- Bayer Submits NDA to the FDA for their Colorectal Cancer Drug
- MRI’s Best for Tracking Chemo Response for Patients with Breast Cancer
- Breast Cancer Tumors Reduced by Celldex’s Cancer Drug
- Urologists Protest Government Panel's Recommendation to Stop PSA Tests
- Recommended Guidelines for Lung Cancer Screening
- Cancer Death Risk Increased by Sleep Apnea
- Study Shows Sigmoidoscopy Reduces Colorectal Cancer Rates
- New Drug Shows Positive Results for Elderly Patients with Chronic Leukemia
- J&J’s Prostate Cancer Drug Shows Good Results
- Early Results Show Promise of Breast Cancer Vaccine
- Experimental Combo Drug for Melanoma Slows Cancer
- Study Shows Pfizer’s Xalkori Eliminates Certain Child Cancers
- Study Results Show Pazopanib’s Benefits for Patients with Metastatic Soft-Tissue Sarcoma
- Early Biomarker Identified for Pancreatic Cancer
- Studies Show Positive Results for Multiple Myeloma Patients
- New Imaging Technique Found for Locating Rare Pancreatic Tumors
- Infections Responsible for 2 Million Cancer Cases
- Non-Embryonic Stem Cell Treatment Promising Cancer Cure
- Takeda Announces Initiation of Phase III Aethera Trial of Brentuximab Vedotin for Post-Transplant Hodgkin Lymphoma
- FDA Revises Revlimid's Label Warning Against Increased Risk of Second Primary Malignancies
- Breast Cancer in Men May Be More Deadly
- Walgreens Adds Six Medications to Oral Oncology Clinical Program
- Improvement in Treatment of Melanoma with Personalized Medicine
- FDA Rejects the Expanded Indication for Xgeva
- GSK’s Votrient Receives FDA Approval for Soft-Tissue Sarcoma
- New Interim Guidance Criteria from ALA Regarding CT Screening for Lung Cancer
- NICE Found Unclear Data of Avastin as a First-Line Therapy
- FDA Grants Zaltrap Priority Review Designation
- Study Suggests Long-Term Estrogen Therapy Increases Risk of Breast Cancer
- Study Shows Olaparib Slows Ovarian Cancer
- Ipilimumab Benefits Melanoma with Brain Metastases Patients
- Promising Experimental Vaccine for Melanoma
- GSK’s Votrient Received Positive Votes from ODAC
- Daily-Use of Aspirin may Fight Cancer
- Many Patients on Newer Oncology Treatments Are at Risk for Drug Interactions
- Are Specialized Centers a Better Option for Cancer Patients?
- Increasing Survival Rate of Children with Leukemia
- J&J’s Trial Shows Zytiga Benefits Pre-Chemo Treatment for Patients with Prostate Cancer
- Estrogen-Alone May Reduce Risk of Breast Cancer
- Takeda’s Lymphoma Drug Starts its Phase 3 Trial
- Abbott & Merck Collaborating on FISH-Based Diagnostic Test for Cancer Therapy
- Sleeping Pills Associated with Increased Risk of Death & Cancer
- Counterfeit Avastins’ Contents Determined
- Researchers Found New Melanoma Drug Almost Doubles Life Expectancy
- FDA Assists in Increasing Supply of Cancer Drugs
- AstraZeneca’s Direct-to-Patient Program for ARIMIDEX
- Genzyme Recalls 9,380 Vials of Leukemia Drug, Fludara
- Counterfeit Versions of Avastin Found in the U.S.
- Children's Leukemia Drug in Short Supply
- FDA Panel Votes Against Prostate Cancer Drug
- Genentech’s Breast Cancer Drug on FDA Priority Review
- Decreased Bone Density Risk in Breast Cancer Prevention Drug
- Will SB161 Pass, Allowing Physicians to Dispense Oral Cancer Drugs?
- FDA Okays Vismodegib for Treatment of Advanced Forms of Basal Cell Carcinoma
- Debate Over Avastin in Breast Cancer
- FDA Approves Subcutaneous Delivery of Bortezomib
- Study Shows Roche's Zelboraf Triggers Other Skin Cancer Growth
- A Promising Study for Bayer Colorectal Cancer Drug Regorafenib
- BTG's Drug for Cancer Toxicity Receives FDA Approval
- Risk of Cancer Counterfeits due to Drug Shortages
- FDA Issues Warning Against Drug Brentuximab
- Familial Prostate Cancer Mutation Found
- KRAS-Positive NSCLC Gives Mixed Results for Sorafenib
- Chemokine Agonists May Block Myeloma Disease
- FDA REVOKES APPROVAL OF AVASTIN FOR BREAST CANCER
- Affymax Announces FDA Advisory Committee Will Review Peginesatide
- FDA Approves Pfizer's Xalkori
- FDA Modifies ESA Dosing Recommendations
- Six-Month Lupron Formulation Receives FDA Approval
- New Oxycontin Formulation, Oxecta, Approved for Pain
- Breast Cancer Genetic Marker Test Approved by FDA
- ASCO 2011: Bevacizumab Extends Progression-Free Survival in Recurrent Ovarian Cancer
- Urocidin(TM) May Hold Promise as Bladder Cancer Treatment
- One-tenth of Cancer Patients Fail to Fill Initial Oral Oncolytic Prescription
- Roche's Vemurafenib Filed with Companion Diagnostic
- FDA approves Zytiga for late-stage prostate cancer
- Breast Fat Injection Causes Confusion on Mammograms
- Immediate Implant Replacement Provides New Option for Reconstruction After Mastectomy
- FDA approves new treatment for a type of late-stage skin cancer
- Sweeping View Of Prostate Cancer Genome Yields Deep Insights
- Studies Show New Bone Marrow Biopsy Technology Delivers Superior Samples, Less Pain When Compared To Manual Devices
- Purdue University Researcher's Technology Listens To Cancer Cells, Shows Effects Of Drug Therapies
- Diamyd Medical: Diamyd Phase II Study In Cancer Pain Posted On ClinicalTrials.gov
- EU Initiative In Research Into Living Cancer Cells In Time And Space
- Osteoarthritis
- Study Shows ZyCal's Cyplexinol Decreases Pain and Stiffness and Increases Quality of Life for Osteoarthritis Patients
- Evidence Presented Linking Obesity with Osteoarthritis
- Watson’s Generic Arthritis Drug Receives ANDA
- Liver Injury Linked to Arthritis Medication
- Uric Acid May Increase Likelihood Of Severe Osteoarthritis
- ADX71943 Effective In Osteoarthritis Pain Model: Addex Pharma
- GSK and BJD collaborate on a new educational programme to reduce global burden of joint pain
- Convergence Pharmaceuticals Successfully Launched out of GSK to Focus on Novel High Value Analgesics
- Pfizer Suspends Tanezumab Osteoarthritis Clinical Trial Program
- Osteoporosis
- Kaiser's Study Shows Nearly 30 Percent of Women with Osteoporosis Don't Pick up Prescriptions
- FDA Panel Recommends the FDA No Longer Support Calcitonin Salmon Products for Treatment of Osteoporosis
- Merck Announces Positive Results from a Phase II Trial for Osteoporosis Drug in Post-Menopausal Women
- Osteoporosis Drug, Binosto, Now Available in the US
- Amgen’s Osteoporosis Drug Gets Expanded Indication
- Merck’s Osteoporosis Drug Trial Stopped Early due to Apparent Effectiveness
- FDA says Shortages of Injectable Boniva in Short Supply
- Bisphosphonate Linked with Atypical Femur Fractures
- The National Osteoporosis Foundation Commends the FDA for Analysis of Long-Term Bisphosphonate Treatment
- Generic Boniva Approved for Osteoporosis
- Implantable Microchip Delivers Medication for Osteoporosis
- Nycomed's novel COPD therapy roflumilast receives FDA approval
- Commonly Prescribed Osteoporosis Drug Associated With Very Low Risk Of Serious Jaw Disease
- Poor Status Of Post-Fracture Care And Osteoporosis Management In Eastern Europe And Central Asia Of Concern
- Daxas® (Roflumilast) included as a new treatment option in latest international COPD guidelines
- Prolia(TM) (denosumab) Receives Best New Drug Honor at Scrip Awards
- Postpartum Hemorrhage
- Psoriasis
- Celgene's Psoriasis Treatment Meets Primary Endpoint in Phase III Study
- Galapagos Announces Initiation of Phase II Study for Psoriasis & SLE Treatment
- Celgene's Psoriasis Drug Meets Primary and Secondary Endpoints in Phase III Trials
- Actelion's Psoriasis Drug Achieved Its Main Goal in a Mid-Stage Trial
- Janssen Submits Applications for Approval of Stelara for Psoriatic Arthritis
- Perrigo Announces FDA Approval of Scalp Psoriasis Treatment
- Novartis Announces Positive Data for Experimental Psoriasis Drug
- TNF Inhibitors May Lower Heart-Associated Risks for Psoriasis Patients
- New Data For Stelara® 5-Year Study Shows Consistent Efficacy and Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis
- New Experimental Drugs for Psoriasis
- CalciMedica Initiates Phase I Clinical Trial Of First CRAC Channel Inhibitor (CCI) For Psoriasis
- New Psoriasis Guidelines Stress Importance Of Individualized Treatment Plans
- Eczema In Children Not Improved By Ion-Exchange Water Softeners
- Anacor Pharmaceuticals Announces First Patient Dosed In A Phase 2b Trial Of AN2728 For Psoriasis
- Psoriasis And Obesity Linked
- Pulmonary Arterial Hypertension
- Bayer's Riociguat Receives Priority Review from the FDA
- FDA Declines to Approve United Therapeutics' Pulmonary Arterial Hypertension Drug
- Bayer Submits its Pulmonary Arterial Hypertension Drug for Regulatory Approval in the US and EU
- Food and Drug Administration to Review Actelion's Pulmonary Arterial Hypertension (PAH) Drug
- Dr. Reddy’s Launches Generic Version of PAH Drug, Revatio
- FDA Rejects United Therapeutics' Oral PAH drug
- Actelion Submits NDA for PAH Drug
- Bayer Announces Positive Results from Phase III Study for PAH Drug
- Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical Trial of APD811 for Pulmonary Arterial Hypertension
- FDA Warns Against Revatio in Pediatric Patients with PAH
- Actelion Announced Positive Study for Treatment of PAH
- FDA warns healthcare professionals of sprycel (dasatinib) and risk of pulmonary arterial hypertension
- FDA warns healthcare professionals of sprycel (dasatinib) and risk of pulmonary arterial hypertension
- FDA Modifies Boxed Warning For Pulmonary Arterial Hypertension Drug Letairis
- For the Treatment of Pulmonary Arterial Hypertension, the Highest Proportion of Surveyed Pulmonologists Identified Actelion’s Tracleer as the Most Effective Therapy, When Compared to Other Available Agents
- Medicare Wrongly Buys Millions Worth Of Viagra For Seniors
- Chronic thromboembolic pulmonary hypertension in pediatric patients
- Grant For Pulmonary Arterial Hypertension Research
- Pulmonary Disease
- FDA Approves Tudorza Pressair to Treat Chronic Obstructive Pulmonary Disease
- Timing of ART Makes a Difference for Those With TB
- Blood tests could forewarn of emphysema
- Questions Remain About Belimumab in Certain Lupus Patient Groups
- Advances in Chronic Obstructive Pulmonary Disease Among Older Adults
- Lesser Known Lung Diseases Can Strike Smokers, Ex-Smokers
- Renal Disease
- FDA Questions if New Data is Needed for Aveo's Kidney Cancer Drug
- Quest Diagnostics Supports New Chronic Kidney Disease Guidelines
- Keryx Biopharmaceuticals' Zerenex Meets Primary and Secondary Endpoints for End-Stage Renal Disease Patients
- Baxter Acquires Gambro to Enhance Renal Therapy Portfolio
- Aveo and Astellas Submit NDA for Tivozanib for Treatment of Advanced Renal Cell Carcinoma
- European Regulators Okay Pfizer’s Inlyta for Kidney Cancer Patients
- Perrigo Receives FDA Approval For Their Experimental Renal Drug
- Pfizer’s Kidney Cancer Drug Fails to Meet Primary Endpoint
- FDA Approves Afinitor for Treatment of Non-Cancerous Kidney Tumors
- The Apothecary Shops and Pfizer come to terms on newly approved cancer drug Inlyta
- Nulojix Approved for Kidney Transplant Patients
- FDA Approves New Contrast Agent for CNS Scans
- More Diagnoses Lead to Lower Fatality Rates
- Whether Chronic Diseases Are Diagnosed May Depend on Where You Live
- Study Questions Tests Used to Spot Heart Risks in Kidney Patients
- ROADMAP Published, But No News on FDA Safety Review of ARB
- Respiratory Syncytial
- Ablynx Announces Positive Results for Their Phase I Study for Treatment of RSV
- Alnylam Pharmaceuticals Reaches Settlement in Litigation Regarding Tuschl Patents
- Rapid antigen testing for detecting RSV in neonates found effective
- NOVAVAX Launches Phase I Clinical Trial To Evaluate Its Novel Vaccine Against Respiratory Syncytial Virus (RSV)
- New Therapies May Follow Discovery Of Link Between Respiratory Syncytial Virus And Oxidative Stress
- Targacept Announces Initiation Of Phase 2 Studies Of TC-6987 In Asthma And Type 2 Diabetes
- Rheumatoid Arthritis
- Pfizer's Xeljanz gets Negative Opinion from EMA Committee
- AstraZeneca Announces Top-Line Results for Fostamatinib for Treatment of Rheumatoid Arthritis
- FDA Accepts Genentech's Biologics License Application for its Subcutaneous Formulation of RA Drug
- Lilly Discontinues Its Phase III Rheumatoid Arthritis Program for Tabalumab
- FDA Gives Clearance to Mesoblast for Initiation of a Phase II Trial Evaluating its Experimental Rheumatoid Arthritis Treatment
- Researchers Find Tofacitinib Slows Disease Progression for Rheumatoid Arthritis Patients
- Report Finds 80 Percent of Rheumatoid Arthritis Prescribers in the US Will Prescribe Biosimilar Versions Within a Year of Approval
- AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
- NICE Draft Guidance Supports RA Drug with Discount
- Study Shows Vitamin C Reduced Inflammation and Pain for RA Patients
- Study Evaluates the Impact of Specialty Pharmacy Management for RA Patients
- The Zitter Group: Payers Will Allow Access to Xeljanz
- Extended Trial Shows Experimental RA Pill Maintains Effectiveness in Reducing Painful Symptoms
- Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression in Patients with Active RA
- FDA Approves Pfizer’s Oral RA Drug
- FDA Approves Expanded Indication for Actemra in RA Patients
- MorphoSys Announces Positive Results for Investigational RA Drug
- Zalicus Discontinues Trial for RA Drug, Synavive
- FDA Panel Recommends Expanded Use of Abbott's RA Drug
- Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
- FDA Extends Review Period for Pfizer’s RA Drug by Three Months
- New Phase Three Study Shows Positive Results for Oral JAK Inhibitors
- Adalimumab Is a Promising Therapy for Children with Crohn’s Disease
- Pfizer Announces Positive Top-Line Results From The ORAL Start Phase 3 Study Of Tofacitinib In Rheumatoid Arthritis
- Analysis of Krystexxa® Phase III Data Demonstrates Improved Health-Related Quality of Life and Physical Function in Refractory Chronic Gout Patients
- Ablynx’s Arthritis Drug Shows Greater Benefits than Competitor
- Nanotechnology Products Linked to Autoimmune Disorders
- RAPID™-PsA Study Showed that Certolizumab Pegol Improved the Signs and Symptoms of Psoriatic Arthritis
- Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Peripheral Spondyloarthritis
- Actemra Shown to be More Effective than Humira for RA Patients
- Risk of Rheumatoid Arthritis Higher in Obese Women
- Gout Flares Substantially Increased with Certain Foods
- Methotrexate Injection Not Superior to Oral Therapy in Treating Juvenile Arthritis
- Gout Awareness Day Brings New Recommended Guidelines
- FDA Panel Recommends Pfizer’s Oral RA Drug
- Pfizer’s Experimental RA Drug Raises FDA’s Concern
- Biologic in Early RA Effective as Monotherapy
- Studies Present Reassuring data on RA Treatment Safety
- Steroids in Children with Arthritis Linked to Increase of Infections
- ISMP Warns of Adverse Effects Related to Infliximab Therapy
- Rilonacept Study Shows Reduction in Gout Flares Linked with Uric-Acid Lowering Therapy
- Obese Women May Be At Higher Risk for RA
- Bartonella Infection Linked with RA
- Pfizer’s RA Drug: Will Safety Concerns Determine Its Fate?
- Biologics & Non-TNF Agents Potentially Winners in the New ACR Guidelines for Early & Experienced Rheumatoid Arthritis (RA) Patients
- Non-Compliance of Statins Could Lead to Mortality for RA Patients
- Methotrexate Plus Prednisone Shows Good Results for Early RA
- Rheumatoid Arthritis Patients at Increased DVT Risk
- Anti-TNF Treatment Fails to Cut Acute Coronary Risk in RA
- No Problems with Interruption in Biologic RA Therapy
- Merck signs pact to develop biosimilar etanercept
- Sirukumab Phase II Results Show Promise for RA
- Rain as Cause of Pain in Rheumatoid Arthritis Continues to Baffle the Medical World
- SANTARUS : Initiates Phase I Clinical Study with SAN-300
- Exposure to Insecticides May Up Autoimmune Disease Risk
- Protalex, Inc. Announces Enrollment of First Patients in 3rd Cohort of Its Ongoing Phase 1b Dose Escalation Study of PRTX-100 in Patients With Active Rheumatoid Arthriti
- Be Attuned to Extracutaneous Manifestations of Psoriasis
- 2nd UPDATE: Pfizer Arthritis Drug Meets Goal In Second Trial
- Transplantation
- FDA Approves Implantable Pump for Heart-Transplant Candidates
- Genzyme Recalls Its Kidney Transplant Drug
- Novartis' Drug Shows Positive Results for Liver Transplant Patients
- Lung Stem Cell Discovery May Lead To New Treatments
- High risk transplant patients should use high volume transplant centers
- Plastic Surgery the Key to Historical First U.S. Full Face Transplant
- One In Four Of Those Waiting For Kidney Transplant Are Black Or Asian
- Nanoscale Whiskers From Sea Creatures Could Grow Human Muscle Tissue
- Vaccines and Immunizations
- Von Willebrand Disease
- World’s First Intensive Study of Postpartum Women with von Willebrand Disease Shows Potential Risk of Delayed Hemorrhage, Despite Treatment
- HealthyWomen Asks: Do You Know the Signs and Symptoms of Von Willebrand Disease (VWD)?
- Researchers Focus on Rare Bleeding Disorders
- Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra Treatment in Patients With Primary Immunodeficiencies
- Galapagos and AbbVie Expand Collaboration to Include Crohn's Disease Program
- Sanofi's JAK2 Inhibitor Meets Primary Endpoint in Late-Stage Trial for Treatment of Myelofibrosis
- Unraveling Accreditation, Certification, and Certificate Programs
- Gilead Announces Positive Phase II Trial Results for its Leukemia Drug
- Roche's Investigational Leukemia Drug Shows Impressive Results in Its Phase III Trial
- Bristol-Myers Squibb's Combination Treatment Demonstrates Promising Results for Patients with Advanced Melanoma
- National Association of Specialty Pharmacy™ (NASP™) appoints Mark Montgomery, CEO, Axium Healthcare Pharmacy, to Board of Directors
- Merck's Investigational Lung Cancer Drug Fails to Meet its Primary Endpoint in a Phase III Trial
- AstraZeneca Plans to Move Three Cancer Compounds to Phase III Development
- FDA Approves Bayer's Prostate Cancer Drug
- National Association of Specialty Pharmacy™ (NASP™) Launches the Specialty Pharmacy Education Center™ (SPEC™)
- Study Shows Variance in Initiatives with Specialty Drugs by Health Plan Type
- Roche's Tarceva Tablets and Cobas EGFR Mutation Test Receives FDA Approval
- The University of Colorado Signs Licensing Agreement with Syndax for Novel Cancer Treatment Approach
- AbbVie Secures Rights to Alvine's Experimental Treatment for Patients with Celiac Disease
- Walgreens Extends CVS Caremark's Network Provider Agreement
- Janssen's Investigational Hepatitis C Treatment is Granted Priority Review by the FDA
- FDA Accepts Biogen's BLA for its Hemophilia A Candidate
- Use of Statins Prior to Diagnosis Reduced Prostate Cancer Mortality
- CytRx Discontinues Tamibarotene Trial and Focuses on Aldoxorubicin and Expanded Oncology Pipeline
- Specialty Pharmacy Certification Board™ (SPCB™) Announces Board Education Director
- Cornerstone Therapeutics Acquires Exclusive Rights for Pertzye in the US
- Lilly Discontinues Development of Enzastaurin After Phase III Trial Results
- Novartis' Ilaris Receives FDA Approval for Treatment of Systemic Juvenile Idiopathic Arthritis
- Lumena Receives $23 Million Funding for its Lead Program for Rare Liver Disease
- NASP and ASCP Discuss Future of Specialty Pharmacy in Aging Market at Upcoming ASCP Conference
- Specialty Pharmacy Certification Board™ (SPCB™) Setting the Standard for Specialty Pharmacy Practice
- Florida Compounding Pharmacy Recalls Drugs Due to Sterility Issues
- Takeda Acquires Inviragen for Vaccines for Infectious Diseases
- Specialty Pharmacy Certification Board™ (SPCB™) Establishes Code of Conduct, Eligibility Requirements and Fees for Certified Specialty Pharmacist™ (CSP™) Program
- Nimbus and Shire Partner for Therapies for Rare Diseases
- GenomeDx Releases Positive Results for Decipher in Predicting Metastasis for Prostate Cancer Patients
- Eisai Files for Expanded Indication to the EMA for its Breast Cancer Drug
- Specialty Pharmacy Certification Board™ (SPCB™) Approves Content for Certified Specialty Pharmacist™ (CSP™) Certification Exam
- FDA Warns Risk of Confusing Kadcyla and Herceptin While Using Generic Names
- Florida Approves a Bill Blocking Provisions in Biosimilars Bill
- Celgene Corp Enters $300 Million Deal for Concert Pharmaceuticals' Deuterium-Modifying Platform
- FDA Approves Bristol-Myers Squibb's Sustiva for Pediatric Patients with HIV
- Association for Value-Based Cancer Care's (AVBCC) Annual Conference Highlights
- AbbVie's Investigational Hepatitis C Combination Drug Receives Breakthrough Therapy Designation from the FDA
- Armada's Specialty Pharmacy Summit Brings Together Industry Leaders
- Drug Trend Insights Report Shows Prescription Drug Costs Increase Driven by Specialty Drugs
- Allergan's Trial for its Macular Degeneration Drug is Delayed, Causing Shares to Drop
- Arseus Acquires US Compounder Freedom Pharmaceuticals
- Janssen's Investigational Multiple Myeloma Drug Receives Breakthrough Therapy Designation from the FDA
- Valence Life Sciences Provides Funding to Support Celator's Acute Myeloid Leukemia Late-Stage Trial
- Genentech's Actemra Receives FDA Approval for Rare Form of Arthritis in Children
- Scioderm Receives Breakthrough Therapy Designation for its Investigational Rare Disease Product for Epidermolysis Bullosa
- FDA Questions if New Data is Needed for Aveo's Kidney Cancer Drug
- Raptor Pharmaceuticals' Procysbi Receives FDA Approval for Cystinosis
- FDA Approves CSL Behring's Kcentra
- OncoGenex Initiates Phase II Trial Evaluating Bladder Cancer Drug
- Oxford BioTherapeutics and Boehringer Ingelheim Collaborate for Discovery of Novel Cancer Antibody Targets
- Plaintiffs Awarded $6.5 Million for Damages Associated with Takeda's Actos
- Pfizer and Merck Collaborate for Type 2 Diabetes Treatment
- FDA Says it Cannot Approve Gilead's Current Applications for HIV Treatment Regimens
- Proposal Seeks to Boost FDA's Oversight on Compounding Pharmacies
- PhRMA Reports Over 240 Medicines in Development for Treatment of Blood Cancers
- Government Halts Largest HIV Vaccine Trial After Interim Review
- Janssen Submits Marketing Application for Approval of Its Hepatitis C Drug in Europe
- Pfizer's Xeljanz gets Negative Opinion from EMA Committee
- Study Shows Thalamic Atrophy Associated with Multiple Sclerosis
- Delaying Initiation of Treatment Among Young Women with Breast Cancer Significantly Decreases Survival Rate
- OPKO to Acquire Prolor for $480 Million
- National Association of Specialty Pharmacy Appoints Thomas Blissenbach, RPh, MS as a Member of The Board of Directors
- Teva Announces Creation of Global Specialty Medicines Group
- Merck's Investigational Cancer Drug Receives Breakthrough Therapy Designation
- NACDS Awards Bob Loeffler and David Pinto with the Sheldon W. Fantle Lifetime Achievement Award
- FDA Grants Orphan Drug Designation to Teva and Xenon's Pain Drug for Rare Autosomal Condition
- Alchemia Collaborates with AstraZeneca for VAST Discovery Platform
- GSK and Avalon Ventures Collaborate to Fund up to 10 Drug Discovery Startup Companies
- Boehringer Ingelheim Announces Positive Results from Its Phase 3 Study of its Combination Regimen for Hepatitis C Patients
- NACDS Announces New Roles of the Association and Foundation at its Annual Meeting
- Horizon and AstraZeneca Partner for Development of Novel Cancer Therapies
- AstraZeneca and BIND Therapeutics Collaborate on Nanotech Drug for Cancer Treatment
- NACDS Kicks off its Annual Meeting Marking its 80th Year
- Merck and BMS Enter a Non-Exclusive Agreement for a Phase II Trial for a Combination Regimen for Hepatitis C
- Epizyme and Abbott Enter Agreement for Companion Diagnostic Test for Cancer
- Kaiser's Study Shows Nearly 30 Percent of Women with Osteoporosis Don't Pick up Prescriptions
- Vertex Announces Positive Results from Mid-Stage Study of Combination Drug for Lung Function in Cystic Fibrosis Patients
- Avella Specialty Pharmacy Assists Patients to Lower Cost of Specialty Drugs
- Illinois House Approves Marijuana for Certain Medical Conditions
- Ropers to Acquire MHA for $1 Billion
- Savara Pharmaceuticals Begins Phase 2 Trial of AeroVanc for MRSA in Cystic Fibrosis Patients
- Pfenex and Agila Biotech Enter Joint Venture to Develop Biosimilar Products
- HealthGuard Emergency Card Available for Patient Protection
- American Management Association and Biogen Partner to Develop Workshops for Hemophilia Patients
- World Federation of Hemophilia Announces 50 Years of Improving Care on World Hemophilia Day
- Eli Lilly Releases Positive Results from Additional Trials for its Diabetes Drug
- Roche and Ascletis Collaborate to Advance Hepatitis C Treatment Options in China
- FDA Clears Echosens' FibroScan for Non-Invasive Liver Diagnosis
- CSL's Berinert Receives Expanded Approval from European Health Authorities
- ASCP's Upcoming Spring Conference and Exhibition Covers Several Hot Topics in the Healthcare Industry
- Study Shows One-Quarter of Cancer Patients & Caregivers are Dissatisfied with Cancer Care
- FDA Committees will Reassess Safety of GSK's Diabetes Pill, Avandia
- Pharmacy Advantage Specialty Pharmacy Receives URAC Accreditation
- Orphan Drug Accelerator, Cydan, Announces Launch with $16 Million in Financing from NEA & Pfizer
- Walgreens Research Shows How Health Systems could Prevent Triple Fail Events
- FDA Clears Elekta's Versa HD for Shipping and Installation in the US
- Coldkeepers, LLC Announces International Expansion through Partnership with European Packaging Leader Sofrigam S.A.
- FDA Grants Breakthrough Therapy Designation for Pfizer's Breast Cancer Drug
- Study Shows ZyCal's Cyplexinol Decreases Pain and Stiffness and Increases Quality of Life for Osteoarthritis Patients
- Janssen Announces Release of Doxil to Market
- Cleave Biosciences Receives $10 Million Investment from NEA to Fund its Lead Cancer Program
- Gilead Submits NDA to the FDA for Sofosbuvir for Treatment of Hepatitis C
- NASP Announces Jim Smeeding, RPh, MBA, as Executive Director
- Millennium's Velcade Shows Strong Results in Meta-Analysis for Patients with Multiple Myeloma
- Bayer's Riociguat Receives Priority Review from the FDA
- Ibrutinib Receives Third Breakthrough Therapy Designation from the FDA
- MHA Completes Sixth Annual Independent Long Term Care Study
- Astellas and Ambrx Collaborate for Development of Cancer Products
- Vertex and Bristol-Myers Squibb Enter Agreement for Phase 2 Studies of Hepatitis C Combo Treatment
- Navidea Announces Results of Lymphoseek in Patients with Head and Neck Cancer
- AstraZeneca Announces Top-Line Results for Fostamatinib for Treatment of Rheumatoid Arthritis
- Avella Announces Launch of Dispensing Excellence
- Covis Announces Agreement with Sanofi for Commercial Rights of Several Drugs in the US
- NASP Closes Inaugural Specialty Conference to a Sell-Out Crowd
- Elan Announces Closing of Tysabri Deal with Biogen
- Bind Therapeutics and Pfizer Collaborate to Develop and Commercialize Multiple Accurins
- European Commission Grants Marketing Authorization for CSL's Privigen for Treatment of Rare Neurological Disorder
- NASP Specialty Pharmacy Conference Highlights
- NASP Inaugural Specialty Pharmacy Conference Sells Out – More than 500 Individuals Attend
- BioPlus Guarantees Patient Acceptance in Two Hours
- Janssen's Invokana Receives FDA Approval for Type 2 Diabetes
- Health Departments Launch Investigation on Oklahoma Dentist who May have Exposed 7,000 to HIV and Hepatitis C
- Varian Medical Systems Highlights its Calypso for Reduced Risk of Heart Disease following Breast Cancer Treatment
- Experimental Hepatitis C Drug Shows Promising Results
- NICE Issues Final Draft Guidance Not Recommending Pfizers Kidney Cancer Drug
- FDA Approves Biogen's Tecfidera for Multiple Sclerosis
- Oncodesign and Sanofi Sign Second Research Collaboration Agreement
- Federal Guidelines Recommend New HIV Testing Method
- Ziopharm Terminates Development of Cancer Treatment Palifosfamide
- FDA Grants Orphan Drug Designation to Acceleron's Rare Blood Disorders Drug
- Genzyme's Aubagio is Recommended for Approval by the EMA
- Novartis' TOBI Podhaler Receives FDA Approval for Certain Patients with Cystic Fibrosis
- Biogen's Multiple Sclerosis Drug is Recommended for Approval in the EU
- FDA Declines to Approve United Therapeutics' Pulmonary Arterial Hypertension Drug
- Managed Health Care Associates, Inc. (MHA) Announced Erik Halstrom, Vice President of MHA Specialty Pharmacy Solutions, Will Serve on The National Association of Specialty Pharmacy (NASP) Board of Directors
- NICE Rejects Novartis’ Afinitor for Breast Cancer
- James Lang Joins NASP Board of Directors
- AstraZeneca and Moderna Enter Exclusive Agreement for Development of New Treatment Options
- FDA Warns of Additional Compounding Pharmacy Recalls
- Study Shows Genetic Variations have Major Impact on Childhood Leukemia Risk
- Pharmacy Quality Alliance and CECity Launch Quality Measurement, Benchmarking, and Reporting Platform for Pharmacies and Health Plans
- Biogen's Multiple Sclerosis Drug Receives Patent Extension from the US Patent and Trademark Office
- Amgen's Melanoma Drug Meets Primary Endpoint in its Phase III Trial
- Pharmaxis Receives a Complete Response Letter from the FDA Regarding Bronchitol for Cystic Fibrosis Patients
- AmerisourceBergen Announces Long-Term Relationship with Walgreens and Alliance Boots
- EMA Backs Roche's Pegasys for Chronic Hepatitis C in Children Five Years and Older
- Seattle Genetics Submits Supplemental Biologics License Application for Adcetris
- Galena Biopharma Agrees to Acquire Abstral for Oncology Pain
- Biogen Releases Positive Results for Tysabri
- Amdipharm and Mercury Pharma Announce Merger
- Study Shows New Role for Abiraterone in Blocking Tumor Growth for Patients with Castration Resistant Prostate Cancer
- FDA Grants Novartis' Compound LDK378 Breakthrough Therapy Designation
- FDA Investigates Reports of Increased Risk of Pancreatic Cancer with Certain Diabetes Drugs
- Mylan Enters A Settlement Agreement for its Generic Diabetes Drug
- Quest Diagnostics Supports New Chronic Kidney Disease Guidelines
- Navidea's Lymphoseek Receives FDA Approval
- New Leaf Rx Announces Partnership with NASP
- The Scripps Research Institute and Takeda Expand Research Collaboration for New Drug Targets
- Receptos and AbbVie Enter into a Development License and Option Agreement for a Rare Disease Drug
- The NASP-AMCP Specialty Pharmacy Conference Expands Meeting Space
- Biogen Submits a Biologics License Application to the FDA for its Hemophilia A Drug
- Shire Acquires Premacure Expanding Its Rare Diseases Pipeline
- Researchers Discover Possible Origin of Ovarian Cancer
- Gilead's Ranexa Reduces Angina Frequency for Patients with Type 2 Diabetes
- Aeterna Zentaris Discontinues Its Phase III Trial for Multiple Myeloma Treatment
- PhRMA Reports 907 New Biotech Drugs in Development
- Coldkeepers, LLC Announces New Pre-qualified 72 Hour Thermal Shipping Solution for Specialty Pharmacies
- PTC Therapeutics Closes $60 Million in Financing
- Phil Hagerman, CEO, Diplomat Specialty Pharmacy, Joins NASP Board of Directors
- Specialty Pharmacy Certification Board™ Defining Specialty Pharmacy Practice
- Sorrento Signs an Exclusive Option to Acquire IGDRASOL
- Study Identifies Genetic Mutation that May Lead to New Treatment Options for Type 1 Diabetes
- Study Shows Tightly Managed Specialty Pharmacy Benefits Can Cut Specialty Drug Spend in Half
- The FDA Provides Six Tips to Recognize Fraudulent Health Products
- Ajinomoto Agrees to Acquire Althea Technologies
- Teva Enrolls First Patient in Its Third Phase III Study Evaluating Its Multiple Sclerosis Drug
- Hepatitis C Continues to Lead the Specialty Area for Highest Increase in Drug Spend
- CVS' Acordant Health Services Receives URAC's Case Management Accreditation
- FDA Panel Recommends the FDA No Longer Support Calcitonin Salmon Products for Treatment of Osteoporosis
- Innovatix, LLC Joins the National Association of Specialty Pharmacy (NASP) as a Founding Member Sponsor
- Presage Biosciences and Celgene Collaborate to Identify Novel Drug Combinations for Cancer
- Express Scripts' 2012 Drug Trend Report Ranks Specialty Therapy Classes by PMPY Spend
- Novartis' Ilaris Receives EU Approval for Patients with Gout
- FDA Accepts Biogen's Biologic License Application for its Hemophilia B Drug
- First HIV Baby Cured of the Disease
- Celgene's Psoriasis Treatment Meets Primary Endpoint in Phase III Study
- The FDA Conducts Surprise Inspections on Numerous Compounding Pharmacies
- Specialty Pharmacy Certification Board™ Setting the Standard for Specialty Pharmacy Practice
- Ceptaris Resubmitted a New Drug Application for Its Lymphoma Treatment
- FDA Expands Approval of CSL Behring’s Corifact
- FDA Clears Philips' Mammography System
- Takeda and Resolve Partner to Develop Compounds for Treatment of Lupus and Other Autoimmune Diseases
- FDA Accepts Genentech's Biologics License Application for its Subcutaneous Formulation of RA Drug
- Mylan Agrees to Acquire Agila for $1.6 Billion
- Kaiser Permanente Study Shows Diabetes Patients are not at an Increased Risk During Knee Replacement Surgery
- NICE Recommends Novartis' Lucentis for Patients with Diabetic Macular Edema
- Janssen and Araxes Collaborate for Development of Cancer Treatment
- Village Fertility Pharmacy Recalls Two Fertility Injectables
- Baxter Submits a Biologics License Application for Its Hemophilia Drug
- Ablynx and Spirogen Collaborate for Development of an Anti-Cancer Drug
- FDA Delays Approval of Dynavax's Hepatitis B Drug
- Study Shows New Diabetes Drug May Double Pancreatitis Risk
- FDA Expands Approval of Stivarga for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
- Royalty Pharma Announces Proposal to Acquire Elan in Response to Elan’s Recent Release on the Company’s Restructuring Plan
- Merck's Brain Cancer Drug Fails to Meet Primary Endpoint in Its Phase III Trial
- Mylan Introduces HIV AIDS Drug Portfolio in South Africa
- FDA Approves Kadcyla for Treatment of Advanced Breast Cancer
- Valeant Pays $65 Million Upfront to Eisai for Rights of Targretin Capsules and Gel
- Abbott to Collaborate with Janssen and Pharmacyclics on Development of Companion Test for Investigational Leukemia Therapy
- Destroying the Status Quo: The Independent Pharmacy Benefits Growth Conference
- Erlotinib & Celecoxib, in Combination, Shows Response in Children With Head And Neck Cancer
- CSL Behring Announces New Vial Size of Privigen
- FDA Grants Special Protocol Assessment for Puma’s Breast Cancer Drug
- Peregrine Revises Results from its Lung Cancer Trial
- Sobi and Savient Agree to Co-Promote Kineret
- Isis Pharmaceuticals Earns $7.5 Million from GSK for Initiating Phase 2/3 Study for Rare Disease Drug
- California Community Pharmacies Applaud Anthem Decision to Suspend HIV Program that Would Have Harmed Patient Choice
- Gilead Announces Positive Results for Hepatitis C Treatment
- Research Team Stops Progress of Colon Cancer
- FDA Accepts Sanofi's Diabetes Drug Application
- Genzyme Announces Positive Results from Its Phase III Studies for Treatment of Gaucher Disease
- Roche and Chiasma Collaborate for Development and Commercialization of Chiasma’s Octreolin
- AbbVie Announces Positive Results for Humira in Pediatric Patients with Crohn's Disease
- FDA Grants Priority Review for ViiV's Dolutegravir for Treatment of HIV
- Managed Health Care Associates, Inc. (MHA) Announced as Founding Member Sponsor of The National Association of Specialty Pharmacy (NASP)
- Peregrine Announces Positive Results for Bavituximab in Patients with Pancreatic Cancer
- Mylan and Biocon Enter an Agreement for Three Insulin Products
- Third Rock Forms Jounce Therapeutics for Discovery and Development of Cancer Treatments
- Cardinal Announces Plans to Acquire AssuraMed
- FDA Grants Priority Review for Algeta and Bayer's Oncology Drug
- Lycera and Merck Announce A Collaborative Agreement for Developement of Novel Autoimmune Disorder Treatments
- ZIOPHARM’s Palifosfamide Reaches Target Number of PFS Events in First-Line Metastatic Soft Tissue Sarcoma
- Study Shows Nurses Involvement with TheONC.org Improves Care for Cancer Patients
- FDA Grants Pharmacyclics Ibrutinib Breakthrough Therapy Designation
- New Regulations for Compounding Pharmacies on the Horizon
- Researchers Identify a Potential HIV-Fighting Protein
- Perrigo Acquires Rosemont Pharmaceuticals for $283 Million
- Bayer Submits its Pulmonary Arterial Hypertension Drug for Regulatory Approval in the US and EU
- Walgreens Infusion Services Prevented an Estimated 429 Hospital Days in 3 Months
- The FDA Approves Celgene’s Pomalyst and Accepts Its Filing for Revlimid for Multiple Myeloma Patients
- Study Discovers a New Protein to Target for Treatment of Lymphoid Leukemia
- The FDA Rejects Novo’s Diabetes Drug
- Oncolytics Announces Positive Results from Its Phase II Lung Cancer Clinical Trial
- NASP Announces Partnership with Gerry Crocker to Advance Specialty Pharmacy Industry
- FDA Warns of Counterfeit Versions of Injectable Cancer Drug
- Lilly Discontinues Its Phase III Rheumatoid Arthritis Program for Tabalumab
- Banner MD Anderson Cancer Center Acquires Elekta Cancer Management Solutions
- FDA Grants Orphan Drug Designation to Apgenix's Apocept for Myelodysplastic Syndromes
- Biogen Agrees to Purchase Elan's Interest in Tysabri, Obtaining full Strategic, Commercial and Decision-Making Rights to the Drug
- Opexa and Merck Serono Execute an Agreement for Development of Tcelna for Treatment of Multiple Sclerosis
- Galapagos Announces Initiation of Phase II Study for Psoriasis & SLE Treatment
- National Association of Specialty Pharmacy Board of Directors Call for Volunteers
- Aduro Acquires GVAX Assets from BioSante Expanding its Cancer Portfolio
- CVS Expands ExtraCare Loyalty Program Rewarding Customers for Filling Prescriptions
- Idenix Will Discontinue Development Programs for Two Experimental Hepatitis C Treatments
- Gilead’s Sofosbuvir Meets Primary Endpoints in Two Phase III Studies for Treatment of Hepatitis C
- FDA Approves Generic Version of Cancer Drug to Assist with Drug Shortages
- Walgreens Enables Third-Party Mobile App Developers to Leverage Its Prescription Refill Technology
- Biotest Announces First Commercial Sales and Shipments of Bivigam
- 7 Tips for Selling Your Pharmacy
- FDA Approves Hyperion’s New Orphan Drug
- Interferon for Retreatment of Hepatitis C May be More Harmful than No Treatment
- FDA Gives Clearance to Mesoblast for Initiation of a Phase II Trial Evaluating its Experimental Rheumatoid Arthritis Treatment
- Celsion's Experimental Liver Cancer Treatment Fails in Late-Stage Trial
- Genentech's Investigational Cancer Drug Meets Primary Endpoint and Shows Superiority Compared to Rituxan
- Pharmaxis' Cystic Fibrosis Drug is not Recommended for Approval by the FDA Advisory Committee
- Crown Marketing Pharmaceuticals Announces Positive In-Vitro Testing Results for Diabetes Drug
- CSL Behring Awards Grants for Patient Advocacy Organizations Promoting Early Diagnosis and Access to Care
- Pharmaxis Will Meet with an FDA Advisory Committee to Review its Cystic Fibrosis Drug
- Generex Provides a Status Update on its Cancer Immunotherapy Product
- Researchers Find Tofacitinib Slows Disease Progression for Rheumatoid Arthritis Patients
- Keryx Biopharmaceuticals' Zerenex Meets Primary and Secondary Endpoints for End-Stage Renal Disease Patients
- Judge Freezes Assets of Meningitis-Linked Pharmacy Owners
- Merck Initiates Phase III Study of Investigational Pancreatic Cancer Drug, Earning Threshold a $30 Million Milestone Payment
- Genzyme's Multiple Sclerosis Treatments Receive Positive News
- Evidence Presented Linking Obesity with Osteoarthritis
- Report Shows an Innovative and Robust Biopharmaceutical Pipeline
- The 2nd Annual Foundation for Managed Care Pharmacy (FMCP) Research Symposium Releases Research Proceedings
- Takeda’s Three New Diabetes Therapies Receive FDA Approval
- FDA Approves Novartis' Gleevec for Pediatric Patients with Leukemia
- Study Projects High Impact of Prostate Cancer in 2013
- Olean General Hospital Notifies Patients of Possible Sharing of Insulin Pens
- Biogen Announces Positive Results for its Multiple Sclerosis Drug
- The Leukemia & Lymphoma Society and Avella Specialty Pharmacy Present Free Chemotherapy Program
- Baxter Agrees to Acquire Inspiration BioPharmaceuticals’ Investigational Hemophilia Compound
- FDA Approves New Use of Genentech's Avastin for Patients with Colorectal Cancer
- FDA Expands Approval of Novartis' Exjade to Treat Rare Genetic Blood Disorder
- Progenics Acquires Molecular Insight Expanding Its Oncology Pipeline
- Researchers Discover Gene Variant that Drives Breast Cancer Spread
- EntreMed Initiates Phase II Trial for Metastatic/Soft Tissue Carcinoma
- Celgene's Abraxane Shows Promise in Phase III Study for Treatment of Pancreatic Cancer
- H.D. Smith Announces Establishment of H.D. Smith Specialty Solutions
- The National Comprehensive Cancer Network (NCCN) Includes NovoTTF Therapy in its Guidelines as a Standard Treatment Option
- Thermal Shipping Technologies – Packing Heat?
- Study Associates Regular Aspirin Use with Macular Degeneration
- AIDS Healthcare Foundation Announces Rebranding of MOMS Pharmacy
- New Childhood Cancer Prevention and Screening Clinic Announced by Texas Children's Cancer Center
- Why the NASP - AMCP Inaugural Specialty Pharmacy Conference is Different
- First Patient Enrolled in CSL Behring’s Pediatric Phase III Study for Hemophilia Treatment
- Costco Launches Pharmacy Benefit Management Business
- Researchers Develop a New Mobile Device that Performs Laboratory-Quality HIV Testing
- Boehringer Ingelheim Enrolls First Patients in its Phase III Trial for Interferon-Free Hepatitis C Program
- Octapharma's Octaplas Receives FDA Approval for Patients with Blood Clotting Disorders
- Important Discovery Made that Could Lead to Better Detection and Treatment of Prostate Cancer
- Early Treatment for HIV Optimal for Better Recovery
- Fitango Launches e-Health Platform to Improve Patient Adherence
- Report Finds Specialty Drug Spend will Exceed Traditional Drug Spend by 2018
- Biogen and Elan Submit Applications Requesting Expanded Indication for Tysabri
- Boehringer Ingelheim's Investigational Oncology Compound is Granted Priority Review
- The FDA Accepts Astellas' New Drug Application for Its Lung Cancer Drug
- Generic HIV Drugs Could Save Patients Financially but not Clinically
- Kaiser Study Shows PSA Measurements Over Time Improve Accuracy of Detecting Prostate Cancer
- Horizon Discovery and Boehringer Ingelheim Enter Collaboration Agreement to Advance Oncology Research
- H.D. Smith Announces Its Plans on Securing Majority Ownership in Pharmacy Support Services Company Triplefin
- GlaxoSmithKline Submits a Regulatory Application for its Diabetes Drug
- Possible Exposure of HIV and Hepatitis from Reused Insulin Pens at the Buffalo VA Medical Center
- Centene Corporation to Acquire Specialty Therapeutic Care Holdings
- ArQule and Daiichi Announce Phase 2 Results for Colorectal Cancer Drug
- Newly Passed Medicare IVIG Access Act Eases Burden of PIDD Patients
- Expert Panel Recommends Approval of Johnson & Johnson's Diabetes Pill
- Vertex Outlines Its Business Priorities of 2013, Revealing its First Two Breakthrough Therapy Designations
- Study Shows a Strong Demand for Online Services for Chronic Disease Patients and Caregivers
- Teva Files Petition Requesting that the FDA not Approve New MS Drugs
- Savient's Krystexxa Receives Final Approval by the EU for Chronic Tophaceous Gout
- FDA Requires Additional Time for Review of Idenix’s Hepatitis C Treatment
- CSL Behring Launches Co-Pay Assistance Program for Berinert Patients
- URAC Releases Revised Claims Processing Accreditation Standards
- Baxter Announces Positive Results from Hemophilia Study
- FDA Grants Fast Track Designation for GTx’s Enobosarm
- Celgene's Psoriasis Drug Meets Primary and Secondary Endpoints in Phase III Trials
- Ernst & Young Report Shows Future Difficulty for Big Pharma to Close Growth Gap
- The European Group for Blood and Marrow Transplantation Selects Remedy Informatics as Registry Solution
- Gilead Shares Positive Update on Hepatitis C Developments
- Adventist Medical Center Provides Advanced Cancer Treatment Technology
- Governor Proposes New Rules for Tighter Regulations on Compounding Pharmacies
- Baxter Submits Investigational New Drug Application to the FDA for Its Hemophilia A Treatment
- Vaccinex Initiates Phase 1 Trial for Experimental Multiple Sclerosis Treatment
- Biogen Submits Biologics License Application to the FDA
- Novartis’ Lucentis Wins Backing from NICE
- Rebif Rebidose Receives FDA Approval
- Biogen Discontinues Its Asmyotrophic Lateral Sclerosis Drug After It Fails in a Phase III Study
- Hepatitis C Pills Show Promising Future
- Nexavar Meets Primary Endpoint in Phase III Study for Thyroid Cancer
- CVS Caremark’s Study Associates Practical Social Support with Improved Medication Adherence
- Sphingotec Announces Launch of Test for Prediction of Breast Cancer
- The FDA Approves 39 New Drugs in 2012, a 16-Year High
- BelHealth Acquires Town Total and Hires Michael A. Nameth as CEO
- Dune Medical Devices Receives FDA Approval for Breast Cancer Assessment Tool
- 2012 Year in Review: SPJ Top 10 Articles
- Watson Confirms Patent Challenge for Oncology Drug
- Phil Hagerman of Diplomat Specialty Pharmacy Named A Michigander to Watch by MLive Media
- Victory Pharma Pays $11.4 Million to Settle Kickback Claims
- Bladder Cancer Treatment May Be Shaped by Gene Variation
- Study Suggests Eye Scan May Show Progression of Multiple Sclerosis
- Walgreens Infusion Services Chosen as Contracted Provider for Gattex
- National Shortage of Cancer Drug Linked to Higher Relapse Rates in Children
- WellPoint Completes Acquisition of Amerigroup
- The New England Compounding Center Files for Bankruptcy
- The Immune Deficiency Foundation Announces the Medicare IVIG Access Act Passed by Congress and Goes to President
- Halozyme Partners with Pfizer for $8 Million
- The Implications of the Meningitis Outbreak on Specialty Pharmacy
- Humana RightSource Specialty Pharmacy Launches Split-Fill Program For Improved Outcomes and Quality of Life
- Biotest’s Bivigam Receives FDA Approval
- Sanofi Settles False Claims Case for $109 Million
- LeClairRyan Reacts to Additional Oversight on Compounding Pharmacies Although CDC Says Meningitis Outbreak Could Have Been Worse
- Proteins Found That May Enable Diagnosis of Rare Disease in Children
- Incivek Label Revised to Include Warning of Fatal and Non-Fatal Serious Skin Reactions
- Merck's Investigational Non-Small Cell Lung Cancer Drug Did Not Meet Its Primary Endpoint
- Public Citizen Expresses Strong Opposition of FDA Proposals for Compounding Pharmacies
- Long-Term Aspirin Use in Older Adults Linked to Higher Risk of Macular Degeneration
- Report Finds 80 Percent of Rheumatoid Arthritis Prescribers in the US Will Prescribe Biosimilar Versions Within a Year of Approval
- Meningitis-Related Deaths Continue to Rise
- Generic Version of HIV Therapy Receives FDA Approval
- Actelion's Psoriasis Drug Achieved Its Main Goal in a Mid-Stage Trial
- University of Florida Oncologists Tracking Metastatic Cancer with New Device
- Bayer Submits a New Drug Application to the FDA for Prostate Cancer Drug
- Novartis’ Signifor Receives FDA Approval for Cushing’s Disease
- FDA Approves Ariad's Leukemia Drug
- Food and Drug Administration to Review Actelion's Pulmonary Arterial Hypertension (PAH) Drug
- National Association of Specialty Pharmacy (NASP) and the Academy of Managed Care Pharmacy (AMCP) Collaborate to Support all Specialty Pharmacy Stakeholders by hosting the Inaugural AMCP/NASP Specialty Pharmacy Conference
- AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
- ViroPharma Launches ‘Moments Missed’ Campaign for Hereditary Angioedema
- Biogen & Eisai Align to Strengthen Manufacturing Capabilities
- National Association of Boards of Pharmacy Develops Action Plan to Support State Board of Pharmacy Efforts to Regulate Compounding Pharmacies
- Gilead to Acquire YM BioSciences Expanding Its Oncology and Inflammation Pipeline
- Boehringer Ingelheim Will Initiate a Phase III Study for Experimental Acute Myeloid Leukemia Drug
- Celgene’s Experimental Multiple Myeloma Drug Demonstrates Significant Progression-Free and Overall Survival Improvement
- Walgreens Gains Ownership Stake in Cystic Fibrosis Specialty Pharmacy
- Aetna and Cardinal Health Specialty Solutions Design Program to Improve Cancer Care in Michigan
- Seattle Genetics Highlight Clinical Data from Genentech's Two Anti-Body Drug Conjugate Programs
- Biodel's Glucagon Receives Orphan Drug Designation
- FDA Expands Approval for J&J’s Zytiga
- Meningitis Outbreak: Lawmakers Investigate Compounding Pharmacy Group; Drug Shortages Increase
- MD Anderson & GSK Collaborate to Develop New Approach to Cancer Immune Therapy
- Amgen to Acquire deCODE Genetics for $415 Million
- Ariad Presents Positive Results for CML Drug
- Trials Suggest Pharmacyclics’ Ibrutinib Showed High and Durable Response in Chronic Lymphocytic Leukemia
- Protalix & Pfizer Expand Agreement for Gaucher Drug
- Janssen Submits Applications for Approval of Stelara for Psoriatic Arthritis
- NICE Draft Guidance Supports RA Drug with Discount
- Lilly & Arcolab Collaborate to Expand Delivery of Cancer Medications in Emerging Markets
- Longer Use of Tamoxifen May Reduce Breast Cancer Deaths
- New Meningitis Legislation Introduced by US House Democrats
- Study Shows Vitamin C Reduced Inflammation and Pain for RA Patients
- Pfizer’s Experimental Breast-Cancer Drug Shows Promising Results
- Geron Announces Discontinuation of GRN1005 to Focus on Development of Imetelstat
- QS/1 Partners with CoverMyMeds to Automate the PA Process
- Exelixis Selects Diplomat Specialty Pharmacy as the Exclusive Distributor for Cometriq
- Study Shows Aspirin Reduced Risk of Developing Liver Cancer
- Baxter Acquires Gambro to Enhance Renal Therapy Portfolio
- Vertex's Kalydeco Receives Approval for Use in Cystic Fibrosis Patients in Canada
- Grand Jury Searching Pharmacy Linked to Meningitis Outbreak
- Study Shows Diabetes Drug May Treat Ovarian Cancer
- Report Shows Cancer Drug May Eliminate Latent HIV Infection
- AIDS Foundation of Chicago Partners with Abbott to Launch Need2Know HIV
- Your Opportunity to Participate in Defining Specialty Pharmacy Practice
- BioCryst and Presidio Mutually Terminate Merger Transaction
- FDA Approves Cometriq for Treatment of Medullary Thyroid Cancer
- Public Citizen Group Asks FDA to Re-Inspect 16 Compounding Pharmacies
- Perrigo Announces FDA Approval of Scalp Psoriasis Treatment
- Judge Allows Civil Suits in Meningitis Outbreak to Progress
- FDA Agrees to Review Experimental Kidney Cancer Drug
- Study Evaluates the Impact of Specialty Pharmacy Management for RA Patients
- NCPA Releases Report Examining Their Success in Advancing Medication Adherence
- Express Scripts' Drug Trend Reports Specialty Drug Spend Increased 22.6 Percent
- Novo Nordisk Launches HemaGo Application for Hemophilia Patients and Caregivers to Track Treatment Details
- St. Joseph's Hospital Launches State-Wide Program to Help Diagnose and Treat Hep C Patients
- CDC Report: Over Half of Young HIV Infected Americans Are Unaware They Have It
- European Commission Approves Eylea for Wet AMD
- Gilead Announces Positive Results from Phase III Study for All-Oral Hep C Drug Program
- FDA Grants Orphan Drug Status for Seattle Genetics' Adcetris
- Continuing Efforts by Health Departments As Meningitis Infection Sickens Over 500 Nationwide
- Study Shows Tivantinib Effective As Second-Line Therapy for Certain Patients with HCC
- Specialty RN Source Announces Agreement to Provide Nursing Services for The Hemophilia Alliance Members
- New Rule Approved Prompted by National Meningitis Outbreak
- Aspireo Receives Positive Opinion from EMA for Orphan Disease Designation for Somatoprim
- Atox Bio Announces Positive Results in Phase II Trial of Experimental Drug AB103 for Treatment of NSTI
- UNAIDS World AIDS Day Report Shows Promising Results
- Study Identifies Communication Gap Between Physicians and Pharmacists
- Lawyers Argue Over Motion to Freeze Assets of NECC Companies & Executives
- FDA Approves Implantable Pump for Heart-Transplant Candidates
- Shire & Boston Children’s Hospital Collaborate for Novel Therapies in Rare Diseases
- HHS Releases Implemented Provisions to Healthcare Law
- FDA, State Pharmacy Boards, and CMS Receive Letters Questioning Regulatory Actions Related to the Meningitis Outbreak
- Study Shows Avastin Effective for Newly Diagnosed Glioblastoma Patients
- IntelliDex Developing Capability for Pharmaceutical Knowledge/Decision Support System to Read EHR
- Cystic Fibrosis Foundation Therapeutics Partners with Pfizer to Discover New Treatments for Patients with Most Common Mutation
- Dr. Reddy’s Launches Generic Version of PAH Drug, Revatio
- FDA Approves Promacta for Hep C Patients with Low Blood Platelet Counts
- Financial Affordability Considered Main Cause for Lack of Compliance to Current Guidelines
- FTC Gives Clearance For Valeant Medicis Deal
- The Zitter Group: Payers Will Allow Access to Xeljanz
- New Regulatory Rules Needed for Compounding Pharmacies
- Kroger Announces Merger with Axium Pharmacy, Gaining Entry to the Specialty Pharmacy Market
- Pernix Acquires Cypress and Hawthorn for $101 Million
- CSPN Signs Distribution Agreement with Dara BioSciences for Soltamox
- MannKind Sells Cancer Drug Rights to Colby
- Panel Rigorously Questions FDA Over Lack of Regulation on Compounding Pharmacies Acting As Manufacturers
- State pharmacy officials knew convict led oversight firm
- Genzyme Announces Supply of Oncology Drug, Thyrogen, Has Been Fully Restored
- Extended Trial Shows Experimental RA Pill Maintains Effectiveness in Reducing Painful Symptoms
- ViiV Announces Dolutegravir Reduces Virus Count in Treatment-Resistant HIV Patients
- Synthetic Biologics to Acquire Clinical-Stage C Diff Infectious Disease Program
- FDA Reports Contamination Issues at Ameridose
- Novogen to Acquire Triaxial for $1.8 Million
- Celgene's Pancreatic Cancer Drug Met Primary Endpoint in Phase III Study
- FDA Approves Higher Strength of HIV Drug
- Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression in Patients with Active RA
- Specialty Pharmaceuticals: Facts, Figures and Trends Executive Summary
- Abbott Plans Phase III Studies for Hep C Drugs Due to High Cure Rates in Aviator Trial
- Ameridose Will Lay off Hundreds of Employees As Meningitis Investigation Continues
- Immune & EpiCept Enter into Definitive Merger Agreement
- Analysis Finds Improvements in Health-Related Quality of Life for Hereditary Angioedema Patients Treated with C1-Inhibitor
- National Hemophilia Foundation’s Annual Meeting: “Mapping Our Future”
- Director of Massachusetts Pharmacy Board Fired
- Study Suggests Statins May Reduce Risk of Cancer-Related Death
- FDA Advisory Panel Votes 10-0 in Favor of Novartis' Signifor for Cushing's Disease
- Obama's Re-Election Eliminates Repeal of Healthcare Reform Law, but Challenges Still Exist
- FDA Approves Pfizer’s Oral RA Drug
- FDA Grants Priority Review for Genentech's Breast Cancer Treatment
- NECC Co-Founder Subpoenaed; Front-Line Employees Could Lose License
- Panel Hearings Scheduled on Meningitis Outbreak
- Supermolecule Could Detect Cancer Early to Help Destroy Tumors and Monitor Treatment
- OncoGenex Completes Patient Enrollment for Phase 3 Study For Prostate Cancer Drug
- Novartis' Treatment for Cushing's Disease Appears to Be Effective
- BioMarin Announces Positive Results from Phase 3 Study for Treatment of Rare Disease, MPS IVA
- Two New Illnesses Reported In Successfully Treated Meningitis Patients
- FDA Will Delay Decisions For Certain Drugs Whose Target Dates Were During Hurricane Sandy
- MorphoSys and Xencor Report Clinical Data for CLL Drug
- Massachusetts Board of Pharmacy Approves Emergency Regulations on Compounding Pharmacies
- NICE Issues Final Draft Guidance Recommending Two New Treatments for Advanced Malignant Melanoma
- Vertex & GSK Collaborate for Hep C Treatment
- NECC Sister Company Recalls Products Due to Potential Sterility Concerns
- Watson Announces Their New Name: Actavis
- J&J Announce New Supplies of Crucial Cancer Drug in Europe
- Trials Show Lemtrada May Be Useful for Treating MS, But Costs May Be Too High
- Express Scripts Study Shows Medication Use for Normal Aging Conditions Overtakes Costs of Treating Most Chronic Diseases
- Meningitis Outbreak: 28 Deaths & Compounded Pregnancy Drug Under Scrutiny
- Beaumont Health System & Henry Ford Health System Plan to Merge
- BioCryst Withdraws Investigational New Drug Application for HCV Drug
- Walgreens & Alliance Boots Form Joint Venture Company
- Crisis of Contaminated Drugs Spreads to 19 States, and Causes A Second Compounding Pharmacy to Shut Down
- Amgen & KPCB Form Atara Biotherapeutics Focused on Therapies for Chronic Diseases
- Celldex Announces Positive Results in Early Study for Experimental Tumor Vaccine
- ViiV & Shionogi Announce New Agreement for HIV Integrase Portfolio
- Meningitis Outbreak Investigation Continues
- Oncology Systems Limited Signed a Multi-Year Research & Collaboration Agreement with UHB
- FDA Approves Teva’s Leukemia Drug
- Value Creation in the Specialty Space- The Investor’s Perspective Panel Discussion
- The Evolution of the Specialty Pharmacy Industry Panel Discussion
- FDA Grants Priority Review of Ariad Leukemia Drug
- Catamaran Launches BriovaRx Specialty Pharmacy Program
- Meningitis Cases Rise to 317, Deaths total 24, Victims File Suit Against Physicians and Clinics for Administering Tainted Shots
- Therigy Kicks-off 1st Annual Leadership Congress Tonight
- Antiviral Drugs May Reduce Liver Cancer Risk in Patients with Hepatitis C
- FDA Rejects United Therapeutics' Oral PAH drug
- Officials Find NECC's Sterility Process Was Not Up to Standard, Number of Cases Rise to 308
- Therigy’s Specialty Pharmacy Leadership Congress Convenes This Week
- Celgene’s Multiple Myeloma Drug Meets Primary & Secondary Endpoints in a Phase III Study
- Study Finds GSK/Abbott Combo Kills Triple-Negative Breast Cancer Cells
- Actelion Submits NDA for PAH Drug
- Pfizer to Acquire NextWave for up to $700 Million
- The Meningitis Outbreak Continues to Cause Scrutiny for Compounding Pharmacies & Regulatory Agents
- Study Shows Long-Term Use of Multivitamins May Lower Cancer Risk Among Men
- Bayer Announces Positive Results from Phase III Study for PAH Drug
- BioCryst & Presidio Sign Merger Agreement, Expanding Hep C and HAE Portfolio
- Specialty Pharmacy Certification Board Announces Certified Pharmacy Officer Feasibility Study
- FDA Extends Review of Biogen's Multiple Sclerosis Drug
- Federal Authorities Confirm the Meningitis Outbreak Source
- BMS’ Metastatic Melanoma Drug, Yervoy Received the Prix Galien USA 2012 Award for
- FDA Approves Jetrea for VMA's
- Pfizer’s Inlyta Misses Primary Endpoint in Trial for Advanced Renal Cell Carcinoma
- The US FDA Under Scrutiny for Improper Regulatory Actions as The Meningitis Outbreak Causes 4 More Deaths
- CSI Group to host 1st Annual TEXAS HOLD ‘EM TOURNAMENT and Silent Auction to Benefit National Hemophilia Foundation Travel Scholarship Fund.
- Merck Announces Positive Results from a Phase II Trial for Osteoporosis Drug in Post-Menopausal Women
- Kerr Drug Launches Mobile Pharmacy App
- Novo Nordisk Submits Regulatory Applications for Hemophilia A Drug
- Lilly's Gastric Cancer Drug Meets Its Primary Endpoint in A Phase 3 Study
- Abbott's Investigational Hep C Drug Cures 99 Percent of Hard-To-Treat Patients
- US FDA Warns of Additional Contaminated Drugs Made by NECC
- Walgreens WellTransitionsSM Provides Discharge Services to Help Hospitals and Health Systems Reduce Readmissions
- FDA Approves Expanded Indication for Actemra in RA Patients
- Health Care Reform Impact: More Insured Americans Compared to 18 Months Ago, BusinessOne Technologies, Inc, Reports
- Celgene Announces FDA Approval of Abraxane for Non-Small Cell Lung Cancer Drug
- Biogen Announces Positive Data for Oral MS Drug
- Meningitis Cases, Deaths Continue to Rise
- Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical Trial of APD811 for Pulmonary Arterial Hypertension
- EMD Serono Launches $1.3 Million Research Grant for Multiple Sclerosis Innovation
- Link Between Gluten and Immune Reaction Revealed for HLA-DQ8 Celiac Disease
- Osteoporosis Drug, Binosto, Now Available in the US
- Study Shows Priority Review Drugs Are More Likely to Have Safety Issues
- Alexion Announces Data from Phase II Study for Experimental Therapy for Rare Neurological Disorder
- Cancer Vaccine Demonstrates for 1st Time that a DNA-Based Therapeutic Vaccine Can Produce Immune Responses to Kill Target Cells
- Oxford BioMedica Closes US Study for TroVax for Treatment of Prostate Cancer
- Meningitis Outbreak Due to Tainted Steroid Injections Cause 12 Deaths in the US
- Cystran Receives FDA Approval for Treatment of Corneal Cystine Crystals in Cystinosis Patients
- Sanofi and Massachusetts General Hospital Launch Oncology Research Collaboration
- MedImmune Joins Forces With Leading Cancer Organizations to Advance Novel Immunotherapy Research
- Orlando to Host World's Largest Cystic Fibrosis Medical Meeting
- National Association of Specialty Pharmacy Inaugural Event Held
- Therigy to Host First Annual Specialty Pharmacy Leadership Congress
- New Model Compares Subcutaneous Immunoglobulin Therapy with Intravenous Immunoglobulin
- Some Physicians Still Using MS Procedure Despite FDA Warning
- Update from AMCP's 2012 Educational Conferece, Cincinnati, Ohio
- Aragon Raises $50 Million to Advance Their Cancer Pipeline
- Celgene Announces FDA's Decision Against Meeting for Cancer Drug
- MRSA Survivors Rally for World MRSA Day
- Merrimack Pharmaceuticals’ Therapies Show Promise in Certain Advanced Breast, Gastric and Gynecological Cancers
- Aethlon Medical Releases Hepatitis C Virus (HCV) Treatment Protocol and Inclusion/Exclusion Criteria Underlying Compassionate-Use Commercialization Program
- Quest PharmaTech Acquires Immunoglobulin E Technology to Strengthen its Combination Therapy Approach for the Treatment of Cancer
- Florida to Test Newborns for SCID, a Life-Threatening Immune Disease
- SPCB contracts with Comira to develop Certified Specialty Pharmacist Exam
- Catamaran Corporation Unveils New Specialty Pharmacy Offering
- New Hepatitis C Data from Boehringer Ingelheim to be Presented at AASLD Annual Meeting
- Aveo and Astellas Submit NDA for Tivozanib for Treatment of Advanced Renal Cell Carcinoma
- FDA Campaign Aims to Protect Consumers from the Risks of Fake Online Pharmacies
- New Boehringer Ingelheim Data to be Presented on Health-Related Quality of Life with Afatinib in Patients with EGFR Mutation-Positive Advanced NSCLC
- West Penn Allegheny Health System Moves On From Affiliation Agreement with Highmark
- AMCP’s 2012 Educational Conference: Last Chance to Register!
- New Methods to Fight HIV Discovered in New Research Study, Significant Connections Made
- Achillion Announces Positive Proof-of-Concept Data with ACH-3102
- FDA Approves Stivarga for Colorectal Cancer
- Novartis Announces Positive Data for Experimental Psoriasis Drug
- Biogen and Sobi Announce Positive Results for Long-Lasting Recombinant Factor IX FC Fusion Protein in Hemophilia B
- Amgen’s Osteoporosis Drug Gets Expanded Indication
- Vertex Ends Work on One Hepatitis C Drug, Continues Another
- CSPN Announces A Preferred Vendor Partnership with Rx Timer Cap
- High-Dose Vitamin C Reduces Inflammation in Cancer Patients Study Shows
- Unraveling Accreditation, Certification, and Certificate Programs
- Valeant Acquires Visudyne Drug from QLT
- Peregrine Says Lung Cancer Trial Data Erroneous, Shares Sink
- MorphoSys Announces Positive Results for Investigational RA Drug
- Novo Nordisk Invests An Additional $100 Million to Expand Facilities in China
- FDA Allows Halozyme & ViroPharma to Resume Clinical Trials for HAE Drug
- Astex Pharma Ends Development of Lung Cancer Drug
- U.S. House of Representatives passes Recalcitrant Cancer Act (H.R. 733)
- EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Wet Age-Related Macular Degeneration in Europe
- New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- Specialty Pharmacy Certification Board Announces Inaugural Board of Directors
- National Association of Specialty Pharmacy (NASP) Plans Launch
- Ablynx Announces Positive Results for Their Phase I Study for Treatment of RSV
- New Imaging Device for Dense Breasts Approved for Cancer Detection
- Lundbeck Notifies Physicians of Discontinuation of Their Leukemia Drug, Elspar
- Kaiser Permanente Study Finds Least Aggressive Form of Breast Cancer Still Poses Risk for Death Years Later
- Scientists Develop A Nose-Like Sensory For Cancer Diagnoses
- Genomic Health Announces Positive Topline Results of Large Prostate Cancer Clinical Validation Study; Company to Proceed with 2013 Commercial Launch
- NIH Study Documents Genetic Mutation That Increases Production of Red Blood Cells in Tumors
- Possible Misleading Data on Threshold’s Prostate Cancer Drug Results in A Major Drop in Stock
- Bionomics Limited Acquires Eclipse Therapeutics
- Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
- Oncolytics Lung Cancer Drug Meets Main Goal in Mid-Stage Trial
- Generex Biotechnology Announces Presentation of Early Results Showing Activity of Cancer Vaccine in Patients with Triple Negative Breast Cancer
- Oncodesign Enters into Agreement with Sanofi for Oncodesign’s Nanocyclix Technology for Advancement of Kinase Programs
- Study Reaffirms Effectiveness of HIV Prevention Pill
- Sanofi’s MS Drug Aubagio Gets FDA Approval
- Published Preclinical Data Demonstrate Ability of Gliknik's Recombinant Stradomers™ to Mimic Anti-Autoimmune Effect of IVIG
- New Common Application for HIV/AIDS Medicines Available Through Johnson & Johnson Patient Assistance Foundation, Inc.
- FDA Postpones Approval of Navidea’s Lymphoseek for Cancer Patients
- Understanding Professional Certification
- New Discoveries about HIV Vaccine Revealed
- Cellectis: Progress Towards a New AIDS Therapy
- Zalicus Discontinues Trial for RA Drug, Synavive
- Geron Halts Breast Cancer Trial, Stock Hits Life Low
- Gastroenterologists Advise on Prescribing Challenges for Emerging Crohn's Therapies
- Experts Determine The HIV Preventive Pill May Have Small Affect in the US
- AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
- Pfizer & SFJ Collaborate to Develop A New Lung Cancer Drug
- Walgreens and Ferring Collaborate to Provide Free Access to Fertility Products for Women with Ovarian Cancer
- Eli Lilly's Lung Cancer Trial Fails to Meet Primary Endpoint
- Faster Approvals for Oncology Drugs than Non-Oncology in the US, But Not in the EU
- Merck Serono Announce An Exclusive Worldwide License Agreement with Symphogen for Treatment of Colorectal Cancer
- Advisers Recommend FDA Approval of Antibiotic for Lung Infections Associated with Cystic Fibrosis
- FDA Delays Decision on Salix’s Drug for HIV-Related Diarrhea
- European Regulators Okay Pfizer’s Inlyta for Kidney Cancer Patients
- Novartis Trial Data Confirms Benefits of Lucentis
- Pfizer’s Leukemia Drug Bosulif Receives FDA Approval
- Valeant Agrees to Acquire Medicis for $2.6 Billion
- Gene Sequencing Project Builds the Foundation for Next Generation of Childhood Cancer Care
- Hepatitis C Biopump Trials Receives Green Light
- FDA Warns Against Revatio in Pediatric Patients with PAH
- Specialty Pharmacy Certification Board (SPCB) Considers Adding Hep C as Additional Qualification to their CSP Credential
- Xtandi Receives FDA Approval for Patients with Prostate Cancer
- Ariad Submits Marketing Authorization Application for Ponatinib to the EMA
- FDA Approves Afinitor Disperz for Pediatric Patients With A Rare Brain Tumor
- The Changing and Challenging Continuum of Care for Specialty Brands
- Janssen Wins Worldwide Agreement with Genmab for Daratumumab
- Treatment for Severe Neutropenia in Select Cancer Patients Gets FDA Nod
- FDA Notifies of The Risk of Cataracts for Pediatric Patients Taking Vertex’s CF Drug
- FDA Grants Priority Review for Janssen’s Zytiga
- Hospira Receives A Warning Letter Over Costa Rica Infusion Pump Plant
- FDA Panel Recommends Expanded Use of Abbott's RA Drug
- Genzyme Recalls Its Kidney Transplant Drug
- Merz Acquires The Orphan Drug Cuvposa Oral Solution
- New Study Suggests NSAIDs Not Linked to Breast Cancer Risk
- What the Future Holds for HCV Sufferers
- Gilead’s Quad Pill Receives FDA Approval for Treatment of HIV
- FDA Puts Hold on Another Idenix Hep C Study
- Roche’s Breast Cancer Drug Improves Survival in Breast Cancer Patients
- Teva Begins Third Round of Research for its Experimental MS Drug
- Navarro Health Care Services' Prescription Fulfillment Center Facility is Leading the Way In Best In Class Pharmacy Care
- Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Metastatic Soft Tissue Sarcoma
- Bristol-Myers Squibb Forced to Halt Studies of its Experimental Hep C Treatment
- Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
- Biodesix Announces New VeriStrat® Data to be Presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology
- FDA Issues A Warning for Reumofan Plus and Reumofan Plus Premium
- Walmart Pharmacy Offers Vaccines for Infectious Diseases
- New Findings Between MS and Vein Trouble
- Allergan Enters into An Exclusive Alliance with Molecular Partners
- NICE Says Avastin’s Benefits Do Not Justify Its Cost for Treatment of Metastatic Breast Cancer
- FDA Extends Review Period for Pfizer’s RA Drug by Three Months
- MOMS Pharmacy Acquired by AIDS Healthcare Foundation
- TNF Inhibitors May Lower Heart-Associated Risks for Psoriasis Patients
- Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
- Updated Oncology Guidelines Reflect the Needs of Obese Patients
- Patient Advocate Foundation Receives Significant Support to Aid Non-Squamous Non-Small Cell Lung Cancer Patients through the Co-Pay Relief Program
- Application of Automatic Co-Pay Reductions Programs On the Rise in Select Therapeutic Categories
- Cancer Treatment Potential Found in “Nanojackets”
- The US Preventive Services Task Force May Make HIV Testing A Standard Practice
- FDA Puts Idenix’s Hep C Drug on Hold due to Heart-Related Side Effects
- At-Home Kits Increase CRC Screening
- Pre-Test Genetic Counseling Benefits Breast Cancer Patients
- Express Scripts Launches New Tool to Help Patients Understand their Therapy
- Study Shows New Drug Extends Survival for Prostate Cancer Patients
- Specialty Pharmacy Certification Board Partners with SeaCrest Company to Develop Certification Program
- Denosumab Shows Superiority for Bone Complications in Patients with Breast Cancer
- Biovest Conducts Phase III Review for their Consolidation Therapy in Non-Hodgkin’s Lymphoma
- HHS Awards $68 million in Grants for HIV/AIDS Care
- Treatment for AML May be Improved Due to Gene Discovery
- New Research Triggers a Need for Updated Guidelines on Radiation for Older Breast Cancer Patients
- Low Dose Ampyra Fails to Confirm Efficacy for MS Patients
- Hepatitis C Treatment May Stunt Growth in Children
- Connection Between Hormonal Contraception and Tenofovir Levels Still Undetermined
- FDA Approves Lucentis for DME
- Novartis' Drug Shows Positive Results for Liver Transplant Patients
- Effects of Daily Aspirin Intake and Risk of Cancer Death Reevaluated
- Bladder Cancer Advocacy Network Announces Major Research Program at Annual Scientific Meeting
- Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC)
- Humira Shows Promising Signs for Children Suffering from Crohn’s Disease
- Supplements Taken During Hormone Depletion Therapy Shown to Increase Cancer Risk
- Baxter Announces Discontinuation of GAMMAGARD S/D
- Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
- FDA Approves Talon's Marqibo for Adults with Rare Leukemia
- New Phase Three Study Shows Positive Results for Oral JAK Inhibitors
- Hospira Re-launches its Generic Chemotherapy Treatment
- Codman’s MEDSTREAM Receives FDA PMA Approval
- Making it Official: Certification of Health Professionals for Specialty Pharmacy
- Teva & Active Biotech Announce a Phase III Trial for their MS Drug
- Agennix’s Experimental Lung Cancer Drug Fails to Meet Primary Endpoint, Shares Fall
- Achillion's Experimental Hep C Drug Shows Promise in Mid-Stage Trials
- Adalimumab Is a Promising Therapy for Children with Crohn’s Disease
- New Class of Cancer Drugs Reduces Cellular Damage from Chemo
- PLX Cells Save Another Life of a Cancer Patient Encouraging Pluristem to Apply for FDA Orphan Drug Approval
- OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
- Qualitest Launches Generic Singulair®
- ViroPharma Receives FDA Approval of Cinryze® (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
- New ALS Study Suggests that Lou Gehrig's Disease Progression May Be Tracked With Simple Blood Test
- Fuse Science Announces Landmark Licensing Agreement with Industry Leader Macular Health
- Zaltrap Gets FDA Approval for Patients with Metastatic Colorectal Cancer
- CSL Behring Awards Advocacy Grants to Patient Groups in Six States: NC, CA, WA, PA, IL, NY
- BMS’ Hep C Drug Clinical Trial Suspended due to Safety Issues
- CoramRx Specialty Pharmacy Services Receives URAC Specialty Pharmacy Accreditation
- FDA Requires More Information on Baxter's Immune Globulin, Shares Plummet
- Prime Therapeutics Announces Prime Therapeutics Specialty Pharmacy
- Vertex's Hep C Drug Shows Positive Results
- Ariad Announces Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration
- Pfizer Announces Positive Top-Line Results From The ORAL Start Phase 3 Study Of Tofacitinib In Rheumatoid Arthritis
- Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) Seven Days After Initiation of Hemopurifier® Therapy in Genotype-1 Patients
- OrPro Therapeutics Receives NIH Grant Award to Advance Development of Recombinant Thioredoxin for Treatment of Cystic Fibrosis
- Cystic Fibrosis Foundation Unveils a New Logo
- Advanced Specialty Rx Opens Long Term Care Pharmacy
- URAC Awards MedPro Rx with Specialty Pharmacy Accreditation
- Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
- CVS/pharmacy's "Project Health" Bringing Free Health Screenings to 10 Cities During August
- New Specialty Pharmacy Certification Board to Certify Specialty Pharmacists
- Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
- Researchers at University of Tennessee Develop Laser that Maps and Zaps Cancerous Tumors
- Ligand and GSK Granted Priority Review for Treatment of Thrombocytopenia in Patients with Hep C
- Idenix's Experimental HCV Drug Granted Fast Track Designation by FDA
- American Society of Hematology Launches Multi-Million-Dollar Grant Program to Support Critical Blood Disease Research
- Walgreens and HHS Collaborate on Development of Medication Therapy Management Model to Help Improve Health Outcomes for HIV Patients
- Aeterna Zentaris Requests Fast Track Designation for Their GHD Diagnostic Test
- Enzalutamide Granted Priority Review by U.S. FDA for the Potential Treatment of Castration-Resistant Prostate Cancer in Patients Previously Treated With Chemotherapy
- Pluristem Prepares to File Application for Orphan Drug Designation for Its Experimental Bone Marrow Therapy
- Biokine Therapeutics Awarded FDA Orphan Drug Designation for Mobilization of Stem Cells in Cancer Patients
- FDA Warns Ampyra Increases the Risk of Seizures in MS Patients
- New Specialty Pharmacy Certification Board™ to Certify Specialty Pharmacists
- FDA Approves Tudorza Pressair to Treat Chronic Obstructive Pulmonary Disease
- CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
- New Study Finds Greatly Elevated HIV Infection Rates Among Young Black Gay and Bisexual Men in the U.S.
- Novartis’ Afinitor Receives FDA Approval for Patients with Advanced Breast Cancer
- U.S. Launches Interactive HIV/AIDS Database on Census.gov
- Diplomat Specialty Pharmacy’s 2012 Physician Satisfaction Survey Results Affirm Success of Company’s Education & Training Program
- FDA Grants Accelerated Approval for Onyx’s Kyprolis Injection for Multiple Myeloma Patients
- Scientists Set New Road Map for AIDS Cure
- BMS' Liver Cancer Drug Fails to Meet Primary Endpoint
- World’s First Intensive Study of Postpartum Women with von Willebrand Disease Shows Potential Risk of Delayed Hemorrhage, Despite Treatment
- The American Fertility Association Announces 'Family Building Options for Men with HIV'
- Galena Awarded Patent For Vaccine To Prevent Breast Cancer Recurrence
- Express Scripts and Walgreens Announce New Pharmacy Network Agreement
- Amicus & GSK Collaborate for Potential Fabry Disease Medications
- Colon and Rectal Tumors Represent a Single Type of Cancer Study Shows
- Zogenix Announces U.S. FDA Acceptance for Review of Zohydro ER(TM) New Drug Application for Treatment of Chronic Pain
- NACDS Briefs Congress on Drug Abuse, Patient Access Strategies
- New Study Shows Interferon Beta to be Ineffective in Preventing MS Patients' Progression to Irreversible Disability
- Vitamin E Intake Associated with Reduced Risk of Liver Cancer
- IVIG Prevents Alzheimer Patients' Cognitive Decline in a Three-Year Study
- Grifols Initiates Safety Study Following Orphan Drug Designation for their CF Drug
- Brain Lesions in MS Patients Reduced by Stress Management
- European Commission Grants Orphan Medicinal Product Designation for Emmaus Medical's Sickle Cell Treatment
- TPG to Acquire Par Pharmaceuticals for $1.84 Billion
- Four Cancer Drugs with Glass Particles Recalled by Hospira
- GSK to Acquire Human Genome Sciences for $3.6 Billion
- New Tools Help Match Cancer Drugs with Gene Targets
- FDA Approves First Drug for Reducing the Risk of Sexually Acquired HIV Infection
- CVS Caremark Research Identifies Positive Link Between Medication Adherence and Employee Productivity
- Eisai’s Halaven Does Not Meet Primary Co-Endpoints in Study
- Watson’s Generic Arthritis Drug Receives ANDA
- Merck’s Osteoporosis Drug Trial Stopped Early due to Apparent Effectiveness
- Gilead's HIV-Prevention Drug Truvada Experiences High Success Rates in Recent Studies
- BioRx Acquires Coagulife Pharmacy
- Omnicare Buys Five Star Pharmacy Business for $30.7 Million
- GSK’s HIV Drug Displays Superiority to Gilead’s Atripla in a Phase III Study
- FDA Puts Hold on Ipsen’s Hemophilia Drug
- Department of Defense Awards SRI International with a Grant for Oral MS Drug
- New Guideline Recommendations for Sentinel Lymph Node Biopsy in Melanoma Patients
- FDA Mandating Opioid Makers Fund Training Programs
- SXC Health Solutions Unveils a New Name Following Merger: Catamaran
- $2.5 million gift to establish new treatment center
- Qiagen’s Gene Testing Kit Approved to Identify Patients who will Benefit from Erbitux
- WellPoint to Acquire Amerigroup Corporation for $4.9 Billion
- Study Suggests Fertility Drugs are Linked to the Risk of Developing Breast Cancer
- Apothecary Shops buys Colorado Pharmacy
- CSL Behring Launches New Hizentra® Dosing Calculator App for Healthcare Professionals on the Move
- Amgen Completes Acquisition of KAI Pharmaceuticals
- Merck’s Stomach Cancer Drug Fails in Late-Stage Trial
- Zytiga Plus Prednisone Show Improvements in Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer
- Unapproved Oxycodone Drugs Ordered Off the Market by FDA
- Walgreens to Acquire USA Drug Pharmacy Chain in Mid-South
- FDA Approves Over-the-Counter HIV Test
- The Zitter Group announces new management team to continue its rapid growth
- Leukemia and Lymphoma Society to Provide Additional $5 Million for Celator's Phase 3 Study of Acute Myeloid Leukemia Drug
- GSK Will Pay $3 Billion for Fraud Settlement
- Analysis of Krystexxa® Phase III Data Demonstrates Improved Health-Related Quality of Life and Physical Function in Refractory Chronic Gout Patients
- Roche Announces FDA Approval of HIV Viral Load Test
- Gilead Submits NDA for Cobicistat, HIV Drug Boosting Agent
- Vertex’s Shares Fall Despite Positive Final Results for Cystic Fibrosis Drug
- How Today's Approval of Obamacare Affected Different Branches of the Health Care Industry
- The FDA Granted Priority Review Designation to Bayer’s NDA for Regorafenib for Colorectal Cancer
- Janssen Completes Acquisition of CorImmun GmbH
- PRIMA Study Shows Treatment with Privigen® Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Multiple Sclerosis Association of America's MRI Institute Marks 10 Years of Helping Individuals with Multiple Sclerosis Obtain MRIs
- ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product for Patients with Sickle Cell Disease
- Texas Children's Cancer Center Receives $10 Million Gift to Open The Fayez Sarofim Lymphoma Center
- Ablynx’s Arthritis Drug Shows Greater Benefits than Competitor
- FDA Approves Blood Test for Detection of Prostate Cancer
- Walgreens, Erase Doubt and Greater Than AIDS Team Up to Give Free HIV Screenings in Honor of HIV Testing Week 2012
- Recommended New Lung Cancer Screening Guidelines
- New Legislation To Make USPSTF More Transparent: Prostate Cancer Roundtable Supports Reform
- China Biologic Receives SFDA Manufacturing Approval Certificate for Human Coagulation Factor VIII
- Protalix and Pfizer's New Gaucher Drug Fails to Gain Recommendation by EU Regulators
- The AIDS Institute Highlights Opportunities for HIV Tests to be Covered by Payers
- New Candidate Drug Stops Cancer Cells, Regenerates Nerve Cells
- New Research Reveals Some Natural Supplements Effective Against Prostate Cancer
- House Sends FDA Bill to Senate
- CMTP Publishes Patient-Reported Outcomes Guidance for Adult Cancer Trials
- Gene Sequencing Project Identifies Potential Drug Targets in Common Childhood Brain Tumor
- Idenix's Experimental Hep C Drug Shows Promise
- Community Specialty Pharmacy Network Announces Partnership with CoverMyMeds
- SXC Health Solutions Awarded URAC Specialty Pharmacy Accreditation
- FDA Issues Complete Response Letter For Pfizer's Tafamidis Meglumine New Drug Application
- Liver Injury Linked to Arthritis Medication
- Health Regulators Say Carfilzomib's Benefits Outweigh its Risks for Patients with Multiple Myeloma
- Walgreens and Alliance Boots Form Strategic Partnership to Create the First Global Pharmacy-Led, Health and Wellbeing Enterprise
- Nanotechnology Products Linked to Autoimmune Disorders
- New Study Links Avastin with Risk of Intraocular Inflammation for Patients with AMD
- Inostic’s BEAMing Technology Detects Cancer Resistance through Blood Tests
- Producers of Biosimilars Concerned About Possible Over-Turning of Affordable Care Act
- Valeant Pharmaceuticals Agreed to Acquire Orapharma for $312 Million
- Teva's New Version of MS Drug Meets Goals in Late-Stage Clinical Trial
- Ophthotech’s Fovista Meets Endpoint for AMD
- Apothecary Shops to Become Avella in August 2012
- Research Shows "Common Cold" Virus Helps Fight Cancer
- Immunomedics Develops Potential New Treatment Regimen For Non-Hodgkin Lymphoma
- Quest PharmaTech Initiates Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in United States
- Florida Hospital Medical Group and MinuteClinic Enter Into Clinical Collaboration in Central Florida
- Upsher-Smith Announces Transaction to Acquire UK-Based Proximagen
- Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
- Tokai Pharmaceuticals’ Galeterone Receives Fast Track Designation from the FDA for the Treatment of Advanced Prostate Cancer
- NIH & Children’s National Medical Center Collaborate to Find New Treatments for Rare Disorders
- Diesel Exhaust Fumes Linked to Lung Cancer
- Patients with Advanced Prostate Cancer Find Hope in Radioisotope Therapy
- Genzyme Submits Applications for Approval of Lemtrada for Patients with Relapsing MS
- HIV Superinfection Rate Similar to Initial HIV Infection
- Mevion S250 Patented Technology Significantly Reduces the Cost of Implementing and Operating Proton Therapy Centers
- Amber Pharmacy and Argus Health Systems Collaborate to Expand Specialty Pharmacy Options
- Gilead’s HIV Prevention Drug’s Expected Approval Date Delayed by FDA
- FDA Approves Roche's Drug for Patients with HER2 Positive Metastatic Breast Cancer
- CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
- FDA says Shortages of Injectable Boniva in Short Supply
- RAPID™-PsA Study Showed that Certolizumab Pegol Improved the Signs and Symptoms of Psoriatic Arthritis
- CT Scans Increase Risks of Cancer in Children
- Study Results Realeased at 2012 ASCO Meeting Proves Chemotherapy Superior to Targeted Treatment
- Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Peripheral Spondyloarthritis
- Perrigo Receives FDA Approval For Their Experimental Renal Drug
- New Data For Stelara® 5-Year Study Shows Consistent Efficacy and Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis
- FDA Demands More Information for Merck/Ariad's Experimental Sarcoma Treatment
- Actemra Shown to be More Effective than Humira for RA Patients
- Express Scripts Sees Benefits from Merger
- Ariad’s Ponatinib Shows Signs of Promise for Leukemia Patients
- Combination Therapy for Inflammatory Breast Cancer Deemed Clinically Insignificant by Researchers
- Shortages of Oncology Drugs on The Decline
- Risk of Rheumatoid Arthritis Higher in Obese Women
- Pharmacyclics® Announces Updated Results for BTK Inhibitor Ibrutinib at ASCO
- Roche’s Cancer Drug Delays Tumor Growth for Patients with Breast Cancer
- CVS Caremark Research Finds Most Consumers who Qualify for Health Care Reform Subsidies Haven't Heard of State Insurance Exchanges
- Gout Flares Substantially Increased with Certain Foods
- Genzyme's MS Drug Reduces Symptoms in their Phase 3 Study
- McKesson and ValueOptions Announce their Strategic Partnership to Increase Coordinated Care
- Methotrexate Injection Not Superior to Oral Therapy in Treating Juvenile Arthritis
- Personalized Exercise May Increase Cancer Patients’ Survival
- Boehringer Ingelheim and CancerCare Launch My Cancer Circle
- House of Representatives Vote in Favor of FDA Funding Bill
- Prime Enhances Its Oncology Management Program
- Clinical Pathways Can Help Manage Cancer Patients
- FDA Rejects Janssen’s Marketing Application for Once-a-Day HIV Drug
- World MS Day 2012: Raising Global Awareness
- HIV-Related Lymphoma Patients Benefit from Combo Treatment
- CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
- Vertex Corrects Previously Reported Data for their Combo Therapy for Cystic Fibrosis
- Anti-Inflammatory Drugs Shown to Reduce Risk of Skin Cancer
- New Phase 3 Study Results Show Anti-TNF Simponi® Induced Clinical Response in Adults with Moderately to Severely Active Ulcerative Colitis
- Antiretrovirals Linked to Decrease In Hospital Mortality Rates in HIV Patients
- Bayer Submits NDA to the FDA for their Colorectal Cancer Drug
- MRI’s Best for Tracking Chemo Response for Patients with Breast Cancer
- Many Health Plans Fail to Meet New Standards In the Evolving Health Plan Landscape
- Breast Cancer Tumors Reduced by Celldex’s Cancer Drug
- FDA Panel Recommends Against Approval of Xarelto for Expanded Use
- Mylan Receives Final Approval to Launch Generic Version of Viramune
- Study Shows Hep C Causing More Liver Damages
- Takeda Drug Impresses in Ulcerative Colitis Study
- Walgreen’s Specialty Pharmacy moving forward with novel patient services
- CVS Research Finds FDA Drug Warnings Can Have Immediate Negative Impact on Medication Adherence
- FDA Reviewers Recommend Rejection of Pfizer’s tafamidis
- FDA Discovers Autoimmune Reactions with Anti-HIV Drug
- Gout Awareness Day Brings New Recommended Guidelines
- Growth Factors in Stem Cells May Spur Recovery from Multiple Sclerosis
- Bisphosphonate Linked with Atypical Femur Fractures
- Urologists Protest Government Panel's Recommendation to Stop PSA Tests
- Recommended Guidelines for Lung Cancer Screening
- Cancer Death Risk Increased by Sleep Apnea
- Study Shows Sigmoidoscopy Reduces Colorectal Cancer Rates
- FDA Approves New Labeling of Isentress
- New Device in Development that could Restore Sight for Patients with AMD
- CDC Proposing Test for Hepatitis C for All Baby Boomers
- FDA Approves Digestive Care Inc's NDA for Pertzye
- New Drug Shows Positive Results for Elderly Patients with Chronic Leukemia
- J&J’s Prostate Cancer Drug Shows Good Results
- Early Results Show Promise of Breast Cancer Vaccine
- Experimental Combo Drug for Melanoma Slows Cancer
- Study Shows Pfizer’s Xalkori Eliminates Certain Child Cancers
- Researchers Identify Most Likely MS Patients to Develop a Rare Brain Infection
- Messaging in Anticoagulants Category Ahead of Plavix Patent Loss
- Pfizer’s Kidney Cancer Drug Fails to Meet Primary Endpoint
- IDF Requests Exemption of Immunoglobulin from Biosimilars Pathway
- Study Results Show Pazopanib’s Benefits for Patients with Metastatic Soft-Tissue Sarcoma
- Early Biomarker Identified for Pancreatic Cancer
- Achillion's Hep C Drug Gets Fast Track Designation by FDA
- FDA Panel Recommends First At-Home HIV Test
- Cornerstone Therapeutics will Acquire EKR Therapeutics
- FDA Expands Use for FilmArray Respiratory Panel
- Walgreens Launches New & Improved Prescriptions Savings Club
- GSK Acquires Cellzome for $99 Million
- Study Suggests Patients with HIV are Four Times More Likely to Die of Sudden Cardiac Death
- Cardinal Health Settles with DEA for Their Lakeland Distribution Center
- Specialty Pharmaceuticals: Pipeline Update
- FDA Issues A Safety Announcement for Gilenya in Patients with Certain Heart Conditions
- FDA Will Review First At-Home Test for HIV
- Takeda's Vedolizumab Meets Primary Endpoints for Crohn's Disease
- FDA Panel Recommends Gilead’s Quad
- Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
- Positive Results for Novartis' Lucentis
- FDA Panel Recommends Gilead’s Truvada for HIV Prevention
- The National Osteoporosis Foundation Commends the FDA for Analysis of Long-Term Bisphosphonate Treatment
- Studies Show Positive Results for Multiple Myeloma Patients
- FDA Warns of Risks Associated with MS Liberation Therapy
- Medicaid Service Fees to Increase with New Health Law
- US & EU Regulators Accept Biogen’s MS Drug Application
- FDA Panel Recommends Pfizer’s Oral RA Drug
- New Imaging Technique Found for Locating Rare Pancreatic Tumors
- Infections Responsible for 2 Million Cancer Cases
- Non-Embryonic Stem Cell Treatment Promising Cancer Cure
- Advisory Panel Votes Against Recommendation of Regeneron’s Gout Drug
- Gilead’s Truvada Favored by FDA for HIV Prevention
- Aethlon Medical Reports Undetectable HCV in Genotypes 1, 3, & 5 Patients Treated with Hemopurifier Therapy
- Takeda Announces Initiation of Phase III Aethera Trial of Brentuximab Vedotin for Post-Transplant Hodgkin Lymphoma
- Pfizer’s Experimental RA Drug Raises FDA’s Concern
- Vertex’s Cystic Fibrosis Combo Improves Patients' Lung Function
- FDA Revises Revlimid's Label Warning Against Increased Risk of Second Primary Malignancies
- Breast Cancer in Men May Be More Deadly
- H.D. Smith Announces Their Three Year Prime Vendor Agreement with PharmacyGPO
- Walgreens Completes Acquisition of BioScrip's Community Specialty Pharmacies & Centralized Specialty Mail Service Pharmacy Businesses
- FDA Expresses Concern of Arcalyst's Risks for Prevention of Gout
- Biologic in Early RA Effective as Monotherapy
- Armada Specialty Summit 2012 Key Highlights
- CSL Behring Initiates SubQ Administration of C1-esterase Inhibitor in Patients with HAE
- Studies Present Reassuring data on RA Treatment Safety
- FDA asks Baxter to provide more long term safety data for combination product of Immunoglobulin and Hyaluronidase.
- CSL Behring Technology & Innovation Meeting Unmet Needs of Specialty Pharmacy Market
- SPECIALTY PHARMACY CERTIFICATION PROGRAM to Launch this Summer
- Armada Summit 2012: Key Highlights
- Walgreens Adds Six Medications to Oral Oncology Clinical Program
- CVS Caremark's First Quarter Results Reflects Strong Performance
- Actelion Announced Positive Study for Treatment of PAH
- Steroids in Children with Arthritis Linked to Increase of Infections
- Patients Taking Interferon for Treatment of Hep C May Develop Depression
- ISMP Warns of Adverse Effects Related to Infliximab Therapy
- FDA Approved Elelyso for Gaucher Disease
- Expansion of Prior Authorization Policies for Oncology Agents
- Rilonacept Study Shows Reduction in Gout Flares Linked with Uric-Acid Lowering Therapy
- Amerigroup Closes Previously Announced Acquisition of Health Plus
- Improvement in Treatment of Melanoma with Personalized Medicine
- Specialty Rx Source Announces Launch of Specialty RN Source at the INS Annual Convention
- Avastin & Lucentis Yield Similar Improvements for Patients with AMD
- Covalon Technologies Introduces IV Clear at the INS Meeting
- Major Breakthrough in Understanding Macular Degeneration
- Obese Women May Be At Higher Risk for RA
- Study Links Macular Degeneration with Increased Risk of Stroke
- FDA Approves Levaquin for Prevention of Plague
- FDA Rejects the Expanded Indication for Xgeva
- GSK’s Votrient Receives FDA Approval for Soft-Tissue Sarcoma
- FDA Approves Afinitor for Treatment of Non-Cancerous Kidney Tumors
- Cigna’s Reliance on Managed Medicare
- OIG Investigators Request CMS to Establish A National Payment Policy for Avastin
- Baxter Completes Purchase of SIGMA
- FDA Issues Drug Safety Communications for Victrelis
- Novartis Challenges the NHS for Use of Avastin for Wet AMD
- Amgen Acquires Mustafa Nevzat Pharmaceuticals
- Study Determines Shingles Vaccine is Safe
- Rotavirus Vaccines Could Save Over 2.4 Million Lives
- New Data for Alzheimer’s Shows the Need of both Plaque & Protein
- Bartonella Infection Linked with RA
- Specialty Pharma First Quarter Earnings Reports
- Therigy Launches eNewsletter: Specialty PharmaSource
- Pfizer’s RA Drug: Will Safety Concerns Determine Its Fate?
- New Interim Guidance Criteria from ALA Regarding CT Screening for Lung Cancer
- NABP Raises Awareness of Internet Drug Sites
- Enbrel Sales Reps Affected by Transition from Pfizer
- Biogen Idec Announces Positive Results for MS Drug
- AstraZeneca to Acquire Ardea for $1.26 Billion
- Infusion Nurses Society to Convene in Las Vegas
- Novartis Changes Gilenya’s Warning Label
- HCV Drug Trial Stopped Due to Cases of Pancreatitis
- ESI-Medco Merger: What Does This Mean For You?
- Use of Drug Following First Sign of Possible MS Reduces Likelihood of Progression to MS
- HealthyWomen Asks: Do You Know the Signs and Symptoms of Von Willebrand Disease (VWD)?
- AMCP’s 24th Annual Meeting & Expo Highlights Specialty Pharmacy
- SXC Health Solutions Buys Catalyst
- NICE Found Unclear Data of Avastin as a First-Line Therapy
- Experimental MS Drug Shows Positive Results
- BioPlus Launches TAP App for Physicians to Monitor Patient Specialty Pharmacy Treatments
- Alaska State Bill Approves "Child-Only" Insurance to Reduce Costs for Specialty Drugs
- CSL Behring Renews Pledge to Provide Significant Funding and Donated Coagulation Factor to World Federation of Hemophilia Over 3-Year Period
- Biologics & Non-TNF Agents Potentially Winners in the New ACR Guidelines for Early & Experienced Rheumatoid Arthritis (RA) Patients
- Express Scripts Launches ScreenRx
- States Attempt to Reduce Out Of Pocket Expenses
- Failed Biologic in Kidney Disorder
- Valeant Pharmaceuticals to Acquire Pedinol Pharmacal
- Data For Gilead’s HCV Drug To Be Presented Next Week
- Abbott's HUMIRA® (adalimumab) Approved in Europe for Treatment of Ulcerative Colitis (UC)
- AnaptysBio Announces Strategic Antibody Discovery Partnership With Celgene Corporation
- WellCare Health Plans, Inc. Agrees to Pay $137.5 Million to Resolve False Claims Act Allegations
- FDA Grants Zaltrap Priority Review Designation
- Abbott’s Hep C Therapy Shows Positive Results for Previously Untreated Patients
- Express Scripts Deal: Injunction Request Date Set
- Express Scripts Completed the Acquisition of Medco Health Solutions
- Amylin Completes Biologics License Application for Metreleptin to Treat Diabetes and/or Hypertriglyceridemia in Patients With Rare Forms of Lipodystrophy
- Cystic Fibrosis Patients Using Antibiotics May be at Risk for Lung Disease
- Study Suggests Long-Term Estrogen Therapy Increases Risk of Breast Cancer
- Health Care Law Outcome to be Decided Today
- Non-Compliance of Statins Could Lead to Mortality for RA Patients
- New Experimental Drugs for Psoriasis
- FDA Okays Omontys for Treatment of Anemia in Patients on Dialysis
- Study Shows Olaparib Slows Ovarian Cancer
- Ipilimumab Benefits Melanoma with Brain Metastases Patients
- Model Shows Broadening HCV Testing to be Cost Effective
- Promising Experimental Vaccine for Melanoma
- Abbott's New Future Research-Based Pharma Company Named AbbVie
- FDA Cites Biogen for Inappropriate Marketing of Avonex
- GSK’s Votrient Received Positive Votes from ODAC
- Lexicon's Telotristat Etiprate is Granted Orphan Drug Designation
- Daily-Use of Aspirin may Fight Cancer
- Generic Boniva Approved for Osteoporosis
- Express Scripts’ Purchase of Medco May be Delayed by Potential Legal Action
- Early Phase of HIV Treatment found Safe & Acceptable
- Many Patients on Newer Oncology Treatments Are at Risk for Drug Interactions
- AmerisourceBergen Agrees to Purchase World Courier Group for $520 Million
- Are Specialized Centers a Better Option for Cancer Patients?
- New MS Pill Delays Disability
- CBO Says Health Law will Cost Less, yet Cover Less
- BCBST Case Settled for $1.5 Million
- Increasing Survival Rate of Children with Leukemia
- Advisory Panel Recommends to Continue Trials of Painkillers
- IDSA Proposes New Drug Approval Pathway for Antibiotics
- Smartphone Users Able to Manage Prescriptions with Walgreens New Tools
- J&J’s Trial Shows Zytiga Benefits Pre-Chemo Treatment for Patients with Prostate Cancer
- Prime Therapeutics Contracts with EMD Serono for Rebif
- Study Shows Gilead’s Quad Pill for HIV Effective & Less Side Effects
- Dymista Shows Positive Results in Three Clinical Studies
- CareFusion to Acquire Pharmacy Automation Technology Leader
- Estrogen-Alone May Reduce Risk of Breast Cancer
- Takeda’s Lymphoma Drug Starts its Phase 3 Trial
- Study Confirms Early Berinert Treatment Provides Faster Relief for HAE Patients
- Abbott & Merck Collaborating on FISH-Based Diagnostic Test for Cancer Therapy
- Methotrexate Plus Prednisone Shows Good Results for Early RA
- Hizentra Could be Effective for Treatment of PIDD
- TherapeuticsMD, Inc. Launches VitaMedMD Plus Rx, the First Prescription Prenatal Vitamin with Quatrefolic and Plant-Based DHA
- Serious Risks Associated with Statins and HIV/HCV Protease Inhibitors
- EURORDIS Recognizes CSL Behring as a “Pioneer” for Rare Diseases
- Walgreens Specialty Pharmacy Study Shows Infusion Costs can be Significantly Reduced Based off Site-of-Care
- DEA Blocks Cardinal Health From Shipping Painkillers in Florida
- Biogen’s MS Autoinjector Pen Approved
- February 29, 2012: Fifth International Rare Disease Day
- Sleeping Pills Associated with Increased Risk of Death & Cancer
- Counterfeit Avastins’ Contents Determined
- Study on Bevacizumab for Neovascular Age-Related Macular Degeneration
- First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
- Study Shows Preventive Defibrotide May Help Kids after Hematopoietic Stem Cell Transplant
- First Cushing’s Syndrome Treatment Approved
- Researchers Found New Melanoma Drug Almost Doubles Life Expectancy
- Increasing Shortages of Infectious Disease Drugs
- FDA Assists in Increasing Supply of Cancer Drugs
- "Rare but Strong Together"- Fifth International Rare Disease Day
- AstraZeneca’s Direct-to-Patient Program for ARIMIDEX
- Implantable Microchip Delivers Medication for Osteoporosis
- Market Dynamics, Biosimilars, HIT and Other Issues Highlighted at Center for Healthcare Supply Chain Research’s First “Specialty Pharmaceutical Supply Chain Issues and Trends Seminar”
- CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and for Hemophilia B Patients Who Have Inhibitors
- Genzyme Recalls 9,380 Vials of Leukemia Drug, Fludara
- Counterfeit Versions of Avastin Found in the U.S.
- Study Shows Some Cells Shielding Themselves from HIV
- Children's Leukemia Drug in Short Supply
- Draft Rules for Biosimilar Drugs Issued by the FDA
- Draft Rules for Biosimilar Drugs Issued by the FDA
- Draft Rules for Biosimilar Drugs Issued by the FDA
- The Apothecary Shops and Pfizer come to terms on newly approved cancer drug Inlyta
- FDA Panel Votes Against Prostate Cancer Drug
- Genentech’s Breast Cancer Drug on FDA Priority Review
- Decreased Bone Density Risk in Breast Cancer Prevention Drug
- Will SB161 Pass, Allowing Physicians to Dispense Oral Cancer Drugs?
- Cost Concerns Continue to Dominate Benefit Design
- Walgreens to Acquire BioScrip Businesses for $225 Million
- Congressman Carney Addresses Drug Shortage Prevention Act
- FDA Approves Ivacaftor, a Cystic Fibrosis Drug
- Antiretroviral Drugs May Lead to Birth Defects
- FDA Okays Vismodegib for Treatment of Advanced Forms of Basal Cell Carcinoma
- FDA Approves Weekly Injected Type 2 Diabetes Drug
- Nail Salon Nightmare
- Amgen Agrees to Buyout Micromet for $1.16 Billion
- FDA Warns Novartis and Celgene on Drug Promotions
- Debate Over Avastin in Breast Cancer
- BioLineRx Becomes a Buyout Target due to Hep C Pill
- Health Technology's New Think Tank
- FDA Approves Subcutaneous Delivery of Bortezomib
- Victory for Women with Blood Disorders
- Idenix's Potential New Hepatitis C Drug
- 11 Deaths Put Novartis’ Pill Gilenya Under Review
- PML Risk Test for Patients on Tysabri is FDA Approved
- Study Shows Roche's Zelboraf Triggers Other Skin Cancer Growth
- A Promising Study for Bayer Colorectal Cancer Drug Regorafenib
- BTG's Drug for Cancer Toxicity Receives FDA Approval
- Risk of Cancer Counterfeits due to Drug Shortages
- New Potential Therapy Approach for Hepatitis C Found
- First Clinical Trial Site Initiated in CSL Behring Phase II/III Pivotal Study of Recombinant Fusion Protein Linking Coagulation Factor IX with Recombinant Albumin
- FDA Issues Warning Against Drug Brentuximab
- Prescription Price Case Settled for CVS
- Familial Prostate Cancer Mutation Found
- KRAS-Positive NSCLC Gives Mixed Results for Sorafenib
- Biopharma and Payers Are Optimistic About the Future of Drug Development
- Inhibitex Acquired by Bristol-Myers Squibb
- Inhibitex Acquired by Bristol-Myers Squibb
- Rheumatoid Arthritis Patients at Increased DVT Risk
- European Study Finds Frequent Aspirin use Associated with Early AMD and Wet Late AMD
- CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
- Anti-TNF Treatment Fails to Cut Acute Coronary Risk in RA
- Shared System REMS for TIRF Products are FDA Approved
- Raltegravir Gets the Nod for HIV-Infected Kids & Teens
- Walgreens Will Move on Without Express Scripts
- Takeda to Acquire Intellikine
- HIV Vaccine Testing gets the Green Light!
- No Problems with Interruption in Biologic RA Therapy
- Highlights from ASH 2011
- Chemokine Agonists May Block Myeloma Disease
- ASHP 2011 Midyear Focus on Pain: REMS, COT, abuse, addiction and the dark side of pain management
- ASHP 2011 Highlights for Specialty Pharmacists: DMARDS, IVIG, and the Good, Bad and Ugly of Specialty Pharmacy in "Who Dat" City
- Subcutaneous Immunoglobulin Replacement Therapy with Hizentra®
- Uncomplicated Skin and Soft Tissue Infections (SSTI): A Comparison of the Old SSTI Guidelines to the New MRSA Guidelines
- FDA REVOKES APPROVAL OF AVASTIN FOR BREAST CANCER
- Therapy Update: C1 Esterase Inhibitors highlighted in treatment of acute edema attacks caused by HAE
- Affymax Announces FDA Advisory Committee Will Review Peginesatide
- FDA Highlights 35 Innovative New Drug Approvals in FY 2011
- Follow-on Biologics & Biosimilars Literature Review: The Current Landscape and Implications of Recent Healthcare Legislation for the U.S. Market
- Cigna Acquires HealthSpring
- Data When You Need It, Where You Need It — The Latest Facts, Figures and Trends
- Data When You Need It, Where You Need It- The Latest Facts, Figures & Trends Now Available
- NORD Study- FDA flexible- Therapies for Rare Diseases
- FDA warns healthcare professionals of sprycel (dasatinib) and risk of pulmonary arterial hypertension
- FDA warns healthcare professionals of sprycel (dasatinib) and risk of pulmonary arterial hypertension
- Pharmasset, Inc. Announces Further Expansion of Electron Trial in Hepatitis C
- FDA Approves Pfizer's Xalkori
- TikoMed AB TM-400 receives orphan drug status
- Hep C patients may see boost with 4-drug combo therapy
- New Advances in Hep C Therapy
- Hepatitis C: Creating Better Outcomes Through Customized Adherence Programs
- High Costs Associated with Precocious Puberty, Researchers Say
- FDA Modifies ESA Dosing Recommendations
- Shire's Firazyr Wins FDA Panel Backing for Angioedema
- FDA Panel Advises Against Gouty Arthritis Biologic
- Six-Month Lupron Formulation Receives FDA Approval
- New Oxycontin Formulation, Oxecta, Approved for Pain
- Nulojix Approved for Kidney Transplant Patients
- Breast Cancer Genetic Marker Test Approved by FDA
- FDA approves Potiga as Add-On Epilepsy Treatment
- Merck signs pact to develop biosimilar etanercept
- Payers Not Leveraging Specialty Pharmacy Programs: EMD Serono Report
- SPJ Exclusive: New Hepatitis C Drugs Create Unique Opportunities, Challenges
- ASCO 2011: Bevacizumab Extends Progression-Free Survival in Recurrent Ovarian Cancer
- Sanofi's Lyxumia Shows Promise In Phase III Trials for Diabetes
- Meta Analysis: Diabetes Add-On Drug Classes Have Similar Benefits
- Urocidin(TM) May Hold Promise as Bladder Cancer Treatment
- Sirukumab Phase II Results Show Promise for RA
- FDA approves Incivek for Hepatitis C
- Edurant (rilpivirine) Approved as New HIV Treatment
- One-tenth of Cancer Patients Fail to Fill Initial Oral Oncolytic Prescription
- Medco Report: Specialty Trend Growth Will Challenge Payers
- Once-Weekly TB Treatment Proven Effective
- APhA releases second REMS white paper
- Halozyme, ViroPharma sign $83M licensing deal
- Michigan Researchers Develop Disease-Specific Stem Cell Lines
- Lung Stem Cell Discovery May Lead To New Treatments
- New induced stem cells may unmask cancer at earliest stage
- Initiation Of Antiretroviral Treatment Protects Uninfected Sexual Partners From HIV Infection (HPTN Study 052)
- Hormone Improves Long-Term Recovery From Stroke
- Pfizer expects to pay almost $1 Billion to settle hormone replacement litigation
- FDA clears first test to quickly diagnose and distinguish MRSA and MSSA
- FDA approves Victrelis for Hepatitis C
- CSL Behring Receives European Commission Marketing Authorization for Hizentra®, the first 20 Percent Subcutaneous Human Immunoglobulin for Treatment of Primary and Secondary Immunodeficiencies
- High risk transplant patients should use high volume transplant centers
- Children on growth hormone more likely to have diabetes
- Actos patients at higher risk for bladder cancer
- Dymista files with FDA
- Meda novel SAR product receives positive results
- Roche's Vemurafenib Filed with Companion Diagnostic
- Eight Megatrends Shaping the Future of Specialty Pharma
- FDA requests input on development of user fee program for biosimilar and interchangeable biological products
- Specialty Pharmacy Education Center (SPEC) Issues Call for Education Gap Analyses and Needs Assessments
- New Imaging Data Back Teriflunomide for Multiple Sclerosis
- Report: Novartis to boost biosimilars portfolio
- Boceprevir Receives FDA Priority Review and EMA Accelerated Assessment
- FDA approves Zytiga for late-stage prostate cancer
- Center For Healthcare Supply Chain Research Publishes Impact Study Of REMS
- HDMA 2010 Specialty Pharmaceuticals: Facts, Figures and Trends
- Biosimilars Coming to US Market but will Face Major Hurdles
- FDA approves Rituxan to Treat Two Rare Disorders
- Do Women with Silicone Breast Implants Need Follow-Up MRI Scans?
- Breast Fat Injection Causes Confusion on Mammograms
- Immediate Implant Replacement Provides New Option for Reconstruction After Mastectomy
- Interstitial Laser Therapy an an Alternative to Open Surgery
- Plastic Surgery the Key to Historical First U.S. Full Face Transplant
- Merck to Buy Eye-Care Firm
- Hormone Combo Boosts Height in Turners Syndrome
- Embattled Drug Maker Halves Price of Makena
- More Data on Diabetes Risk With Statins
- High Levels of PFCs Might Bring Early Menopause
- Valeant CEO showcases savvy dealmaking style
- Actos Cut Risk of Prediabetes Becoming Diabetes in Study
- FDA approves Zostavax vaccine to prevent shingles in individuals 50 to 59 years of age
- FDA approves new treatment for a type of late-stage skin cancer
- Trends by Socioeconomic Status and UV Radiation Exposure
- Xolair Reduces Seasonal Asthma Attacks for Inner City Kids: Study
- Japan Suspends Pfizer Vaccine Amidst Unexplained Deaths
- Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra Treatment in Patients With Primary Immunodeficiencies
- Researchers Focus on Rare Bleeding Disorders
- Recognition and Management of Anaphylaxis to Vaccines
- Biogen to build blood disorder drug franchise
- Lower Cytarabine Doses Effective and Less Toxic in AML Patients
- One In Four Of Those Waiting For Kidney Transplant Are Black Or Asian
- Nanoscale Whiskers From Sea Creatures Could Grow Human Muscle Tissue
- Alnylam Pharmaceuticals Reaches Settlement in Litigation Regarding Tuschl Patents
- Rapid antigen testing for detecting RSV in neonates found effective
- NOVAVAX Launches Phase I Clinical Trial To Evaluate Its Novel Vaccine Against Respiratory Syncytial Virus (RSV)
- New Therapies May Follow Discovery Of Link Between Respiratory Syncytial Virus And Oxidative Stress
- Whether Chronic Diseases Are Diagnosed May Depend on Where You Live
- More Diagnoses Lead to Lower Fatality Rates
- Study Questions Tests Used to Spot Heart Risks in Kidney Patients
- ROADMAP Published, But No News on FDA Safety Review of ARB
- FDA Approves New Contrast Agent for CNS Scans
- Questions Remain About Belimumab in Certain Lupus Patient Groups
- Timing of ART Makes a Difference for Those With TB
- Advances in Chronic Obstructive Pulmonary Disease Among Older Adults
- Lesser Known Lung Diseases Can Strike Smokers, Ex-Smokers
- Blood tests could forewarn of emphysema
- For the Treatment of Pulmonary Arterial Hypertension, the Highest Proportion of Surveyed Pulmonologists Identified Actelion’s Tracleer as the Most Effective Therapy, When Compared to Other Available Agents
- Grant For Pulmonary Arterial Hypertension Research
- Chronic thromboembolic pulmonary hypertension in pediatric patients
- Medicare Wrongly Buys Millions Worth Of Viagra For Seniors
- FDA Modifies Boxed Warning For Pulmonary Arterial Hypertension Drug Letairis
- Psoriasis And Obesity Linked
- Anacor Pharmaceuticals Announces First Patient Dosed In A Phase 2b Trial Of AN2728 For Psoriasis
- Eczema In Children Not Improved By Ion-Exchange Water Softeners
- New Psoriasis Guidelines Stress Importance Of Individualized Treatment Plans
- CalciMedica Initiates Phase I Clinical Trial Of First CRAC Channel Inhibitor (CCI) For Psoriasis
- Nycomed's novel COPD therapy roflumilast receives FDA approval
- Commonly Prescribed Osteoporosis Drug Associated With Very Low Risk Of Serious Jaw Disease
- Poor Status Of Post-Fracture Care And Osteoporosis Management In Eastern Europe And Central Asia Of Concern
- Daxas® (Roflumilast) included as a new treatment option in latest international COPD guidelines
- Prolia(TM) (denosumab) Receives Best New Drug Honor at Scrip Awards
- Pfizer Suspends Tanezumab Osteoarthritis Clinical Trial Program
- GSK and BJD collaborate on a new educational programme to reduce global burden of joint pain
- Convergence Pharmaceuticals Successfully Launched out of GSK to Focus on Novel High Value Analgesics
- ADX71943 Effective In Osteoarthritis Pain Model: Addex Pharma
- Uric Acid May Increase Likelihood Of Severe Osteoarthritis
- Genentech diabetic macular edema drug meets primary endpoint
- Brain Hemorrhage Risk Higher With Late Macular Degeneration
- Advanced Macular Degeneration Is Associated With An Increased Risk Of Bleeding Stroke In Elderly
- Report: Affordable Care Act Controls Costs For Early Retiree Coverage
- Looking For Ways To Bridge Generational Technology Gap
- Synageva BioPharma Corp And To-BBB To Collaborate On Brain Drug Delivery For Rare Diseases
- Rates, risk factors for CV events associated with Fabry’s disease
- FDA Denies Gaucher's Disease Drug; High Jewish Incidence
- Three-Year Data From Phase 2 Trial Of Genzyme Gaucher Disease Oral Compound Suggest Sustained Or Further Improvement Across All Endpoints
- Protalix BioTherapeutics Presents Data On The Company's Fabry Program And Oral Enzyme Gaucher Program With Experts In The Field Of Lysosomal Disorders
- The University of Kansas Cancer Center and U.S. Oncology-Affiliated Kansas City Cancer Center to Merge Operations to Promote Patient Care and Research
- Study: 14.6 percent of docs are not eligible for MU, don't have an EHR
- Researchers Discourage Use of Acid-Suppressive Drugs Outside ICU
- Physician demand strong despite softening of health care market
- News From Annals Of Internal Medicine
- SANTARUS : Initiates Phase I Clinical Study with SAN-300
- New Vector Designed For Gene Delivery
- Sepsis Beware: Discovery Of Protein Secreted By Roundworm Could Lead To New Treatment
- Flu Vaccination At Highest Ever Level In Scotland
- Quarter Of Girls Missing Out On Life-Saving Vaccine: New Website Aims To Reverse Trend, Australia
- Quarter Of Girls Missing Out On Life-Saving Vaccine: New Website Aims To Reverse Trend, Australia
- Cancer And Blood Cell Research Benefits From $38.4M NHMRC Program Grants Scheme
- New CCI Buy Signals - AEZ, ARE, BMO, FRA, NGD.WB
- Most survivors of gynecologic cancers have menopausal symptoms
- Considering hormone replacement therapy?
- Hormonal Therapy For Older, Pregnant Horses?
- Association Between Hormone Therapy Begun At Menopause And Risk For Breast Cancer
- ViroPharma to Participate in Two March Healthcare Conferences
- Hereditary Angioedema: The Unsuspected Diagnosis
- European Commission Approves Self-Administration Label for FIRAZYR(R) (icatibant) for the Symptomatic Treatment of Acute Hereditary Angioedema Attacks
- Pharming's U.S. Rhucin setback sends shares down
- Hepatitis C Infection Rates Are Stable
- Study: Osteoporosis is more common among patients with HIV and hepatitis C
- Blood victims' payouts increased
- Hepatitis C Can Lead to Liver Cirrhosis
- Phase 2 Trial Shows Telaprevir Lowers Hepatitis C Viral Levels In People With HIV And Hepatitis C (CROI 2011)
- Journalism award launched to promote hemophilia awareness
- FDA Approves Revised Alphanate® Labeling to Include Reduced Infectivity of an Experimental Model Agent for vCJD
- CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
- Biogen to build blood disorder drug franchise
- Exposure to Insecticides May Up Autoimmune Disease Risk
- Protalex, Inc. Announces Enrollment of First Patients in 3rd Cohort of Its Ongoing Phase 1b Dose Escalation Study of PRTX-100 in Patients With Active Rheumatoid Arthriti
- Be Attuned to Extracutaneous Manifestations of Psoriasis
- Rain as Cause of Pain in Rheumatoid Arthritis Continues to Baffle the Medical World
- 2nd UPDATE: Pfizer Arthritis Drug Meets Goal In Second Trial
- Chronic graft-versus-host disease may remain stable after hematopoietic cell transplantation
- Allo-HCT in first complete remission extended life expectancy for some intermediate- and unfavorable-risk AML
- Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerix's Lead Antiviral CMX001
- Vical Receives Positive Scientific Advice From EMA for TransVax(TM) Phase 3 Trial
- Sangamo BioSciences Announces Four Data Presentations at CROI 2011 of Novel ZFN Therapeutic Approaches to the Treatment of HIV/AIDS
- Doubts over mild asthma treatment
- Corticosteroid Effective Asthma Rescue Addition
- Test Your Home For Radon; Protect Your Health
- Smoking linked to increased severity of new-onset asthma
- ASA: Early BP Lowering No Help in Acute Stroke (CME/CE)
- Tumor Genes Yield Hypertension Clues (CME/CE)
- Targacept Announces Initiation Of Phase 2 Studies Of TC-6987 In Asthma And Type 2 Diabetes
- HIV Protection Without Circulating Blood Antibodies
- EU Initiative In Research Into Living Cancer Cells In Time And Space
- Diamyd Medical: Diamyd Phase II Study In Cancer Pain Posted On ClinicalTrials.gov
- Purdue University Researcher's Technology Listens To Cancer Cells, Shows Effects Of Drug Therapies
- Studies Show New Bone Marrow Biopsy Technology Delivers Superior Samples, Less Pain When Compared To Manual Devices
- Dual Vaccine Strategy Protects Against Avian Flu (CME/CE)
- Study Reveals How Omega 3's Work In Preventing Several Forms Of Blindness
- Quality Varies In Social Networking Websites For Diabetics
- Medication Education Key To Adherence
- Sweeping View Of Prostate Cancer Genome Yields Deep Insights
- New Diabetes Statistics Further Highlight The Urgent Need For Prevention And Early Detection
- Precise New Sensor Employs Hydrogels
- Why Did The HIV Epidemic Decline In Zimbabwe?
- New Avandia Label Spells Out Restrictions
- Lab Notes: Caps May Sharpen the Intellect
- Type 1 Diabetes Linked to Viruses (CME/CE)
- CV Risk Factors Often Uncontrolled in Uninsured
- Alternaria alternata serine proteases induce lung inflammation and airway epithelial cell activation via PAR2.
- Waistlines Expand Worldwide (CME/CE)
- Blood Test Spots Variant CJD (CME/CE)
- Pandemic Flu Vaccine Was Safe, Chinese Say (CME/CE)
- Incidence Of Hepatitis C Infection In HIV-Infected Men
- Deaths Drop With ICU Care-Quality Program (CME/CE)
- HPV Vaccine Prevents Genital Warts in Young Men (CME/CE)
- Teens With HIV At High Risk For Pregnancy, Complications
- Control of Cardio Risk Factors Lags
- GSK Settles More Avandia Suits
- HIV Causes Rapid Aging In Key Infection-Fighting Cells, Research Suggests
- Lab Notes: Cancer Drug May Shine in Spinal Injury
- Disparities Cut Both Ways in Nephrology (CME/CE)
- Gene Variant Protects Against Anemia in HCV Tx (CME/CE)
- tPA Busts Dialysis Catheter Complications (CME/CE, with audio)
- Diabetes Rising in U.S., CDC Reports
- Performance Incentives Flop in Hypertension (CME/CE)
- FDA Rejects Inhaled Insulin
- CVD Risk Linked With Bone Loss
- Antioxidants May Boost Male Fertility
- Antidepressant a Chill Pill for Hot Flashes
- Osteoporosis Recs Urge Screening for More Women
- Comparing Nevi Avoids Unneeded Excisions (CME/CE)
- Alcohol Linked to Psoriasis in Women (CME/CE)
- Eli Lilly Halts Melanoma Trial
- Painkiller Shows Promise in Prevention of Skin Cancer (CME/CE)
- Panel Splits over Skin Cancer Detection Device
- Am I Young Yet?
- Involuntary childlessness more detrimental than originally thought, study suggests
- Cyclists Said to Back Claims That Lance Armstrong Doped
- Sperm may be harmed by exposure to BPA, study suggests
- The hormone IGF-1: A trigger of puberty
- Baseball Using Minor Leagues for a Drug Test
- New test to predict success of IVF treatment
- Human sperm gene is 600 million years old, scientists discover
- Assistant to Galea Pleads Guilty
- Waterloo U. in Canada Bars Team for Steroids Use
- Drug Maker From China Pleads Guilty
- Modifying Neural Stem Cells Improves Their Therapeutic Efficacy
- Glial cells can cross from the central to the peripheral nervous system
- Early protein processes crucial to formation and layering of myelin membrane
- Factors from common human bacteria may trigger multiple sclerosis
- Multiple sclerosis is more aggressive in children but slower to cause disability than in adults
- Business News
- About Us
- Mission & Vision
- Advisory Board
- Rosalyn Padiyara Vellurattil, PharmD, CDE
- Ashish Advani
- Dr. Michele B Kaufman
- Stacey Ness, PharmD
- Charlotte E. Sibley
- Kevin G. Cast, MS
- Carl Rowe
- Bonnie A. Labdi
- Jeffrey Lombardo, PharmD, BCOP
- Philip E. Johnson, MS, RPh, FASHP
- Xiaodong Feng
- Ryan Goldstein
- Gollapudi Shankar
- Khemraj Hirani
- Melissa Badowski, PharmD, BCPS, AAHIVE
- Dr. John W. Sleasman
- Hetty A. Lima, RPh, FASHP
- Marilyn N. Bulloch, Pharm.D.,BCPS
- Ann Nguyen, Pharm.D.
- David C. Calabrese, M.H.P., R.Ph
- Dea Belazi, PharmD, MPH
- Elie Bahou, Pharm.D., MBA
- F. Randy Vogenberg, RPh, PhD
- Gaston L. Bernstein
- John F. Aforismo, B.Sc. Pharm, R.Ph., FASCP
- Kurt Harlan, PharmD
- Michael A. Nameth, RPh, MBA
- Quintin Jessee R.Ph. D.Ph.
- Linda R. Young, Pharm.D.
- Michael Toscani, Pharm.D.
- J. Richard Thompson, PharmD, MBA, BCPS
- Elizabeth Mauer
- Jeffrey A Bourret, RPh, MS, FASHP
- Samir Bhattacharyya
- Sharon Ferrer
- Suzette DiMascio, CHE, CMCE, CPC
- Karen J. Ribler
- Eric M. Tichy, PharmD, BCPS
- Mary Choy
- Nicole A. Weimert-Pilch, PharmD, MSCR, BCPS
- Steven Gabardi
- Contact Us
- Career Opportunities
- SPJ Author Guidelines
- Surveys
- Blog
- Education
- Certification
- Login
- Login
- RSS
Policies Footer Menu
News Menu
- Allergic Asthma
- Cardiology
- Dermatology
- Diabetes
- Plaintiffs Awarded $6.5 Million for Damages Associated with Takeda's Actos
- Pfizer and Merck Collaborate for Type 2 Diabetes Treatment
- Eli Lilly Releases Positive Results from Additional Trials for its Diabetes Drug
- FDA Committees will Reassess Safety of GSK's Diabetes Pill, Avandia
- Janssen's Invokana Receives FDA Approval for Type 2 Diabetes
- FDA Investigates Reports of Increased Risk of Pancreatic Cancer with Certain Diabetes Drugs
- Mylan Enters A Settlement Agreement for its Generic Diabetes Drug
- Gilead's Ranexa Reduces Angina Frequency for Patients with Type 2 Diabetes
- Study Identifies Genetic Mutation that May Lead to New Treatment Options for Type 1 Diabetes
- Kaiser Permanente Study Shows Diabetes Patients are not at an Increased Risk During Knee Replacement Surgery
- Study Shows New Diabetes Drug May Double Pancreatitis Risk
- FDA Accepts Sanofi's Diabetes Drug Application
- Mylan and Biocon Enter an Agreement for Three Insulin Products
- The FDA Rejects Novo’s Diabetes Drug
- Crown Marketing Pharmaceuticals Announces Positive In-Vitro Testing Results for Diabetes Drug
- Takeda’s Three New Diabetes Therapies Receive FDA Approval
- GlaxoSmithKline Submits a Regulatory Application for its Diabetes Drug
- Expert Panel Recommends Approval of Johnson & Johnson's Diabetes Pill
- Zogenix Announces U.S. FDA Acceptance for Review of Zohydro ER(TM) New Drug Application for Treatment of Chronic Pain
- FDA Approves Weekly Injected Type 2 Diabetes Drug
- Sanofi's Lyxumia Shows Promise In Phase III Trials for Diabetes
- Meta Analysis: Diabetes Add-On Drug Classes Have Similar Benefits
- Actos patients at higher risk for bladder cancer
- More Data on Diabetes Risk With Statins
- Actos Cut Risk of Prediabetes Becoming Diabetes in Study
- New Diabetes Statistics Further Highlight The Urgent Need For Prevention And Early Detection
- Precise New Sensor Employs Hydrogels
- Medication Education Key To Adherence
- Quality Varies In Social Networking Websites For Diabetics
- Study Reveals How Omega 3's Work In Preventing Several Forms Of Blindness
- Endocrinology
- First Cushing’s Syndrome Treatment Approved
- High Costs Associated with Precocious Puberty, Researchers Say
- Hormone Improves Long-Term Recovery From Stroke
- Osteoporosis Recs Urge Screening for More Women
- Antidepressant a Chill Pill for Hot Flashes
- Antioxidants May Boost Male Fertility
- CVD Risk Linked With Bone Loss
- FDA Rejects Inhaled Insulin
- Growth Hormone
- Aeterna Zentaris Requests Fast Track Designation for Their GHD Diagnostic Test
- Children on growth hormone more likely to have diabetes
- Hormone Combo Boosts Height in Turners Syndrome
- Drug Maker From China Pleads Guilty
- Waterloo U. in Canada Bars Team for Steroids Use
- Assistant to Galea Pleads Guilty
- Baseball Using Minor Leagues for a Drug Test
- Cyclists Said to Back Claims That Lance Armstrong Doped
- Am I Young Yet?
- Hematopoietics
- FDA Grants Orphan Drug Designation to Apgenix's Apocept for Myelodysplastic Syndromes
- Study Shows Preventive Defibrotide May Help Kids after Hematopoietic Stem Cell Transplant
- New induced stem cells may unmask cancer at earliest stage
- Sangamo BioSciences Announces Four Data Presentations at CROI 2011 of Novel ZFN Therapeutic Approaches to the Treatment of HIV/AIDS
- Chronic graft-versus-host disease may remain stable after hematopoietic cell transplantation
- Allo-HCT in first complete remission extended life expectancy for some intermediate- and unfavorable-risk AML
- Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerix's Lead Antiviral CMX001
- Vical Receives Positive Scientific Advice From EMA for TransVax(TM) Phase 3 Trial
- Hemophilia
- FDA Accepts Biogen's BLA for its Hemophilia A Candidate
- American Management Association and Biogen Partner to Develop Workshops for Hemophilia Patients
- World Federation of Hemophilia Announces 50 Years of Improving Care on World Hemophilia Day
- Biogen Submits a Biologics License Application to the FDA for its Hemophilia A Drug
- FDA Accepts Biogen's Biologic License Application for its Hemophilia B Drug
- Baxter Submits a Biologics License Application for Its Hemophilia Drug
- Baxter Agrees to Acquire Inspiration BioPharmaceuticals’ Investigational Hemophilia Compound
- First Patient Enrolled in CSL Behring’s Pediatric Phase III Study for Hemophilia Treatment
- Octapharma's Octaplas Receives FDA Approval for Patients with Blood Clotting Disorders
- Baxter Announces Positive Results from Hemophilia Study
- Baxter Submits Investigational New Drug Application to the FDA for Its Hemophilia A Treatment
- Biogen Submits Biologics License Application to the FDA
- Novo Nordisk Launches HemaGo Application for Hemophilia Patients and Caregivers to Track Treatment Details
- Specialty RN Source Announces Agreement to Provide Nursing Services for The Hemophilia Alliance Members
- National Hemophilia Foundation’s Annual Meeting: “Mapping Our Future”
- Novo Nordisk Submits Regulatory Applications for Hemophilia A Drug
- Biogen and Sobi Announce Positive Results for Long-Lasting Recombinant Factor IX FC Fusion Protein in Hemophilia B
- Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
- American Society of Hematology Launches Multi-Million-Dollar Grant Program to Support Critical Blood Disease Research
- FDA Puts Hold on Ipsen’s Hemophilia Drug
- China Biologic Receives SFDA Manufacturing Approval Certificate for Human Coagulation Factor VIII
- CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
- CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
- CSL Behring Renews Pledge to Provide Significant Funding and Donated Coagulation Factor to World Federation of Hemophilia Over 3-Year Period
- First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
- CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and for Hemophilia B Patients Who Have Inhibitors
- First Clinical Trial Site Initiated in CSL Behring Phase II/III Pivotal Study of Recombinant Fusion Protein Linking Coagulation Factor IX with Recombinant Albumin
- TikoMed AB TM-400 receives orphan drug status
- Michigan Researchers Develop Disease-Specific Stem Cell Lines
- Biogen to build blood disorder drug franchise
- ViroPharma to Participate in Two March Healthcare Conferences
- Journalism award launched to promote hemophilia awareness
- CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
- FDA Approves Revised Alphanate® Labeling to Include Reduced Infectivity of an Experimental Model Agent for vCJD
- Hepatitis C
- Janssen's Investigational Hepatitis C Treatment is Granted Priority Review by the FDA
- AbbVie's Investigational Hepatitis C Combination Drug Receives Breakthrough Therapy Designation from the FDA
- Janssen Submits Marketing Application for Approval of Its Hepatitis C Drug in Europe
- Boehringer Ingelheim Announces Positive Results from Its Phase 3 Study of its Combination Regimen for Hepatitis C Patients
- Merck and BMS Enter a Non-Exclusive Agreement for a Phase II Trial for a Combination Regimen for Hepatitis C
- Roche and Ascletis Collaborate to Advance Hepatitis C Treatment Options in China
- FDA Clears Echosens' FibroScan for Non-Invasive Liver Diagnosis
- Gilead Submits NDA to the FDA for Sofosbuvir for Treatment of Hepatitis C
- Vertex and Bristol-Myers Squibb Enter Agreement for Phase 2 Studies of Hepatitis C Combo Treatment
- Experimental Hepatitis C Drug Shows Promising Results
- EMA Backs Roche's Pegasys for Chronic Hepatitis C in Children Five Years and Older
- Hepatitis C Continues to Lead the Specialty Area for Highest Increase in Drug Spend
- Gilead Announces Positive Results for Hepatitis C Treatment
- Idenix Will Discontinue Development Programs for Two Experimental Hepatitis C Treatments
- Gilead’s Sofosbuvir Meets Primary Endpoints in Two Phase III Studies for Treatment of Hepatitis C
- Interferon for Retreatment of Hepatitis C May be More Harmful than No Treatment
- Boehringer Ingelheim Enrolls First Patients in its Phase III Trial for Interferon-Free Hepatitis C Program
- FDA Requires Additional Time for Review of Idenix’s Hepatitis C Treatment
- Gilead Shares Positive Update on Hepatitis C Developments
- Hepatitis C Pills Show Promising Future
- Incivek Label Revised to Include Warning of Fatal and Non-Fatal Serious Skin Reactions
- St. Joseph's Hospital Launches State-Wide Program to Help Diagnose and Treat Hep C Patients
- Gilead Announces Positive Results from Phase III Study for All-Oral Hep C Drug Program
- FDA Approves Promacta for Hep C Patients with Low Blood Platelet Counts
- Abbott Plans Phase III Studies for Hep C Drugs Due to High Cure Rates in Aviator Trial
- Vertex & GSK Collaborate for Hep C Treatment
- BioCryst Withdraws Investigational New Drug Application for HCV Drug
- Antiviral Drugs May Reduce Liver Cancer Risk in Patients with Hepatitis C
- Abbott's Investigational Hep C Drug Cures 99 Percent of Hard-To-Treat Patients
- Aethlon Medical Releases Hepatitis C Virus (HCV) Treatment Protocol and Inclusion/Exclusion Criteria Underlying Compassionate-Use Commercialization Program
- New Hepatitis C Data from Boehringer Ingelheim to be Presented at AASLD Annual Meeting
- Achillion Announces Positive Proof-of-Concept Data with ACH-3102
- Vertex Ends Work on One Hepatitis C Drug, Continues Another
- Hepatitis C Biopump Trials Receives Green Light
- What the Future Holds for HCV Sufferers
- FDA Puts Hold on Another Idenix Hep C Study
- Bristol-Myers Squibb Forced to Halt Studies of its Experimental Hep C Treatment
- FDA Puts Idenix’s Hep C Drug on Hold due to Heart-Related Side Effects
- Hepatitis C Treatment May Stunt Growth in Children
- Achillion's Experimental Hep C Drug Shows Promise in Mid-Stage Trials